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Abstract 
 
Thrombospondin: An emerging keystone in skeletal muscle structure and 
function 
 
Gerald N. Audet 
 
Our objective was to elucidate the effects of TSP-1 on skeletal muscle structure and 
function, and its potential role in the progression of skeletal muscle dysfunction.  The central 
hypothesis was that TSP-1 is a critical negative regulator of skeletal muscle angiogenesis.  In 
chapter 3, we used a TSP-1 mimetic delivered by mini osmotic pumps to show that TSP-1 can 
reduce capillarity across three distinct muscle types.  We found that those given the mimetic had 
a 35% decrease in soleus capillarity, a 20% decrease in the gastrocnemius, and an 11% decrease 
in the plantaris.  This confirmed the critical role that TSP-1 plays in physiological skeletal 
muscle angiogenesis.  Despite previous evidence showing that TSP-1 is an important regulator of 
apoptosis in tumorigenesis, we found no apoptosis in the skeletal muscle of those animals treated 
with the TSP-1 mimetic, as measured by TUNEL staining or cell death ELISA.  Further, again 
using this same mimetic,  in chapters 3 and 4 we failed to find any change in whole body 
exercise, as measured by maximal running speed, or direct muscle function as measured by ex 
vivo muscle simulation, in relation to the TSP-1 induced capillary rarefaction.  This may further 
support the notion that it is not simply one factor that controls exercise capacity, but a 
combination of many different components and systems.  Further, previous evidence suggested 
that a TSP-1/TNFα axis could be controlling skeletal muscle capillarity rarefaction in chronic 
systemic inflammation.  In chapter 5 we examined the role overexpression of TNFα has on 
skeletal muscle capillary regression in a mouse model of chronic lung disease.  Despite showing 
a 16% decrease in capillarity of the soleus, we found no change in TSP-1 expression.  What 
factors are at play in this specific disease model remains unknown; however our data suggests 
that TSP-2 could be central to pathological capillary regression seen with this model.  Finally, in 
chapter 4 we also suggest that TSP-1 may be playing a role in the regulation of mitochondrial 
electron transport enzyme activity, and hence perhaps mitochondrial function.  This could 
provide a new and exciting role for TSP-1.  This will require further investigation.  Together, the 
studies in this document build upon data showing that skeletal muscle angiogenesis is a dynamic 
process controlled by positive and negative angiogenic proteins.  It provides new and exciting 
evidence for the importance of negative angiogenic proteins, specifically that of TSP-1 and TSP-
2, and lays the groundwork for investigation into potential medical therapies targeting aberrant 
angiogenesis in skeletal muscle. 
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Chapter 1: Purpose, Specific Aims, 
Introduction, and Significance 
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Introduction 
Purpose: 
Meeting the metabolic demands of skeletal muscle during exercise is critical for optimal 
muscle function.  Dysregulation of the delivery of oxygen and nutrients to muscle can contribute 
to chronic disease morbidity and mortality.  Because of this, skeletal muscle capillarity and 
angiogenesis play essential roles in both health and disease.  Angiogenesis is a dynamic process 
thought to be controlled by the balance between positive and negative angiogenic proteins.  
While there is an established body of literature pertaining to the positive regulators in angiogenic 
responses to exercise and disease, the identification and precise role of negative regulators 
remains poorly understood but may prove to be important in treating the aberrant angiogenesis 
found in some disease states. 
One potentially critical anti-angiogenic protein is thrombospondin-1 (TSP-1). TSP-1 has 
a wide range of functions, which include the regulation of wound healing, apoptosis, and 
angiogenesis.  As an anti-angiogenic factor, TSP-1 suppresses the essential processes of vascular 
growth by inhibiting endothelial cell proliferation, survival, and migration.  Through these 
pathways, and others, it is possible that TSP-1 plays a role in skeletal muscle capillary 
rarefaction and contributes to the skeletal muscle comorbity seen in chronic diseases like cancer, 
diabetes mellitus, cardiovascular disease (CVD) and chronic obstructive pulmonary disease 
(COPD). 
Our objective is to elucidate the effects of TSP-1 on skeletal muscle structure and 
function, and its potential role in the progression of skeletal muscle dysfunction.  The central 
hypothesis is that TSP-1 is a critical negative regulator of skeletal muscle angiogenesis.  To test 
our hypothesis, we will examine gain and loss in the function of TSP-1 and explore a potential 
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connection between TNFα induced systemic inflammation and TSP-1-induced 
pathological/physiological changes in skeletal muscle. 
Specific Aims: 
Specific Aim 1: Examine the role of TSP-1 in exercise training-induced skeletal muscle 
angiogenesis using 1) a TSP-1 mimetic and 2) TSP-1 knock-out mouse model. 
In wild-type (WT) mice administered a TSP-1 mimetic, we hypothesize that exercise 
training induced angiogenesis will be attenuated or ablated.  We expect to find greater muscle 
fatigue, persistently lower levels of positive angiogenic proteins, and decreased exercise and 
skeletal muscle performance when compared to WT trained animals.    
In TSP-1 KO mice, we hypothesize exercise training induced angiogenesis will be 
increased, and the time course of capillary adaptation will be accelerated compared to WT 
animals.  We also expect to find decreased muscle fatigue, higher levels of positive angiogenic 
proteins, and increased exercise and skeletal performance when compared to WT trained 
animals. 
Specific Aim 2: Examine the connection between TNFα-and TSP-1 regulated skeletal muscle 
capillarity and exercise capacity 
TNFα is an inflammatory cytokine that appears central to many chronic diseases, 
including COPD and CVD. We hypothesize that chronic TNFα overexpression will produce 
increased chronic systemic inflammation leading to increased skeletal muscle TSP-1 expression, 
which in turn will decrease muscle capillarity, decrease exercise capacity, and decrease skeletal 
muscle performance compared to control animals. 
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Background: 
Skeletal muscle dysfunction can be a significant barrier in the daily lives of those 
suffering with chronic disease, such as chronic heart failure (CHF), chronic obstructive 
pulmonary disease (COPD), diabetes mellitus, and cancer [1-8].  While COPD patients exhibit 
altered muscle fiber composition, decreased muscle fiber size, decreased skeletal muscle 
capillarity and decreased overall strength [9-11], the origin of chronic skeletal muscle pathology 
remains poorly understood. 
Skeletal muscle capillarity is an important factor in normal skeletal muscle function.  An 
increase in skeletal muscle capillarity occurs with exercise training and this in turn helps to meet 
the demand for more oxygen and nutrients.  In chronic disease decreased skeletal muscle 
capillary-to-fiber ratio (C:F) likely contributes to reductions in overall exercise capacity [1, 12].  
Indeed, there is a significant decrease in C:F in CHF and COPD, as well as evidence of a 
decreased C:F in diabetes mellitus, the metabolic syndrome, and obesity [1, 12-14].  While 
decreased C:F is emerging as an important contributor to disease morbidity, the molecular 
mediators of this process, and the pathways responsible, are still poorly understood.   
Thrombospondin-1 (TSP-1) is a large (450kD) extracellular protein that has a wide array 
of functions [15].  First discovered for its role in wound healing, it has been shown to play roles 
in apoptosis, inflammation, nitric oxide signaling, and calcium binding [14, 16-19].  Acting 
through multiple receptors, including the essential receptors CD36 and CD47, TSP-1 has been 
shown to prevent endothelial cell adhesion, growth, and migration, and therefore it is implicated 
as a key negative regulator of angiogenesis and vascular homeostasis.  Decreased TSP-1 has 
been shown to increase tumor vessel growth, and pharmacological administration of several 
different TSP-1 mimetics has helped decrease tumor size and disease progression in canines and 
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mice [20-23].  More recently, TSP-1 mRNA and protein levels have been shown to be important 
in acute responses to exercise [24], and it’s suggested that TSP-1 may play an important role in 
regulating exercise-induced skeletal muscle angiogenesis [25].  Also, recent evidence shows that 
hindlimb unloading in rats increases TSP-1 in association with decreases in skeletal muscle C:F 
ratio [26].  While these data hint at the importance of TSP-1, they are largely circumstantial and 
there is need for direct evidence showing that TSP-1 plays a role in normal physiological 
function, as well as in the development of skeletal muscle dysfunction. 
 It has been suggested that chronic inflammation both contributes to, and results from, the 
primary pathologies found in CVD, COPD, diabetes mellitus, and obesity [1, 27-29], and 
therefore likely contributes to skeletal muscle dysfunction [31].  While there are many 
inflammatory mediators, TNFα has received much attention in COPD and diabetes mellitus [29-
31], however the mechanisms by which it decreases skeletal muscle function and increases 
comorbidity is still unknown.  There are data to suggest that TNFα may be at the heart of 
capillary rarefaction seen with chronic pathology.  Interestingly, there is a proposed connection 
between TNFα and TSP-1 that shows TNFα acts to increase human skeletal myoblast expression 
of TSP-1 [32] in a tissue specific manner.  Additionally, increased systemic TNFα has been 
shown to increase circulating TSP-1 protein levels in humans [33]. There is also evidence that 
TNFα KO mice have increased running capacity [34], suggesting that TNFα, perhaps via 
lowered basal TSP-1 expression, may play a role in altering muscle capillarity.  Collectively 
these data point to a potential mechanism that may link chronic inflammation, through TNFα, in 
the development of skeletal muscle capillary rarefaction, through TSP-1, resulting in overall 
muscle dysfunction [35]. 
 
6 
 
Significance:   
There is little information about the role that angiogenic inhibitors play in the etiology of 
skeletal muscle dysfunction.  These data will add significantly to the understanding of the role 
and importance of TSP-1 in regulating skeletal muscle structure and function in basal 
physiology, exercise, and disease.  Indeed, if TSP-1 can be confirmed as a central factor in 
regulating skeletal muscle angiogenesis and vascular function, it may provide a potential 
therapeutic target aimed at alleviating skeletal muscle capillary rarefaction and vascular 
dysfunction found in many chronic diseases. 
 
Terms: 
3TSR: Type I repeat region of Thrombospondin-1 
ABT: 30mg/kg/day ABT-510 Treated Wild-type Mice 
ABT-510: Abbot Laboratories Compound 510 
bFGF: Basic Fibroblast Growth Factor 
C:F: Capillary to Fiber Ratio 
CD: Capillary Density 
CD36 KO: CD36 whole-body KO mice 
CD36: Cluster of Differentiation 36 
CD47/IAP: Cluster of Differentiation 47 
CHF: Chronic Heart Failure 
CON: Control mice 
COO region: Carboxy terminal region of TSP-1 
COPD: Chronic Obstructive Pulmonary Disease 
CVD: Cardiovascular Disease 
DM: Diabetes Mellitus 
EC: Endothelial Cell 
EDL: extensor digitorum longus 
EGF: Epidermal Growth Factor 
eNOS: Endothelial Nitric Oxide Synthase 
FCSA: Fiber Cross Sectional Area 
Flk-1/VEGFR-2: Vascular Endothelial Growth Factor Receptor 2 
GA: Gastrocnemius 
IGF: Insulin-like Growth Factor 
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IL: Interluekin 
IP: Inducible Protein 
LRP-1: lipoprotein receptor-related protein-1 
MMP:  Matrix Metalloproteinase 
mRNA: Messenger Ribonucleic acid 
NO: Nitric Oxide 
PLT: Plantaris 
P-VEGFR-2: Phosphorylated Vascular Endothelial Growth Factor 
Receptor 2 
sGC: Soluble guanylyl cyclase 
sGK-1: soluble glucocorticoid-inducible kinase 
SOL: Soleus 
TGFβ: Transforming Growth Factor Beta 
TNFα: Tumor Necrosis Factor Alpha 
TNFα+: Tumor Necrosis Factor Alpha Lung-specific Overexpressing Mice 
TSP-1 KO: Full-body Thrombospondin-1 KO 
TSP-1: Thrombospondin-1 
TSP-2: Thrombospondin-2 
VEGF: Vascular Endothelial Growth Factor 
WT: Wild-type mice 
α3β1:  Alpha-3 Beta-1 Integrin 
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Skeletal muscle angiogenesis 
Skeletal Muscle: A remarkably adaptable organ 
Skeletal muscle makes up approximately 30 to 40% of the total mass of the average 
healthy adult body, dependent on gender.  It is an incredibly plastic organ, allowing it to be both 
energetically economical while also providing the necessary adaptation required to respond to a 
wide variety of conditions and stimuli.  That is, by being extremely adaptable, skeletal muscle 
provides maximum performance capacity at the minimum energy cost to the rest of the 
organism.  The different systems that make up a muscles overall function (e.g. force production, 
endurance capacity, etc) respond differently along a spectrum depending on the type and 
duration of the stimulus, as well as the genetic and environmental differences between 
individuals.  This leads to an vast amount of adaptation that can occur across the many different 
systems of skeletal muscle, which can include the actual contraction apparatus (i.e. myosin and 
actin) as well as all the other associated systems (e.g. neuronal input, calcium handling, 
mitochondrial content, vascularity, etc).  The variations in muscle contractile and metabolic 
systems, and the ability to adapt, gives different muscles throughout the body different functional 
capacities and provides the organism with a range of kinetic abilities.  These range from high-
force anaerobic muscles, to low-force high aerobic muscles, and an almost infinite continuum 
between these two extremes.  The changes that occur in skeletal muscle in response to 
physiological and pathological stimuli have been well reviewed [1-7] and involve a host of 
molecular mediators. 
One of the changes that can occur in skeletal muscle in response to a physiological or 
pathological stimulus (e.g. exercise, chronic inflammation) is angiogenesis, or capillary growth.  
Capillaries are the smallest blood vessels in the body and are responsible for the diffusion of 
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oxygen and nutrients to the muscle, as well as removal of carbon dioxide and metabolic waste.  
This is a vital process in skeletal muscle, as muscle is capable of an extremely high metabolic 
rate that requires both high levels of oxygen and nutrients, as well as the constant removal of 
various forms of waste.  To this end, it has been shown repeatedly in both rodents and humans 
that with a chronic exercise stimulus there is an increase in the number of capillaries in skeletal 
muscle.  This increase has been shown in terms of overall vessel density and in direct 
comparison to the number of myocytes, also known as the capillary-to-fiber ratio (C:F) [8-20].    
It has been suggested that skeletal muscle capillarity may be one of the most important 
adaptations to occur with an exercise stimulus [21-24].  Indeed, genetic differences in angiogenic 
factors and angiogenic expression have been linked to overall exercise capacity, illustrating this 
important connection [9, 25]. 
Skeletal Muscle Angiogenesis 
The vascular bed in-of-itself is capable of dramatic growth and regression in concert with 
the other physiological systems of skeletal muscle.  Exercise training studies in humans, rodents, 
and other animal models have shown repeatedly that there is a dramatic increase in capillarity 
with exercise training in healthy subjects [7, 26, 27], while detraining and chronic disease 
decreases capillarity [14, 28].  There are relatively few studies in skeletal muscle examining what 
controls angiogenesis, especially when compared to tumorigenesis and other systems in vitro.  
Further still, what proteins and molecular mediators trigger the growth and regression of the 
vascular bed in skeletal muscle is still relatively unknown.  However, from what data does exist 
it appears the majority of the angiogenic process in skeletal muscle, and the mediators of this 
process, are very similar to that of other angiogenic systems, like tumorigenesis [26, 29].  
However, unlike in tumorigenesis where hypoxia appears to be the primary trigger, there are a 
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striking number of different stimuli that can trigger angiogenesis in vivo in skeletal muscle.  
While hypoxia has been implicated as one of the largest factors in triggering physiological and 
pathological angiogenesis in skeletal muscle, pH level, physical stretch of the muscle, nerve 
innervation, vibration, and sheer stress have all been implicated in triggering angiogenesis [26, 
27, 30-38].  It is likely a combination of all of these factors, and potentially others, which trigger 
capillary growth in skeletal muscle.  The importance of each may vary depending on an 
additional multitude of factors, including genetics and environment [9, 12]. 
The process of angiogenesis can be broken down into a series of general steps, which will 
be summarized very briefly here (figure 1).  These steps have been intensely studied in 
tumorigenesis as a way to prevent tumor growth and metastasis. The process is first triggered by 
a stimulus (e.g. hypoxia, sheer stress) that prompts angiogenic proteins to be released from the 
tissue being subjected to the stimulus.  Many different tissues and cell types have been shown to 
release angiogenic proteins, including endothelial cells (EC), adipocytes, myocytes, and many 
others [9, 17, 35, 39-47].  An example of one of these angiogenic proteins that is released from a 
variety of  tissues is vascular endothelial growth factor (VEGF) [48-55].  However, there are 
many other angiogenic factors that can play important roles in angiogenesis [38, 56-58].   
Once released angiogenic proteins bind a host of specific and non-specific receptors on 
EC’s and cause the cells to become “activated”.  This can result in two distinct types of vessel 
growth.  In development and tumorigenesis, as well as in a more limited capacity in adult tissue, 
new vessels can be formed from the existing networks via vessel sprouting.  However, in skeletal 
muscle and other adult tissues, it is thought that intussusception, or the splitting of intact vessels, 
may be the primary form of angiogenesis [59, 60].  Interestingly, depending on the stimulus, 
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timing, and amount released, different angiogenic proteins can trigger either or both types of 
angiogenesis [26, 60].   
The process of sprouting starts when the EC’s push into the surrounding tissue [35, 61].  
This requires a complex concert of molecular mediators to break down the basement membrane 
that holds the vessel and surrounding tissue together, while still retaining vessel integrity as the 
ECs sprout a new vessel bud.  The EC’s then migrate along a chemotaxic pathway towards the 
area that is in need of increased vascularity [26, 62-64].  Matrix metalloproteinases (MMPs), 
another group of important angiogenic proteins, play a critical role in breaking down the 
basement membrane and allowing the endothelial cells to migrate forward [58, 65-68].   
As the ECs migrate, the extracellular matrix around the vessel is remodeled and stabilized 
to facilitate the new vessel.  Once the budding vessel has reached the area in need, such as a 
tumor or hypoxic region of skeletal muscle, the endothelial cells narrow and flatten, creating a 
tube where by plasma and red blood cells can travel to the tissues in need.  Finally, the new 
vessel is stabilized and continues to grow as it loops back to the existing vasculature to create a 
new capillary-venule loop [26, 62, 64, 69].  
Intussusception is slightly different than sprouting in that it does not necessarily require 
EC migration.  Instead, it is the process by which a vessel splits to form two new intact vessels.  
This is triggered by many of the same stimuli and angiogenic mediators as sprouting [59, 70-72].   
Intussceptive angiogenesis starts when a pillar forms in the existing vessel from the endothelial 
cells on each side of the vessel.  These pillars eventually reach each other in the middle of the 
vessel, and interendothelial cell contact is made.  This is stabilized by other cells surrounding the 
vessel, like pericytes and myofibroblasts.  Collagen is then deposited and the post expands and 
leads to a new hole occurring through the vessel that is sealed from the surrounding tissue.  This 
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continues to enlarge, splitting the vessel, and the vessel diverges into two new branches.  If this 
continues many times, a single vessel branch can become a mesh-work of new smaller vessels 
covering much more area, effectively and dramatically increasing overall vascular density.  
Intussception has been suggested to be the primary form of angiogenesis that occurs in adult 
tissue [60, 70].  However, both of these processes seem to be occurring in skeletal muscle, yet 
what stimulus triggers which, and why, is yet unknown. 
Physiological Skeletal Muscle Angiogenesis 
Skeletal muscle capillarity has been shown to be a critical component of exercise 
training.  Dr. Peter Wagner and his colleagues have shown repeatedly that oxygen diffusion to 
the myocyte is a critical determinant of overall exercise capacity, and that capillarity plays a 
imperative role in this process [13, 21, 26].  Further, in transgenic mouse models, it has been 
shown that skeletal muscle angiogenesis is directly linked to whole body exercise capacity [18, 
22, 23, 73].  In these studies, animals with more capillaries have increased exercise capacity, and 
the opposite is true for those with decreased capillarity. In humans, skeletal muscle angiogenesis 
occurs with only a week of aerobic exercise, and in rodents it may occur even more quickly [8, 
20].   This adaptation occurs in concert with an increase in expression of positive angiogenic 
factors, and a decrease in anti-angiogenic factors [40, 74].  This differential expression has been 
suggested to serve as a complicated balance and interplay that controls vessel growth.  This idea 
of an angiogenic balance was first introduced by Dr. Judith Folkman almost 30 years ago in 
tumorigenesis [75], but has since been shown to be applicable to a wide range of physiological 
and pathological states, including skeletal muscle [18, 23, 26].  Much work has been done in 
identifying the positive angiogenic factors and their roles in angiogenesis, including potent pro-
growth proteins like fibroblast growth factor (bFGF), insulin like growth factor (IGF), and  
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vascular endothelial growth factor (VEGF).  Of the long list of positive angiogenic factors 
discovered, VEGF has been proven to be one of the most ubiquitous and most potent pro-
angiogenic proteins [9, 48, 49, 51-55, 76].  It has been shown to be essential in many different 
vascular systems, including skeletal muscle [18, 23].   
For some time it was assumed that VEGF and the positive angiogenic proteins were the 
most important factors in controlling vessel growth in all systems, including in skeletal muscle.  
Figure 1: The general steps of sprouting and intussception mediated angiogenesis.  In 
both sprouting and intussception an angiogenic stimulus (e.g. hypoxia, sheer stress, pH) 
triggers the release of angiogenic proteins from those cells and tissues undergoing the 
angiogenic stress.  This tips the balance towards a pro-angiogenic state, and triggers vessel 
growth which is translated through a variety of cell receptors.  “Sprouting” induced vessel 
growth (top of figure 1) requires activation of endothelial cells (EC) (orange circles), the 
breakdown of the basement membrane (dashed lines), proliferation of ECs, EC migration to 
the site in need of new vasculature, and finally stabilization and loop formation.  
“Intussception” induced vessel growth (bottom of figure 1) requires activation of ECs, the 
initiation of an endothelial post that splits the vessel (black circle), proliferation, migration, 
and invasion of ECs to complete the split, and finally stabilization of the new branches.  
More details can be found on pages 14-19 of chapter 2. 
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More recently, anti-angiogenic proteins have been identified as being just as important, or more, 
than the positive angiogenic proteins [57].  Of these, Thrombospondin-1, or TSP-1, has been 
shown to be one of the most critical.  TSP-1 has been shown to be vital in controlling tumor 
angiogenesis [77-81].  The theory of this control, the idea of an angiogenic balance, is best 
explained through the analogy of an automobiles gas and brake pedals.  Positive angiogenic 
factors can be thought of as the “gas-pedal” in angiogenesis, the negative angiogenic factors 
serve as the “brake-pedal”.  It has been suggested that without removal of the “brake”, even if 
the “gas-pedal” is full “on”, angiogenesis cannot occur.  That is, even if pro-angiogenic proteins 
are elevated, if anti-angiogenic proteins are also elevated, angiogenesis will not occur, or occur 
to a diminished extent [57].  This lends a potentially essential role to TSP-1 and other anti-
angiogenic proteins as the primary regulators of angiogenesis.  
This is shown in skeletal muscle by looking at mRNA responses to exercise training in 
the gastrocnemius muscle of rats by two papers [40, 82].  Together these papers show that VEGF 
mRNA increases initially with an exercise stimulus- but so does the mRNA of the important 
angiogenic regulator thrombospondin-1 (TSP-1).  Over a period of 3 days of training, the TSP-1 
mRNA response is reduced, while the VEGF response stays elevated.  This change in mRNA 
expression occurs along the same timeline as the adaptation to exercise, as capillary adaptation 
has been shown to occur in rodents between 3 and 7 days [20].  This has led us and others to 
suggest that TSP-1 may serve as the primary negative angiogenic protein, or “brake”, in skeletal 
muscle angiogenesis. 
Thrombospondin-1: An important regulator of angiogenesis 
There has been a wide array of angiogenic proteins indentified in vivo and in vitro.  Many 
of these proteins are responsible for spurring vessel growth and formation.  As discussed 
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previously, the list of negative angiogenic proteins is relatively smaller, and less well studied, 
especially in the context of skeletal muscle [29].  However, it is now hypothesized that 
angiogenesis is controlled as much by negative, as positive angiogenic, proteins.  Of the growing 
list of negative angiogenic proteins, thrombospondin-1 has been shown to be especially potent in 
several different physiological and pathological conditions. 
TSP-1: A multi-domain, multi-function protein 
TSP-1 is a large, 450kD, homo-trimeric extracellular glyco-protein that has been shown 
to have a wide array of functions [80, 83-85].  TSP-1 belongs to a family which includes six 
different proteins (Thrombospondin-1 through Thrombospondin-6).  TSP-1 was the first 
discovered, now over 40 years ago, for its role in wound healing.  In this setting, it makes up the 
majority of the protein content of stimulated α-granules in platelets [86].  Upon activation, TSP-1 
is released from the α-granules where it helps in platelet aggregation and stabilization.  It wasn’t 
until some years later, in 1990, when Good et. al. first showed that an unknown potent inhibitor 
of tumor vascularity was identical in structure to that of TSP-1, and indeed was TSP-1 [79].  
They further went on to show in vivo that TSP-1 was a potent anti-angiogenic protein, which 
could antagonize the actions of other pro-angiogenic proteins under physiological conditions.  
They suggested that loss of TSP-1 could be a mechanism by which tumors were able to acquire 
and control vascular growth, allowing unbridled expansion [79]. 
TSP-1 has multiple functional domains that gives it the ability to interact with a variety of 
receptors and proteins resulting in a large range of actions throughout many different systems 
[78, 80, 83, 85].   TSP-1 has been shown to have 6 distinct regions, with 4 of these being shown 
to have significant anti-angiogenic action.  This is what is hypothesized to give TSP-1 a greater 
angiogenic capacity over the closely related TSP-2 protein (and the other members of the TSP 
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family), which lacks several of the regions essential to TSP-1’s antiangiogenic capacity [80, 85, 
87].  Of the four regions found to be important in TSP-1’s anti-angiogenic capacity, three are the 
most significant and most well studied.  These are the amino-terminal region, the type I repeats, 
and carboxy-terminal region (figure 2) [85, 88].  This review will focus on these regions, 
however for additional information please see selected sources [78, 80, 83, 85].  
  
 
 
 The first of the important anti-angiogenic regions of TSP-1 is the amino terminal end.  
The amino terminal end has been shown to play a role in attachment, migration, and the 
endocytosis of TSP-1 in endothelial cells [78, 80, 85].  This region interacts with the α3β1 
integrin, which is potentially the most important of several integrins that TSP-1 can bind and 
interact with.   Integrins in of themselves regulate a wide range of functions, from cell 
Figure 2: The important anti-angiogenic regions of TSP-1. 
Representative structure of one of the homotrimeric stalks of TSP-1.  The important regions 
for the regulation of angiogenesis have been highlighted.  A) The different regions of TSP-1 
and their corresponding receptors and ligands.  B) Some of the important functions 
mediated by TSP-1 receptor/ligand binding 
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attachment, to growth and migration, and have been shown to be important in angiogenesis [89-
91].  The association between TSP-1 and α3β1 has been revealed to be significant in some 
cancers, where it has been suggested that the interaction may play a role in tumorigenic potential 
[87, 92, 93].   The association of the amino terminal region with α3β1 has also been shown to 
function in the innate inflammatory response in damaged tissue.  Chronic inflammation has been 
implicated as a potential mediator of the loss in capillarity seen in some diseases, and may have a 
component in which TSP-1 plays a pivotal role (discussed in chapter 5, starting on page 96). 
The amino terminal end of TSP-1 can also interact with the low-density lipoprotein 
receptor-related protein-1 (LRP-1).  This receptor has been shown to be important in 
internalization of TSP-1 and catabolization of the protein [94, 95].  Endocytosis can play an 
important role in the actions of angiogenic proteins, as has been shown in VEGF [54].  
Greenaway and colleagues 2007 showed that binding of VEGF by TSP-1directly, and then 
internalization of the complex by TSP-1’s binding to LRP-1,  could effectively reduce many of 
the markers of angiogenesis- including reducing endothelial cell growth, and an increase in 
apoptosis [94].  This may be an important mechanism by which TSP-1 indirectly controls 
angiogenesis, in concert with its direct effects. 
TSP-1 also contains an important region known as the type I repeat region (type I), or 
thrombospondin repeat region (TSR).  The type I region are an important portion of the stalk of 
the protein, where they are repeated three times in succession.  This region has been the focus of 
much intensive study for its potent ability to control angiogenesis and counter other positive 
angiogenic proteins [84].  This region is only found in TSP-1 and TSP-2, while the other 
members of the family, TSP-3-6, are missing this important region.  The type I region has been 
shown to work in concert with the amino terminal region to bind the afore mentioned α3B1 
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integrins [96].  It has also been shown to be the region that can bind and activate the latent 
antiangiogenic protein transforming growth factor beta (TGF-β) [80, 97-99].  Activation of TGF-
β requires the cleavage of a pro-domain from the full length peptide, resulting in a functional 
protein.  The activation of the TGF-β by TSP-1 requires two specific part of the type I regions, 
the first to bind TGF-β (the WSHWSPW region) and the second to activate it (the RFK region) 
[80, 85].  While there is some conflicting data, TGF-β has been shown repeatedly to be important 
in regulating endothelial cell growth and inhibiting angiogenesis [98-105].    It has been 
suggested that a portion of TSP-1’s anti-angiogenic activity is through its activation of latent 
TGF-β.  While this could certainly play some role in its ability to inhibit endothelial cell growth, 
TSP-1 also has its own inherent anti-angiogenic capacity, independent of TGF-β. 
One of the most well studied of these inherent anti-angiogenic activities, and one of the 
important roles for the type I repeats, is the binding of the CD36 receptor [42, 84, 85, 106-112].  
This interaction, first identified by Dawson et. al. in 1997, has since been shown to be vitally 
important in tumorigenesis [42, 85, 107, 110, 112].  CD36 is a ubiquitously expressed receptor 
with an array of functions.  Of these, it’s initial role was thought to be as a simple fatty acid 
translocation and cholesterol uptake channel, as well as serving as a general multi-ligand 
scavenger receptor [107, 113].  Since these discoveries, it has also been shown repeatedly that 
TSP-1 binds CD36 through the 2
nd
 type I repeat region, an area with a conserved CSVTCG 
amino sequence [84, 85].  This interaction has been shown to decrease endothelial cell growth 
and migration [42].  Additionally, some cancers have been shown to decrease TSP-1 expression, 
and CD36 expression has also been associated with colon cancer prognosis [111].  Jimenez et. al. 
2000 showed that the inhibition of angiogenesis via TSP-1 is deficient in CD36 KO mice [109], 
suggesting a critical role for this interaction.  The same study also showed that TSP-1’s 
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interaction with CD36 is an important pathway in the induction of endothelial cell apoptosis.  
Since this important paper was published, several other studies have provided more evidence that 
TSP-1 is a potent stimulator of apoptosis, and that this could be occurring through the CD36 
receptor [109, 114-117].  This induction of apoptosis is likely an important pathway in the anti-
angiogenic capacity of TSP-1. 
TSP-1 has also been shown to bind VEGF directly, and this seems to also be occurring 
via the type I repeat region.  This binding results in the disruption of VEGF induced cell growth 
and migration, and can ablate the anti-apoptotic actions of VEGF [84, 118, 119].  Further, the 
type I region of TSP-1, in concert with CD36, has been shown to directly bind the VEGF 
receptor Flk-1, also known as VEGFR-2, and both decrease VEGF binding as well as inhibit 
receptor phosphorylation [110, 120, 121].  This interaction may also require the additional TSP-1 
receptor CD47 [122].  VEGFR-2 receptor phosphorylation is critical for the downstream effects 
of the receptor-ligand binding, and provides another mechanism by which TSP-1 is preventing 
vascular growth and potentially inducing regression [76, 123]. 
Since the interaction between TSP-1 and CD36 has been identified as an important part 
of TSP-1’s antiangiogenic capacity, several type I mimetics specifically targeting CD36 have 
been developed to help combat tumorigenesis in human conditions.  One example of these is the 
TSP-1 mimetic ABT-510, developed by Abbot Pharmaceuticals (Figure 3).  ABT-510 is a 
mimetic of the 2
nd
 type I repeat of the TSP-1 stalk (figure 3).  There have been several novel 
substitutions in the amino structure of ABT-510 that result in nanomolar concentrations having 
an approximately 1000-fold increase in anti-angiogenic activity compared to endogenous TSP-1 
in vitro [124].   ABT-510 has been shown to decrease cell growth, decrease cell adhesion, 
counter the actions of VEGF, and induce apoptosis in vitro, as well as decrease tumor size in 
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vivo [108, 116, 121, 125-130].  Several other peptides have also been created, and all have 
shown varying degrees of success, with and without other forms of cancer treatment [130, 131].  
These mimetics are in different stages of clinical trial, and pharmaceutical companies continue to 
try and develop and improve new mimetics [127, 129]. 
 
 
 
The next portion of TSP-1 that has been shown to play a critical role in its anti-
angiogenic activity is the carboxy-terminal region (COO region).  Investigation of this region has 
identified the important TSP-1 receptor CD47, or integrin associated protein (IAP).  CD47, like 
CD36, is a multi-functional protein with a variety of functions, including neutrophil activation, 
cell adhesion, and cell communication [132, 133].  CD47 has also been shown to be important in 
immune system activation, as shown by the susceptibility of the CD47 KO mouse to lethal 
infections [134].  Also like CD36, the TSP-1/ CD47 interaction has been shown to be powerfully 
anti-angiogenic.  The TSP-1/CD47 axis has been shown to be pro-apoptotic, anti-proliferative, 
Figure 3: ABT-510 is a mimetic of the type I repeat region of TSP-1.  ABT-510 is based 
on the GVITRIR amino sequence of the 2
nd
 type I repeat of ABT-510.  With several novel 
additions, ABT-510 has many of the same in vivo actions as endogenous ABT-510.  Both 
the Type I repeats and ABT-510 have been shown to act through the CD36 receptor at the 
CLESH domain. 
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and can interact with the VEGFR2 receptor to block angiogenesis, independent of CD36 [80, 
122, 132, 133, 135-137].  While there have been several different down-stream mechanisms 
suggested for TSP-1/CD47’s anti-angiogenic activities, the work by Dr. Jeff Isenberg and 
colleagues over the last decade have shown that it is likely due to TSP-1s inhibition of nitric 
oxide (NO) [122, 132, 136, 138-140].  Nitric oxide is a small highly reactive molecule that is 
critical in signal transduction in many different physiological processes [141].  NO has been 
shown to be pro-angiogenic and induces endothelial cell growth [139, 142, 143]. TSP-1, acting 
through CD47, has been shown to block the actions of NO through multiple different 
mechanisms, including the inhibition of soluble guanylyl cyclase (sGC), cyclic guanosine 
monophosphate, and cGMP-dependent kinase type I (sGK-1), which are the proteins that 
translate NO into downstream signals within the cell [138-140].  TSP-1/CD47 has also shown to 
alter endothelial intracellular calcium release, which is also important in NO signaling [144].  
Finally, TSP-1/CD47, as mentioned previously, can block VEGFR-2’s downstream actions, 
which include stimulating NO release via endothelial nitric oxide synthase (eNOS) [122].  
Isenberg et al. 2012 suggests that through blocking NO signaling, TSP-1/CD47 could serve as a 
global regulator of cardiovascular function, which includes it’s ant-angiogenic effect [140]. 
Thrombospondin-1 in Skeletal Muscle 
Through these multitude of effects discussed, TSP-1 has been suggested to be critical in 
cancer, tumorigenesis, and in endothelial cells.  Hundreds of studies spanning many different 
types of cancer suggest it is critical in the regulation of tumor growth.  However, the evidence 
for TSP-1’s actions in skeletal muscle capillarity is significantly less.  There is some work to 
suggest that TSP-1 expression increases with muscle damage, which would be in congruence 
with its role in wound healing [145].  Also in skeletal muscle, as discussed previously, TSP-1 
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mRNA has been shown to increase initially with an exercise stimulus.  This has been suggested 
to be an evolutionarily evolved trait that provides an initial “brake” against un-needed vascular 
adaptation.  However, with exercise training, this mRNA response disappears, and as it does, is 
associated with vascular adaptation (capillary growth) [40].  Therefore it was suggested that 
TSP-1 could act as a master controller of angiogenesis in skeletal muscle under physiological 
conditions. 
Perhaps the strongest evidence for the importance of TSP-1 in skeletal muscle comes 
from [22].  In this study, TSP-1 whole-body knock-outs (TSP-1 KO), were shown to have 
dramatically increased skeletal muscle capillarity across three distinct muscle types, as well in 
cardiac tissue [22].  These animals also had significantly increased aerobic exercise capacity, as 
well as increased levels of VEGF.   
Further evidence has shown that in a diabetic insult TSP-1 is increased in skeletal muscle, 
and skeletal muscle capillarity is decreased [146, 147].  This is also true of hind-limb unloading, 
where TSP-1 expression increases as capillarity decreases [14].  Interestingly, we have also 
shown previously that TSP-1 is lower in the plantaris of mice with high-endurance capacity and 
increased skeletal muscle capillarity [9].  Finally, CD47 KO and TSP-1 KO mice have been 
shown to have decreased mitochondrial content, which may be another important component of 
TSP-1’s action on skeletal muscle [148].  Given this relatively small body of work, much still 
needs to be done to determine TSP-1’s role and importance in controlling skeletal muscle 
capillarity under both pathological and physiological conditions. 
Skeletal Muscle Angiogenesis, Chronic Disease, and Chronic Inflammation 
Chronic diseases, such as CVD, CHF, COPD, DM, and obesity, are responsible for the 
largest percentage of deaths in the United States of America (USA) [149].  These diseases are 
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costing the USA billions of dollars a year [150-154].  While each of these disease affects the 
bodies systems in different ways, common between all of them is a chronic systemic level of 
inflammation that is a result of the primary pathology.  This increased chronic systemic 
inflammation in-of-itself can be as significant to a patients mortality and morbidity, and in some 
pathologies is implicated as being as important a risk of death as the primary pathology [155-
165]. 
An additional important co-morbidity in chronic disease, skeletal muscle dysfunction has 
been shown in many of the same diseases as chronic systemic inflammation.  Indeed, skeletal 
muscle dysfunction, as measured by decreased overall muscle force, has been associated with 
decreased life span in congestive heart patients, independent of the primary disease state [166] 
and it has been shown to be a particularly important comorbidity of COPD [10, 28, 167-173].  
Decreased skeletal muscle function has also been shown to be important in a multitude of other 
diseases [165, 166, 174-180], as well as in aging, bed rest, and obesity [181-184].  As discussed 
previously, skeletal muscle capillarity is an important component of overall skeletal muscle 
function, especially endurance capacity.  Skeletal muscle capillarity and angiogenesis has been 
shown to be decreased in these same diseases with global skeletal muscle dysfunction.  Indeed, 
in COPD there has been work to try and identify if a decrease in vascularity is occurring and how 
it contributes to overall disease morbidity [10, 28, 167, 169, 171, 185], however to this point it 
has been mostly correlative in nature. 
It has been suggested that chronic systemic inflammation may be the connection between 
chronic disease and decreased skeletal muscle function and capillarity.  This is due in large part 
to the observation that many of the same diseases that have increased systemic inflammation are 
associated with decreased skeletal muscle capillarity [155, 158, 162, 183, 186].  Acutely 
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inflammation can be pro-angiogenic, but on a chronic systemic level, inflammation has been 
shown to negatively affect skeletal muscle and capillarity [158, 168, 183, 185, 187-189].  
Inflammation, much like angiogenesis, is controlled by a complex interplay between many 
different inflammatory mediators.  One of these mediators that is common between many of 
these diseases is tumor necrosis factor-alpha (TNFα).  TNFα has been shown to be a potent 
stimulator of the inflammatory process in vitro, in vivo, and has been implicated in the chronic 
systemic inflammation seen many chronic pathologies [156, 165, 186, 187, 190-195].  
Interestingly, in COPD those patients with the most severe skeletal muscle dysfunction (muscle 
mass loss) also have the most severely elevated TNFα levels [190]. 
TSP-1 may serve as the axis by which TNFα decreases skeletal muscle capillarity in 
chronic pathology.  It has been shown in vitro that increased TNFα increases TSP-1 in human 
skeletal muscle cells.  This does not occur when the cells were treated with a variety of other 
inflammatory mediators [196], suggesting a TNFα-TSP-1 specific interaction.  This increase of 
TSP-1 was also associated with increases in both of the important TSP-1 receptors CD36 and 
CD47.  Interestingly, it has also been shown that children with defects in the TNFα gene 
resulting in a higher TNFα expression also have increased circulating levels of TSP-1 [197].  
TNFα also has been shown to decrease striated (cardiac and skeletal) muscle mitochondrial 
function and density, potentially by multiple mechanism [186, 198, 199].  This has also been 
shown for TSP-1 [148].  It is plausible that the resultant increase in TSP-1 from increased TNFα 
could be the mechanism by which TNFα decreases mitochondrial density.  Interestingly, TNFα 
KO animals also have increased running capacity [200], which leads to speculation that they 
have increased skeletal muscle function, and perhaps lower TSP-1 levels.  Further, increased 
TSP-1 has actually been shown to increase TNFα in brain epithelial cells [201], which may 
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suggest a feed-forward system.  While this data together does not provide direct evidence for a 
TNFα-TSP-1 axis, it does provide a potential mechanism for the decrease in capillarity seen in 
skeletal muscle of afore mentioned chronic diseases. 
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Abstract 
 
Angiogenesis is an essential process for normal skeletal muscle function. There is a growing 
body of evidence suggesting that thrombospondin-1 (TSP-1), a potent antiangiogenic protein in 
tumorigenesis, is an important regulator of both physiological and pathological skeletal muscle 
angiogenesis.  We tested the hypothesis that chronic exposure to a TSP-1 mimetic (ABT-510), 
which targets the CD36 TSP-1 receptor, would decrease skeletal muscle capillarity as well as 
alter the balance between positive and negative angiogenic proteins under basal conditions.  
Osmotic minipumps with either ABT-510 or vehicle (5% dextrose) were implanted 
subcutaneously in the subscapular region of C57/BL6 mice for 14 days.  When compared to the 
vehicle treated mice, the ABT-510 group had a 20% decrease in capillarity in the superficial 
region of the gastrocnemius (GA), 11% decrease in the plantaris (PLT), and a 35% decrease in 
the soleus (SOL).  ABT-510 also decreased muscle protein expression of vascular endothelial 
growth factor (VEGF) in both the GA (-140%) and SOL (-62%); however there was no change 
in VEGF in the PLT.  Serum VEGF was not altered in ABT-510 treated animals.  Endogenous 
TSP-1 protein expression in all muscles remained unaltered.  Tunnel staining revealed no 
difference in muscle apoptosis between ABT-510 and vehicle treated groups.   These data 
provide evidence that the anti-angiogenic effects of TSP-1 are mediated, at least in part, via the 
CD36 receptor.  It also suggests that under physiologic conditions the TSP-1/CD36 axis plays a 
role in regulating basal skeletal muscle microvessel density.     
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Introduction 
Physiologic angiogenesis and homeostasis of adult blood vessels is a complex process 
that is highly regulated by a balance between positive and negative angiogenic proteins.  While 
there is a substantial body of evidence on the role positive angiogenic factors, such as vascular 
endothelial growth factor (VEGF) [1,2,3], the role of negative angiogenic factors is incomplete 
and poorly understood [4]. 
There are a number of known angiogenic inhibitors, of which thrombospondin-1 (TSP-1) 
is thought to play a prominent role in skeletal muscle angiogenesis [4].  TSP-1 is a large (450kD) 
extracellular protein that has a wide array of functions [5].  First discovered for its role in wound 
healing and platelet activation, it also has important roles in apoptosis, inflammation, nitric oxide 
signaling, and inhibition of positive angiogenic proteins [6,7,8,9,10].  Acting through CD36 (one 
of its receptors), TSP-1 has been shown to prevent endothelial cell adhesion, growth, and 
migration, as well as increase apoptosis [11,12,13].  The anti-angiogenic effects of TSP-1 in 
cancer pathology are well established.  For example, a reduction in TSP-1 has been shown to 
increase tumor vessel growth, whereas pharmacological administration of several different TSP-
1 mimetics has helped decrease tumor size and disease progression in animal models 
[14,15,16,17].   
Under physiologic conditions, TSP-1 expression has been shown to be responsive to 
exercise [18,19], which suggests that TSP-1 may play a role in regulating exercise-induced 
skeletal muscle angiogenesis.  TSP-1 KO mice have elevated skeletal muscle capillarity 
compared to wild-type mice, suggesting a critical role for TSP-1 in the physiological 
maintenance of capillaries [4].  Evidence in rats also shows that hindlimb unloading increases 
TSP-1 in association with decreases in skeletal muscle capillarity [3].  Recently, TSP-1 and it’s 
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receptor CD47 have also been suggested to play a pivotal role in skeletal muscle mitochondrial 
biogenesis, and therefore it is likely to be important in overall skeletal muscle function and 
adaptation to exercise stress [20]. 
Given the growing data implicating that importance of TSP-1 as a key angiogenic 
regulator in skeletal muscle, we sought to determine the consequences of chronically stimulating 
the TSP-1 pathway using ABT-510.  ABT-510 is a mimetic of the conserved type I repeat region 
of TSP-1 which has been shown previously to inhibit angiogenesis through the CD36 receptor 
[12,13,21].  ABT-510 has been synthesized to have a longer half life in circulation than the 
native type I repeats of TSP-1 which allows for increased chronic stimulation of the TSP-1/CD36 
pathway [22].  ABT-510 has been shown to be a potent inhibitor of vascular growth in 
tumorigenesis both in vitro and in vivo [15,23,24,25,26,27,28], which has been attributed to its 
binding to the CD36 receptor.  Using this peptide we aimed to examine whether increased 
stimulation of the CD36 arm of the TSP-1 pathway affected skeletal muscle structure and 
function.  Given that TSP-1 is a negative angiogenic regulator, we hypothesized that mice 
subjected to the ABT-510 would have lower skeletal muscle capillarity, mirrored by an altered 
balance between positive and negative angiogenic proteins. 
Methods 
Animals 
This study used 10-12 week old male C57BL/6 mice purchased from Jackson 
Laboratories (Strain no. 000664, C57BL/6J, Bar Harbor, ME).  Mice were randomly selected to 
be placed in two groups (control, n=8; experimental n=8).  All procedures that involved animals 
were approved by the West Virginia University Institutional Animal Care and Use Committee. 
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Osmotic Pump Drug Delivery 
The TSP-1 mimetic ABT-510 was generously provided by Abbott (Abbott, IL).  This 
compound was chosen for use in this study based on previous and preliminary work showing its 
effectiveness in decreasing capillarity in tumors, both in vitro and in vivo [15,22,23,24,25,29,30].  
ABT-510 was dissolved in 5% dextrose (vehicle) over a 48 hour period to ensure the compound 
was fully dissolved, and then inserted into mini-osmotic pumps (Model 1002, Alzet Osmotic 
Pumps, Cupertino, CA,).  Pumps were filled with either the drug or vehicle solution 24 hours in 
advance of implantation as per manufacture instructions.   We delivered the maximum 
concentration of 30 mg/kg/day based on the maximum pump capacity (100µL), the mass of the 
animals, and the solubility of the drug (ABT-510 solubility curves [22]).  Pumps were surgically 
inserted (flow-moderator first) subcutaneously in the scapular region while the mice were under 
anesthesia (2% isoflurane).  The surgical site was disinfected with iodine and closed using 
sutures.  Animals were then housed individually and observed daily for the remainder of the 
study for pain or distress.  Pumps remained in the animals for 14 days, after which they were 
sacrificed and tissue/organ samples were collected and stored at -80° for later analysis.   
Morphometry   
Hindlimb skeletal muscle was surgically excised and frozen in isopentane cooled by liquid 
nitrogen.  Frozen tissue was cut using a -20°C cyromicrotome (Jung-Reichert Cryocut 1800: 
Cambridge Instruments, Germany) to yield 10µm transverse sections.  Great care was taken to 
ensure the cryosectioned muscles were cut along the transverse plane.  Sections were stained for 
dipeptidly-peptidase IV (DPP IV) and alkaline phosphatase (AP) following the method of Lojda 
(1979), as applied to skeletal muscle tissue [31,32].  A light microscope (Zeiss primo star, Zeiss, 
Oberkochen, Germany) was used to digitally acquire (Axiocam IC c3, Axiovision 4.8.2.0, Zeiss, 
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Oberkochen, Germany) 20X images of the gastrocnemius, plantaris, and soleus.  Capillary and 
myofiber counting was performed by a single individual blinded to group identification.  For the 
gastrocnemius muscle, we obtained images in a checkerboard fashion across the entire muscle, 
thus both superficial and deep regions within the gastrocnemius could be included in the 
analysis.  For the plantaris and soleus muscles, respectively, the entire muscle was imaged and 
analyzed.  Counting was performed by visualization from acquired images using a custom 
program in MATLAB (version 7.0.0.27, The Mathworks, MA, USA) allowing the operator to 
visually mark and count the capillaries and fibers on each image.  Capillary-to-fiber ratio (C:F, 
number of capillaries/number muscle fibers), capillary density (CD, number of capillaries/mm
2
 
muscle fiber area), and fiber cross sectional area (FCSA) were separately calculated for the 
gastrocnemius (GA), soleus (SOL), and plantaris (PLT) (n= 33-101 images/muscle/group). 
Protein Analysis   
GA, SOL, and PLT muscles from each group were excised and flash frozen in liquid 
nitrogen.  They were then separately homogenized in a lysis buffer containing 50 mM Tris/HCl 
(pH 7.4), 150mM NaCl, 0.5% Triton X-100, and protease inhibitors (Complete Tablet, Roche 
Applied Science, Indianapolis, IN).  Homogenates were centrifuged at 4°C, at 8,000g for 10 
minutes, and supernatants removed and placed in new tubes.  Blood samples were obtained from 
the heart and allowed to coagulate on ice.  They were then centrifuged at 3000 g for 10 minutes 
and flash frozen in liquid nitrogen.    Total protein was measured by bradford assay (#23236 
Pierce Coomassie Plus Protein Assay Kit, Thermo Scientific, Rockford, IL).   
Quantification of VEGF was made from a total of 100μg of protein using a commercially 
available ELISA kit according to the manufactures instructions (# MMV00, R&D Systems, 
Minneapolis, MN, USA).  Quantification of VEGFR-2 and P-VEGFR-2 were made from a total 
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of 100μg of protein using a commercially available ELISA kit according to the manufactures 
instructions (# 7335S, #7340S, Cell Signaling, Danvers, MA, USA).  TSP-1 and CD36 were 
analyzed via western blot.  In brief, samples were separated on a 3-8% SDS-PAGE (NuPAGE 
Novex 3-8% Tris-Acetate Midi Gel, Invitrogen, Burlington, ON, Canada) and blotted onto a 0.45 
μm nitrocellulose membrane (Pierce nitrocellulose membrane, Thermo Scientific, Rockford, IL).  
After blocking with 5% fat-free milk, membranes were probed using antibodies against TSP-1 
(1:1000, clone A6.1, #399300, Invitrogen, Burlington, ON, Canada), β-tubulin (1:1000, #2148, 
Cell Signaling), CD36 (1:250 #552544, BD Pharmingen, Franklin Lakes, NJ, USA), secondary 
HRP-conjugated anti-mouse (1:1000,  #p0260, Dako, GE Healthcare, Piscataway, NJ) and 
secondary HRP-conjugated anti-rabbit (1:1000,  #p0217, Dako).  Proteins were visualized using 
chemiluminescence detection (Pierce ECL, Thermo Scientific, Rockford, IL) and digitally 
imaged (G:BOX Gel imager, Syngene, Cambridge, UK) using Genesnap software (Ver. 7.01, 
Syngene, Cambridge, UK). Equal protein loading was verified by immunodetection of β-tubulin 
as our loading control.  Quantification of protein expression levels were carried out using NIH 
Image J Software (v1.62) and expressed as densitometric arbitrary units (AU). 
Apoptosis 
Nuclei exhibiting apoptotic changes were identified by TdT-mediated dUTP nick end 
labeling (TUNEL) according to the manufacturer’s recommendations (Roche Molecular 
Biochemicals, Pleasanton, CA).  Briefly, muscle cross sections were cut on a cryostat (10µm) 
and fixed in 4% paraformaldehyde at room temperature, blocked in 3% H2O2 in 100% methanol 
at room temperature, and permeabilized in 0.1% Triton X and 0.1% sodium citrate. TUNEL 
reaction mix was added in a 1:7.5 dilution, and the sections were incubated at 37°C for 1 h. 
Sections were reacted with fluorescein antibody for 30 min at 37°C, and substrate was added for 
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color development. To control for false-positives, samples were then counter stained by DAPI 
staining to identify the nucleus. TUNEL staining was performed using a fluorescein TUNEL kit 
at 1:7.5 dilution as recommended by the manufacturer (Roche Molecular Biochemicals, 
Pleasanton, CA).  Positive nuclei were counted, and at high power (x400), it was determined 
whether they were associated with the myofiber or with the interstitial space. The number of 
positive nuclei is expressed per whole muscle section.   Positive controls were created using a 
DNase treatment of 1 serial section (# AM1906, DNA-free, Ambion, Austin, TX).  Negative 
controls were created by staining 1 serial section only for DAPI without TUNEL staining.  This 
resulted in each sample containing 1 negative, 1 positive, and 2 experimental sections per slide. 
Statistics 
All data are presented as means +/- SEM.  To examine body mass, organ masses, muscle 
capillarity and molecular responses we used a student’s T-test.  A repeated measures ANOVA 
was used to analyze the maximal running test.   An alpha level at P < 0.05 was selected for 
statistical significance. 
 
Results 
Exercise Testing and Morphometry 
Body and Muscle Mass: There was no significant difference in the absolute body or 
individual hindlimb muscle masses between ABT-510 (mimetic) and vehicle treated groups 
(Table 1).  Heart and skeletal muscle normalized to body mass were not different between the 
groups (Table 1). . 
Maximal Running Test: There was no difference in maximal running speed between 
vehicle and mimetic treated animals pre- or post-treatment. 
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Morphometry:  In the superficial region of the gastrocnemius (GA) muscle there was a 
20% decrease in C:F (P<0.05) and a similar trend in CD (25% decrease, P=0.055) in the mimetic 
group compared to vehicle (Figure 1 & 2).  There was no statistical difference in C:F of the deep 
portion of the GA between groups, however there was a significant 25% decrease in CD 
(P<0.05).  FCSA was not significantly different between groups in either portions of the GA. 
In the plantaris (PLT) muscle, there was a 11% decrease in the C:F in the PLT in the 
mimetic group compared to vehicle (P<0.05) (Figure 3).  There was no difference in CD or 
FCSA in the PLT. 
In the soleus (SOL) muscle, there was a 35% decrease in the C:F in the SOL in the 
mimetic group compared to vehicle (P<0.01) (Figure 3).  There was no difference in CD 
(P=0.08) or FCSA (P=0.09). 
 
Endogenous VEGF, VEGFR-2, p-VEGFR-2, TSP-1, and CD36 Levels 
Skeletal muscle VEGF protein expression was decreased by 147% and 62% in the GA 
and SOL respectively (P<0.05, Figure 4).  In contrast, no significant change in VEGF protein 
expression was seen in the in the PLT.  Serum VEGF levels were unchanged between ABT-510 
and vehicle treated animals. 
Total VEGFR-2 and phorphylated-VEGFR-2 (p-VEGFR-2) levels were also assessed in 
the GA. There was no difference in total VEGFR-2 levels, p-VEGFR-2 levels, or a ratio of 
VEGF-R2/p-VEGF-R2 between ABT-510 and vehicle treated mice (data not shown). 
Endogenous TSP-1:  protein expression of endogenous TSP-1 was not significantly 
different in any of the muscles analyzed (SOL, PLT, GA) between the treated groups (data not 
shown). 
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CD36 levels:  There was no difference in the receptor levels of CD36 in the GA as 
assessed by western blot (data not shown). 
 
Apoptosis 
Apoptosis was assessed using TUNEL staining for fragmented DNA.  There was no 
difference in the number of TUNEL positive nuclei in any of the muscles between the two 
treated groups (Figure 5). 
 
Discussion 
The main finding of this study is that chronic exposure to the TSP-1 mimetic ABT-510 
significantly decreases skeletal muscle capillarity (Figure 1).  To our knowledge, these are the 
first data to show that chronic stimulation of the TSP-1/CD36 pathway in healthy mammals 
results in decreased skeletal muscle capillarity.  These data are consistent with the anti-
angiogenic function of TSP-1 and, more importantly, support the notion that TSP-1 through its 
CD36 receptor is a critical regulator of skeletal muscle capillarity under physiologic conditions.  
Indeed, when coupled with the previous observation that loss of TSP-1 increases skeletal muscle 
capillarity (25) these data provide evidence that the actions of TSP-1 directly influence 
homeostatic maintenance and/or development of skeletal muscle microvessels.     
 
Skeletal muscle capillarity is decreased in mimetic treated mice. 
TSP-1 has been shown previously to be important in maintaining skeletal muscle 
capillarity, where TSP-1 KO mice have approximately 2 fold the number of capillaries as WT 
controls [33].  Further, TSP-1 has been shown to be important in maintaining capillarity with 
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hindlimb unloading [34].  In this manuscript we build upon this small body of evidence for the 
importance of TSP-1 in the context of the basal regulation of angiogenesis.  
The actions of TSP-1 are complex and multifunctional, due in large part to the diversity 
of receptors it binds, such as lipoprotein receptor-related protein 1 (LRP-1), CD47, and CD36 
[11,35].  Our use of the TSP-1 mimetic ABT-510, which is a potent CD36 binding peptide, 
resulted in a decrease in capillarity across three different distinct skeletal muscles.  This suggests 
that TSP-1s anti-angiogenic properties in skeletal muscle involve a CD36 mediated mechanism.  
Indeed, this is consistent with the physiological activity of CD36 where TSP-1 binding to CD36 
has been shown to be anti-proliferative, anti-angiogenic, and pro-apoptotic [12].  The importance 
of the TSP1/CD36 pathway has been proven in tumorigenesis, where down regulation of TSP-1 
and its binding to CD36 results in a pro-tumorigenesis environment and increase in tumor size 
[14,36,37,38].  Here we show similar actions in skeletal muscle under physiological conditions.  
This suggests a putative role for TSP-1 in decreasing vascularity across multiple tissues, and not 
just in tumors. 
Given these findings, it is tempting to speculate that elevated skeletal muscle TSP-1 may 
serve as a biomarker for skeletal muscle dysfunction associated with several chronic conditions 
known to result in muscle capillary rarefaction, such as that found in diabetes [39,40], and 
chronic heart and lung disease [41].  It may even be that therapeutic interventions to limit basal 
TSP-1 expression and/or reduce circulating levels of TSP-1 could be clinically exploited to 
attenuate the decrements in skeletal muscle function often accompanying these diseases. 
 
Chronic stimulation of the TSP1 / CD36 pathway decreases VEGF.   
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 It has been shown previously that TSP-1 can counter the effects of VEGF by multiple 
mechanisms; including interacting directly with VEGF protein and disrupting its actions at the 
receptor level [42,43,44,45,46].  For example, TSP-1 has been suggested to bind VEGF via its 
type I repeat region (or 3TSR).  Once bound the protein heterodimer is internalized by the 
scavenger receptor low density lipoprotein receptor-related protein 1 (LRP-1).  Here, we show 
that a chronic administration of ABT-510 (a TSP-1 type I repeat mimetic), results in a decrease 
in total VEGF protein in both the gastrocnemius muscle and the soleus muscle, along with the 
decrease in capillarity.  It is unclear why a similar decrease in VEGF protein was not seen in the 
PLT which also showed decreased capillarity, nevertheless these data support previous studies 
suggesting that TSP-1 may be binding and sequestering VEGF – resulting eventually in 
internalization and biological inactivation [42,43,44,45,46].  Explanations for the reduction in 
VEGF may also involve suppression of VEGF production and/or VEGF signaling.  For example, 
there is a growing body of evidence showing that the internalization of the VEGF/VEGFR-2 
complex by endocytosis results in downstream activation of several different signaling pathways 
[47].  There is also evidence that both CD36 and CD47 can associate with VEGFR-2, and when 
TSP-1 is present this association can prevent the VEGF ligand binding to its receptor, as well as 
inducing receptor dephosphorylation and preventing dimerization [13,21,48,49].  In this way, 
TSP-1 could prevent activation and/or endocytosis of the VEGF receptor, blocking yet another 
biologically active arm of VEGF/VEGF-R complex.  Regardless of the mechanism, our data 
supports the notion that TSP-1 likely plays a regulatory role involving VEGF, thereby enhancing 
its already potent inherent anti-angiogenic capacity. 
In endothelial cells, TSP-1 can also disrupt VEGF actions at the receptor level by 
dephosphorylating the important receptor VEGFR-2 (Flk-1) [50].  TSP-1 can disrupt VEGFR-2 
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activation by binding the CLESH region of CD36, triggering a cascade of events which results in 
direct binding of VEGFR-2, and a resultant decrease in tyrosine phosphorylation of VEGFR-2 
[12,13,21].  This includes dephosphorylating the important tyrosine 1175 region; which is 
critical to initiate downstream VEGF signaling.  While it has also been shown previously that 
ABT-510 significantly decreases the amount and phosphorylation status of VEGFR-2 in 
endothelial cells in vitro [24,51], in vivo we found no significant change in the phosphorylation 
levels of tyrosine 1175 of VEGFR-2.  Given that the mimetic is a type I repeat, and that total 
VEGF protein levels were decreased, we were surprised that VEGFR-2 phosphorylation was also 
not decreased.  But, because we only have one time point, it could be that levels of 
phosphorylation were lower earlier in the chronic dosage but by the end of the study returned to 
normal levels.  While ABT-510 has been shown to decrease VEGFR-2 phosphorylation in 
tumors [24], it may be that this response is different in skeletal muscle under physiological 
conditions.  It could also be that phosphorylation status in vivo is not lowered by endogenous 
TSP-1 (or the addition of a mimetic), rather TSP-1 limits or prevents an increase in 
phosphorylation levels with a VEGF stimulus.  This is yet to be elucidated. 
Administration of ABT-510 did not significantly alter endogenous levels of TSP-1 in 
skeletal muscle, indicating that there was no feedback response from the mimetic binding to 
CD36 to alter endogenous TSP-1 levels in skeletal muscle.  However, the reduction of skeletal 
muscle VEGF protein levels in association with the mimetic adds support to the idea that 
physiologic angiogenesis is controlled by a balance between both positive and negative 
angiogenic factors, particularly VEGF and TSP-1.  It would have been interesting to deliver a 
higher dose of ABT-510 (> 30 ug/kg/day) which may have resulted in greater reductions in 
muscle VEGF and capillarity; however the dose used was the maximum we could deliver using 
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the small pumps suitable for mice and the 2-week duration we sought.   Although shorter 
duration would allow greater concentrations of drug delivery, we opted to deliver the drug for 14 
days to ensure that vascular remodeling would have sufficient time to occur.  It could be 
hypothesized that tipping the scale towards an anti-angiogenic state (stimulated by the presence 
of ABT-510) would result in a response of positive angiogenic factors to counter this challenge.  
However, at least with respect to VEGF this was not the case.  A decrease in VEGF and no 
change in endogenous TSP-1 suggests that the muscle has been pushed towards an anti-
angiogenic phenotype. 
Regardless of mechanism, these data show that the altered angiogenic state of the skeletal 
muscle can be driven by an increase in a TSP-1 mimetic.  The resulting decrease in capillarity 
establishes the importance of TSP-1/ CD36 pathway in maintaining and regulating basal skeletal 
muscle microvessel density.  
 
Skeletal muscle and endothelial apoptotic levels do not differ between groups.  
In addition to its anti-angiogenic properties, TSP-1 is also been known to promote 
apoptosis [6,52,53,54,55,56,57,58].  TSP-1 is known to induce apoptosis through the CD36 
pathway, as shown in previous studies, including those using ABT-510 [5,24,59].  Endothelial 
apoptosis is a natural mechanism by which capillary regression occurs [60,61,62,63], and has 
been shown to be central in muscle atrophy during some pathologies, aging, and disuse 
[64,65,66,67,68].  Knowing this, we performed TUNEL staining to look at end stage apoptosis 
(DNA fragmentation) in all three of the excised muscles.  Surprisingly, we found no evidence of 
apoptosis in any of the muscles, either myocyte or endothelial.  The reason for this remains 
unclear.  This is, however, the first in vivo report of ABT-510s affects on skeletal muscle and it 
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could be that ABT-510 is not sufficient to induce myocyte apoptosis in skeletal muscle under 
these conditions.  Indeed, much of the work with TSP-1 and apoptosis pertains to cancer models 
(e.g. tumorigenesis), endothelial cells, and is typically done in vitro.  It is possible that TSP-1 is 
not as potent a pro-apoptotic protein in skeletal muscle as that seen in endothelial cells or tumors.  
This is supported by the finding that there was no change in muscle fiber cross-sectional area 
(Figures 2 and 3).  Whether or not the ABT-510, or the TSP-1/CD36 axis, alters in vivo skeletal 
muscle myocyte apoptosis will require further study. 
However, this does not explain why we saw no endothelial cell apoptosis.  As mentioned 
previously, our study only examines one time point.  It is possible that apoptosis occurred at an 
earlier time point than our assessment at the 14 day time point.  Indeed, it has been shown 
previously that hindlimb unloading results in capillary loss in as little as 5 days [34].  If changes 
in endothelial cell number, and therefore total vasculature, are occurring by 5-7 days it may not 
be surprising that evidence of apoptosis has been lost by the end of the study (14 days).  That is, 
perhaps apoptosis has already occurred, the cells cleared from the tissue, and the architecture of 
the vascular network at 14 days has already returned to a new steady state condition absent of 
apoptotic nuclei. We have yet to elucidate this and more experimentation is needed to determine 
exactly when apoptosis and regression is occurring. 
 
Summary 
 In conclusion, we provide evidence for the importance of TSP-1/CD36 pathway in 
regulating basal skeletal muscle capillarity by showing that a chronic dosage of a TSP-1 mimetic 
for the CD36 pathway decreases skeletal muscle capillarity and VEGF expression.  We did not 
find any differences in the VEGFR-2 expression or its phosphorylation status, nor was there 
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greater skeletal muscle apoptosis.  These data show that, despite the multifunctional effects of 
TSP-1 and its CD36 receptor, the primary consequence of elevating circulating TSP-1 (i.e. using 
a TSP-1 mimetic targeted to its CD36 receptor) relates to its anti-angiogenic function.  These 
data may be useful in exploring therapeutic interventions for individuals with skeletal muscle 
dysfunction resulting from capillary regression.  
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Tables 
Table 1: Muscle and Body Masses 
  Vehicle ABT-510 
Body Mass (g) 27.5 ±1.23 27.1 ±0.87 
GA (mg) 136.8 ±4.56 140.8 ±4.09 
PLT (mg) 19.7 ±0.90 19.0 ± 0.53 
SOL (mg) 7.7 ±0.47 7.8 ±.048 
HRT (mg) 123.5 ±5.76 134.3 ±5.82 
GA/BM (mg/g) 5.0 ±0.07 5.2 ±0.12 
PLT/BM (mg/g) 0.72 ±0.04 0.70 ±0.02 
SOL/BM (mg/g) 0.29 ±0.01 0.28 ±0.01 
HRT/BM (mg/g) 4.4 ±0.26 5.0 ±0.17 
Values: Mean ± Standard Error.  * P= 0.05 
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Figure Legends 
 
Figure 1: Representative figures of the histology sections.  A) Superficial Gastrocnemius Muscle  
B) Deep Gastrocnemius Muscle C) Plantaris Muscle, D) Soleus Muscle.  
 
Figure 2: Superficial gastrocnemius capillarity, but not deep, is decreased in the ABT-510 
group.   
Chronic administration of ABT-510 30mg/kg/day decreased capillary to fiber ratio (C:F) and 
capillary density (CD) in the superficial gastrocnemius (GA).  Despite a similar trend, no 
significant changes in capillarity were seen in the deep GA.  There was no change in fiber cross 
sectional area in either the deep or superficial portions of the GA. *= P<0.05 
 
Figure 3: Plantaris and soleus capillarity is decreased in the ABT-510 group.   
Chronic administration of ABT-510 30mg/kg/day decreased capillary to fiber ratio (C:F) in the 
plantaris muscle (PLT) but did not decrease capillary density (CD).  ABT-510 decreased 
capillary to fiber ratio (C:F) and capillary density (CD) in the soleus (SOL).  There was no 
change in fiber cross sectional area in either the PLT or SOL muscle.  *= P<0.05 
 
Figure 4: Skeletal muscle VEGF protein content is decreased in the ABT-510 group, but not 
serum levels.   
Chronic administration of the mimetic (ABT-510 30mg/kg/day) decreased VEGF protein in the 
GA, and SOL muscles of C57/BLK6 mice.   There was no change in the PLT muscle or in 
Serum levels.  *= P<0.05 
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Figure 5:  There is no difference in skeletal muscle apoptosis between the mimetic and control 
groups 
TUNEL staining shows that chronic administration of the mimetic (ABT-510 30mg/kg/day) did 
not increase or decrease skeletal muscle apoptosis in any of the muscles tested.  Representative 
GA samples, PLT and SOL data not shown.  A) Representative mimetic GA B) Representative 
positive control mimetic GA C) Representative control GA D) Representative positive control 
vehicle GA. 
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Abstract (195 words): 
Thrombospondin-1 (TSP-1) is critical angiogenic mediator in skeletal muscle and recently has 
been shown to be a regulator of mitochondrial biogenesis, however its role in controlling 
mitochondrial function remains unknown. In this study we hypothesized that the TSP-1 mimetic 
(ABT-510) would decrease mitochondrial electron transport enzyme (mETC) activity and 
decrease skeletal muscle function, while an opposite effect was expected for whole-body TSP-1 
KO mice.  We studied 3 month old WT and TSP-1 KO mice.  WT mice were given the TSP-1 
mimetic systemically using osmotic mini pumps for 14 days.  We measured both kinetic and 
fatigue characteristics of the soleus (SOL) and extensor digitorum longus (EDL) muscles of all 
groups.  We found that mimetic treated mice had 29% and 42% decrease in mETC complex III 
and IV activity, respectively, with a similar (albeit not statistically significant) 20% decreased 
complex I activity (p<0.07).  TSP-1 KO mice showed an opposite trend for an increase in 
complex IV (p<0.07).  Surprisingly, we saw no change in either muscle kinetic or fatigue 
characteristics in either the SOL or EDL muscle.  This work suggests, in addition to its anti-
angiogenic effects, TSP-1 can also influence mitochondrial respiration activity through its CD36 
receptor pathway. 
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Introduction 
Thrombospondin-1 (TSP-1) is a large 450kD extracellular protein that has a wide array of 
functions.  First discovered for its role in wound healing and platelet activation, TSP-1 has also 
been shown to influence inflammation, nitric oxide signaling, and matrix remodeling [1-5].  
Acting through the CD36 receptor, TSP-1 has proven to prevent endothelial cell adhesion, 
growth, and migration as well as potently regulate in vivo capillarity in a variety of models [6-
10].  The anti-angiogenic effects of TSP-1 in cancer pathology are well established, and the 
evidence continues to mount for its pivotal role in skeletal muscle [9-12].   
TSP-1 has also recently been shown to decrease mitochondrial biogenesis in young 
animals [13].  The mechanism by which TSP-1 controls mitochondrial biogenesis and density is 
poorly understood, but may be linked to nitric oxide signaling [4, 13-16]. Another mechanism 
may also involve TSP-1s inhibition of angiogenesis, particularly in skeletal muscle [9, 10, 17].  
Indeed, reduced skeletal muscle capillarity could limit the supply of oxygen and substrate 
necessary for mitochondria to produce ATP essential for contractile function and induce a 
reduction in mitochondrial density [18, 19].   
Acting through the CD36 receptor TSP-1 has also been shown to promote apoptosis, [1, 
20-24], however the role of TSP-1 and CD36 in myocyte and endothelial cell apoptosis in vivo is 
not well characterized.  We have shown previously that a 14 day chronic exposure to the TSP-1 
mimetic ABT-510 did not result in apoptosis in skeletal muscle [9].  ABT-510 is a mimetic of 
the conserved type I repeat region of TSP-1 [25] that has been shown previously to inhibit 
angiogenesis through the CD36 pathway [7, 8, 26] and prevent vascular growth through its pro-
apoptotic actions  [27-33].  Nevertheless, we found no signs of apoptosis in skeletal muscle 
following 14 days of treatment with ABT-510, leading to the speculation that apoptosis might 
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have occurred at an earlier time point with this treatment.  If true, apoptotic cells could have been 
removed and the tissue could have been devoid of DNA fragmentation or apoptotic tissue at the 
14-day time point.  Given that apoptosis is the most likely mechanism by which capillaries losses 
are expected [34-37], we hypothesized that skeletal muscle apoptosis would be evident in mice 
with 3 and/or 7 days treatment with ABT-510.   
Given that we have previously shown that a TSP-1 mimetic decreases capillarity, 
whereas whole body loss of TSP-1 increases skeletal muscle capillarity and improves whole 
body exercise [9, 10], we evaluated the effect of a CD36-mediated TSP-1 mimetic on skeletal 
muscle mitochondrial function.  We hypothesized that TSP-1 activation of the CD36 pathway 
could significantly influence mitochondrial activity and therefore increase mitochondrial electron 
transport chain (ETC) enzyme activity in the TSP-1 KO animals, while a decrease in ETC 
activity and muscle function would occur in mice subjected to a chronic treatment with the TSP-
1 mimetic ABT-510.    
 
Materials and Methods: 
Animals 
This study used 10-12 week old male C57BL/6 (WT) and TSP-1 knockout (KO) mice 
purchased from Jackson Laboratories (Strain no. 000664 and 006141, respectively, Bar Harbor, 
ME).  Four groups of WT mice were subject to either 3 or 7 days of mimetic (3-ABT or 7-ABT) 
or vehicle control (3-CON or 7-CON) (3 Day: N=4/group; 7 Day: N=10/group).  Another group 
of WT mice were given a 14 day chronic dose of the mimetic (14-ABT) or vehicle control (14-
CON) (N=8/group).  The final group consisted of untreated TSP-1 KO and WT mice (N=7-
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8/group).   All procedures were approved by the West Virginia University Institutional Animal 
Care and Use Committee. 
Osmotic Pump Drug Delivery 
The TSP-1 mimetic ABT-510 was generously provided by Abbott (Abbott, IL).  This 
compound was chosen for use in this study based on previous work showing its effectiveness in 
decreasing capillarity in tumors, both in vitro and in vivo [25, 27-30, 38, 39].  ABT-510 was 
dissolved in 5% dextrose (vehicle) over a 48 hour period at 4 degrees to ensure the compound 
was fully dissolved, and then inserted into mini-osmotic pumps (Model 1002, Alzet Osmotic 
Pumps, Cupertino, CA).  Pumps were filled with either the drug or vehicle solution 24 hours in 
advance of implantation as per manufacture instructions.   We delivered the maximum 
concentration of 30 mg/kg/day based on the maximum pump capacity (100µL), the mass of the 
animals, and the solubility of the drug (ABT-510 solubility curves [25]).  Pumps were surgically 
inserted (flow-moderator first) subcutaneously in the scapular region while the mice were under 
anesthesia (2% isoflurane).  The surgical site was disinfected with iodine and closed using 
sutures.  Animals were then housed individually and observed daily for the remainder of the 
study for pain or distress.  Pumps remained in the animals for either 3 days (3-CON, 3-ABT), 7 
days (7-CON, 7-ABT) or 14 days, (14-CON, 14-ABT) depending on the randomly assigned 
treatment group, after which they were sacrificed and tissue/organ samples were collected and 
stored at -80° for analysis. 
 Ex vivo muscle function 
Muscle contractile properties were examined in the extensor digitorum longus (EDL) and 
soleus (SOL) muscles.  Parameters analyzed from isometric contractions included peak isometric 
twitch force, time to peak twitch tension, ½ relaxation time of twitch contraction, and peak 
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isometric tetanic force, as previously described [40].  Isometric contractions were stimulated in 
muscles ex vivo using a bi-phase stimulator at a stimulation frequency of 120Hz for EDL 
muscles and 80Hz for soleus muscles, a stimulation current of 28 Volts and lasting 500ms.  
Muscle fatigue was analyzed using a repeated stimulation protocol lasting 6 minutes and 
consisting of repeated 40Hz tetanic trains that occurred once every second and lasted 330 ms 
[41].  Muscle length was adjusted to obtain the maximal twitch response (i.e. L0).  Muscles were 
stimulated in an oxygenated ringers solution composed of: 100mM NaCl, 4.7mM KCl, 3.4mM 
CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4, 25mM HEPES, and 5.5mM D-glucose.  Three twitch 
contractions and three tetanic contractions were performed all separated by 2 minutes.  
Following isometric contractions, the muscles remained in oxygenated ringers for 5 minutes 
prior to the repeated stimulation fatigue protocol.  The fatigue index was calculated as the 
difference in force from the first contraction and every 10
th
 subsequent contraction, and plotted 
as a fatigue curve.  Muscles were flash frozen in isopentane cooled to the temperature of liquid 
nitrogen and stored at -80°C.   Muscle fiber cross sectional area (FCSA) was calculated by 
dividing the muscle mass by the product of the muscle density coefficient (1.06g
.
cm
3
), muscle 
optimal length (L0), and the fiber length coefficient (EDL=0.45, SOL=0.69).  This whole muscle 
CSA value was used to calculate specific force (i.e. absolute force mN
.
muscle CSA
-1
) [42, 43]. 
Cell Death 
 Total cell death of skeletal muscle homogenate was analyzed from 200ug of tissue using 
a commercially available cell death ELISA kit (cat # 11774425001, Roche, Indianapolis, IN, 
USA). 
Mitochondrial Assessments 
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ETC activities of complexes I, III, and IV were measured spectrophotometrically from 
whole muscle homogenate as previously described [44-46]. Briefly, complex I activity was 
determined by measuring the oxidation of NADH at 340 nm as previously described [45]. The 
assay mixture for complex I contained 25 mM potassium phosphate buffer (pH 7.2), 5 mM 
MgCl2, 2 mM KCN, 2.5 mg/ml BSA, 50 µM NADH, 10 µM decylubiquinone, and 2 µg/ml 
antimycin A. The reaction was initiated by the addition of muscle homogenate, and enzyme 
activity was measured for 3 min, with values recorded every 10 s after the initiation of the 
reaction. Complex I-specific activity was inhibited by 2 µg/ml rotenone.  Complex III activity 
was determined as previously described [44, 45] by following the reduction of cytochrome c at 
550 nm in the presence of reduced decylubiquinone (50 µM). Briefly, the assay buffer for 
complex III consisted of 500 mM sucrose, 2 mM EDTA, 100 mM Tris ·HCl, (pH 7.4), 1 mM 
cytochrome c, 200 mM KCN, 1mg/ml antimycin A, and educed decylubiquinone.  Finally, 
complex IV activity was determined by measuring the oxidation of cytochrome c at 550 nm. 
Briefly, the assay mixture for complex IV consisted of 10 mM phosphate buffer (pH 7.4) and 20 
µM reduced cytochrome c. Protein content was determined as described previously via the 
bradford assay [47], and values are expressed as activities in nmol substrate consumed·min 
-1
·mg 
protein
-1
. 
Statistics 
All data are presented as means ± SEM. To examine body mass, organ masses, muscle capillarity 
ex vivo muscle stimulation, and mETC activity we used a student’s T-test. An alpha level at 
P<0.05 was selected for statistical significance. 
 
 
82 
 
Results 
Muscle Mass 
 There was no difference in muscle or body masses between the 3, 7, or 14 day ABT 
animals and their respective controls (Table 1).  There was also no absolute difference in the 
TSP-1 KO muscle mass compared to WT in any of the muscles, but when normalized to for body 
mass GA was decreased by 21% in the TSP-1 KO animals compared to WT controls (P<0.01), 
and a similar trend for a 12% decrease in the PLT (P=0.051)(Table 1).  The SOL was unchanged 
when compared to body mass. These data are similar to those previously observed for these 
muscles in TSP-1 KO mice [10]  
Cell Death 
There was no evidence of cell death as measured by cell death ELISA in the skeletal 
muscle of either the 3-ABT or 7-ABT groups compared to their respective CON groups (Figure 
1).  There was also no significant difference in cell death between 3 and 7 day time points. 
Mitochondrial enzyme activity 
Mice treated with ABT-510 displayed a significant 29% and 42% decrease in complex III 
and IV activity (p<0.05), and to a lesser extent a decrease in complex I activity (p<0.07), in the 
gastrocnemius muscle (Table 2).  In contrast, TSP-1 KO mice tended to display an increase in 
gastrocnemius muscle complex IV activity (p<0.07)(Table 2).  A similar downward trend was 
observed in complex III activity in the SOL muscle (i.e. 50% decrease, p<0.07) of ABT-510 
treated mice, but no significance was reached for any of the complexes in that muscle (data not 
shown).  Likewise, no difference in any of the complexes in the PLT of the ABT treated mice 
was seen (data not shown). 
Ex vivo muscle function 
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 There was a trend for a decrease in peak tetanus force (31%, P=0.06) and peak tetanus 
force/fiber cross sectional area (30%, P=0.12) in the SOL muscle of 14 day ABT treated mice 
compared to CON mice (Figure 2), but neither proved statistically significant.  Surprisingly, no 
difference in fatigue profiles of either the SOL or EDL muscle were seen (Figure 3).  Likewise, 
muscle fatigue response was not different between TSP-1 KO and WT mice (Figure 4).  There 
was no difference in any muscle anatomical or physiological parameter measured during tetanus 
contractions (Tables 3 and 4) 
 
Discussion 
 The main finding of this study is that mitochondrial complex III and IV activity is 
decreased in the gastrocnemius of mice given the TSP-1 mimetic ABT-510, while global 
deletion of TSP-1 resulted in a trend for higher complex IV enzyme activities, suggesting that the 
TSP-1/CD36 pathway can also influence mitochondrial function.  Surprisingly, however we did 
not find any difference in ex vivo muscle function between any of the groups and their respective 
controls.  Moreover, contrary to our hypothesis, we found no evidence of apoptosis (as measured 
by cell death) in skeletal muscle of mice treated with the TSP-1 mimetic, suggesting that losses 
in skeletal muscle capillary are not mediated by apoptosis driven by the TSP-1/CD36 pathway.  
Skeletal muscle mETC activity is altered by TSP-1 
 TSP-1 has recently been identified as a potential mediator of mitochondrial biogenesis 
[13].  While both TSP-1 KO and CD47 KO animals have been reported to have increased 
mitochondrial density, as well as evidence of increased markers of mitochondrial biogenesis 
[13], these are the first data examining the functional measures of mitochondrial respiration 
when stimulating the TSP-1-CD36 receptor pathway. Although, we and others have previously 
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shown that CD36 is important in controlling capillary growth [7, 9, 26, 48-50], and it has also 
been shown that CD36 is found on the mitochondrial membrane [51], these are the first data to 
suggest the TSP-1/CD36 pathway may also influence mitochondrial activity.  Indeed, we find 
that pharmacological overexpression of the TSP-1 mimetic ABT-510 significantly decreased 
complex III and IV mETC activity, and to some extent complex I activity as well.  It could be 
that the decrease in mETC activity is due to a decrease in mitochondria number associated with 
an increase in TSP-1.  This decrease could be driven by a decrease in oxygen delivery, due to 
fewer capillaries, as hypoxia has been shown to decrease mitochondrial content [19, 52].  
Supporting this observation is the finding that TSP-1 KO mice, which have been reported to have 
elevated muscle capillarity [10], displayed an opposite trend for greater complex IV mETC 
activity compared to WT mice. These data suggest that TSP-1 can influence mitochondrial 
biogenesis using the CD36 pathway, in addition to the CD47 pathway,  but further studies will be 
needed to better understand the individual effects and/or differential contributions of these two 
TSP-1 receptor pathways. 
 The fact that the GA and SOL were more affected than the PLT could point to a fiber 
type specific response.  That is, the SOL and the deep portion of the GA are both primarily 
oxidative, while the PLT is primarily glycolytic in nature.  Oxidative fibers have been shown to 
have high levels of mitochondria density, so it could be that these regions are affected first.  
However, previously TSP-1 has been shown to decrease mitochondria in the quadriceps which is 
a primarily glycolytic muscle [13].  Additional analysis of fiber type will need to be addressed to 
answer this question.  
Ex vivo Muscle Function is not different in TSP-1 manipulated mice 
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Because mitochondria are essential for sustaining aerobic exercise we hypothesized that 
muscle fatigue would be increased in animals subjected to a TSP-1 mimetic, and decreased in 
mice lacking TSP-1.  However we found that ex vivo muscle fatigue remained unaltered in TSP-
1 KO and TSP-1 mimetic treated mice.  The lack of difference in ex vivo muscle function and 
fatigue could point to the muscle vascular bed as the potential primary cause for the decrease in 
whole body exercise capacity seen previously in response to TSP-1 [53], and not the decrease in 
mitochondria function per se.  Our findings here suggests that even with decreased mitochondrial 
activity, the muscles can still function normally provided that it has unlimited substrate (as in the 
ex vivo preparation).  
Short term chronic exposure to a TSP-1 mimetic does not increase cell death 
In earlier work we showed that capillarity was decreased with 14-day delivery of ABT-
510 [9].  Despite the reduction in capillarity, we did not see evidence of apoptosis with muscle 
TUNEL staining in those mice.  This was counter to our hypothesis, and the prevailing theory 
that apoptosis is the principle mechanism by which capillary regression occurs in skeletal muscle 
vascular remodeling [20, 24, 35, 37, 54].  While we speculated that apoptosis might have 
occurred at an earlier time point, we were again surprised to still find no evidence of cell death 
with either 3 or 7 day treatment with ABT-510.  These data imply that the reduction in muscle 
capillarity that occurs with chronic exposure to a TSP-1 mimetic is not mediated by a traditional 
cell death mechanism (e.g. apoptosis). 
One hypothesis that could be made is that the capillary network is being effectively 
shrunk, without removal of endothelial cells.  Indeed, it has been shown previously that there is 
capillary recruitment with exercise stimulus, so it could be that recruitment or vascular 
availability is decreased under the ABT-510 exposure [55-58].  However, it is likely that our 
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methodology used to stain for capillaries would still show these intact, but non-functional 
networks.  It could be that the mimetic is causing high levels of autophagy, resulting in ultimate 
cell dysfunction and death.  Autophagy has been shown to be important in other systems, and in 
skeletal muscle [59-61].  While not directly linked to CD36, recently TSP-1/CD47 directed 
mechanisms have been shown to increase autophagy in cancer cells without causing apoptosis 
[62].   It has also been shown that other anti-angiogenic proteins, such as endostatin and K5, can 
trigger autophagy, which results in inhibition of angiogenesis [63].   While only speculative at 
this point, this could be a non-apoptotic mechanism for the removal of endothelial cells in 
skeletal muscle, or reduction in their viability, and hence a resultant shrinking of the capillary 
network. 
 The lack of cell death in the whole skeletal muscle leads to the conclusion that the TSP-1 
mimetic has no effect on the myocyte apoptosis, as suggested previously [9].  This also agrees 
with our functional data showing no difference in both contractile characteristics and fatigue in 
the SOL and EDL muscles of those given a 14 day dosage of ABT-510. 
 
Summary 
 In summary, we found that ABT-510 does not increase cell death in 3 and 7 day chronic 
exposures.  However it does decrease mitochondrial electron transport chain enzyme activities, 
whereas the opposite appears true for mice lacking TSP-1, which have a trend for an increase in 
electron transport enzyme activities.  Surprisingly no change in ex vivo muscle function was 
found to occur in association with the decrease ETC activity.  Nevertheless, these data show that 
in addition to TSP-1 anti-angiogenic effects, it can also influence mitochondrial respiration 
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activity through its CD36 receptor pathway.  The importance of this finding and what component 
this plays in muscle function, and/or whole body exercise, remains to be elucidated. 
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Table 1. 
 
All values ± SE. * P<0.05 from WT  
 
 
 
  3-CON 3-ABT 7-CON 7-ABT 14-CON 14-ABT WT TSP-1 KO 
Age (Days) 81±0 81±0 102±0 102±0 82±5 90±6 94±0 94±1 
Body Mass (g) 25.7±0.7 25.4±0.3 28.3±0.6 28.6±0.4 27.5±1.2 27.1±0.9 22.8±1.7 25.3±1.2 
GA (mg) 139±4 135±2 146±5 146±3 137±5 141±4 133±16 116±5 
PLT (mg) 19.0±0.6 18.0±0.4 21.0±0.4 21.0±0.8 19.7±0.9 19.0±0.5 14.66±0.8 14.59±1.3 
SOL (mg) 8.0±0.4 7.0±.0.6 10.0±0.2 9.0±0.3 7.7±0.5 7.8±0.5 9.4±1.4 7.6±0.4 
GA/BM (mg · g-1)  5.0±0.01 5.0±0.10 5.0±0.01 5.0±.07 5.0±0.1 5.2±0.1 5.8±0.4 4.6±0.1 * 
PLT/BM (mg · g-1)  0.70±0.02 0.70±0.02 0.67±0.05 0.70±0.01 0.72±0.04 0.70±0.02 0.65±0.05 0.57±0.04 * 
SOL/BM (mg · g-1)  0.30±.01 0.30±0.02 0.36±0.05 0.30±0.01 0.29±0.01 0.28±0.01 0.41±0.04 0.31±0.02 
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Table 2: Mitochondrial Electron Transport Enzyme Activities 
 
 
Vehicle ABT-510 WT TSP-1 KO 
Complex I 26 ± 4 17 ± 2 † 19 ± 2 16 ± 1 
Complex III 59 ± 5 42 ± 6 * 49 ± 5 42 ± 3 
Complex IV 62 ± 11 36 ± 5 * 91 ± 8 131 ± 18 †† 
  
All Values ± SE. * P<0.05 compared to Vehicle; 
† P<0.07 compared to Vehicle; †† P<0.07 compared to WT    
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Table 3: Anatomical and physiological characters of the EDL 
EDL Vehicle ABT-510 WT TSP-1 KO 
Muscle Mass 
(mg) 
 
11.40 ± 0.33 11.06 ± 0.38 9.99 ± 0.84 10.31 ± 0.48 
 
CSA (mm
2
) 
 
2.03 ± 0.05 2.00 ± 0.09 1.90 ± 0.10 1.90 ± 0.12 
 
L0 (mm) 
 
11.76 ± 0.22 11.61 ± 0.23 10.96 ± 0.50 11.46 ± 0.27 
Contraction 
time (ms) 
 
20.0 ± 3.1 23.8 ± 1.8 23.8 ± 1.8 25.7 ± 2.0 
½ relaxation 
time (ms) 
 
37.14 ± 1.8 37.50 ± 1.64 41.25 ± 2.27 37.14 ± 2.85 
All Values ± SE. * P<0.05 compared to Vehicle; 
      † P<0.07 compared to Vehicle; †† P<0.07 compared to WT    
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Table 4: Anatomical and physiological characters of the soleus 
SOLEUS Vehicle ABT-510 WT TSP-1 KO 
Muscle Mass 
(mg) 
 
9.06 ± 0.42 8.61 ± 0.31 7.30 ± 0.38 8.63 ± 0.38 
 
CSA (mm
2
) 
 
1.26 ± 0.06 1.18 ± 0.04 1.80 ± 0.10 2.13 ± 0.18 
 
L0 (mm) 
 
9.81 ± 0.16 9.85 ± 0.16 8.50 ± 0.23 7.7 ± 0.44 
Contraction 
time (ms) 
 
42.9 ± 5.2 41.3 ± 3.0 52.5 ± 2.5 36.7 ± 6.7 
½ relaxation 
time (ms) 
 
80 ± 7 65 ± 5 82.5 ± 11.1 70.0 ± 5.8 
All Values ± SE. * P<0.05 compared to Vehicle; 
      † P<0.07 compared to Vehicle; †† P<0.07 compared to WT    
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Figure Legends 
 
Figure 1: 3 & 7 days of ABT-510 treatment does not increase cell death.  ABT-510 animals 
were given 30mg/Kg/day systemic dose delivered by mini-osmotic pump, while vehicle animals 
received 5% dextrose.  Cell death was measured from 100ug of total protein by Cell Death 
ELISA.  Values reported at A.U. absorbance values divided by total protein. N=4/group 3 day 
exposure; N=10/group 7 day exposure. 
Figure 2:  There is a trend for lower peak tetanus force in the SOL of ABT-510 treated 
animals.  While not reaching statistical significance, there was a trend for lower peak tetanus 
(P=0.06) and peak tetanus force/fiber cross sectional area (CSA) (P=0.11) forces of 14 day ABT-
510 treated animals in the SOL muscle.  There was no difference in EDL isometrics between 
groups (not shown). 
Figure 3:  No change in ex vivo muscle fatigue between vehicle and ABT-510 treated mice.  
There is no difference between the fatigue curves of 14 day ABT-510 and vehicle treated 
animals in either the EDL or SOL muscle.  Open Boxes; Vehicle. Closed Diamonds; ABT-510. 
Figure 4:  No change in ex vivo muscle fatigue between WT and TSP-1 KO treated mice.  
There is no difference between the fatigue curves of TSP-1 KO and WT animals in either the 
EDL or SOL muscle.  Open Circles; WT. Closed Triangles; KO. 
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This paper has been formatted for submission to the Journal of Applied Physiology 
Abstract 
Tumor necrosis factor alpha (TNFα) is an important inflammatory cytokine that is 
implicated in several co-morbidities.  High levels of systemic TNFα may be the link between 
chronic inflammation and skeletal muscle dysfunction found in many chronic diseases.  
Thrombospondin-family proteins (such as TSP-1 and TSP-2) are found in skeletal muscle and 
have been shown to be important in capillary rarefaction.  Evidence from cell culture 
experiments also shows that TNFα may act to increase TSP-1 in a skeletal muscle specific 
manner.  We hypothesized that a chronic increase in systemic TNFα would increase TSP-1 
and/or TSP-2 resulting in capillary rarefaction and skeletal muscle dysfunction. We used a lung-
specific TNFa overexpressing transgenic mouse model (TNFα+) which exhibits a chronic 
~300% increase in circulating TNFα levels to evaluate the effects of elevated circulating TNFα 
on skeletal muscle structure and function.  Whole body endurance capacity was decreased by 
120% in the TNFα+ animals, however in vivo muscle stimulated fatigue remained unchanged 
between TNFα+ and litter mate controls (CON). Capillarity was decreased by 16% in the soleus 
(SOL) of TNFα+ animals (P<0.02), but no change was found in the plantaris (PLT), compared to 
CON.  TSP-2, but not TSP-1, was significantly increased by ~80%  (p<0.02) in muscle of 
TNFα+ compared to CON.  Mitochondrial electron transport chain enzyme activity for complex 
III increased by 170% in the SOL, while complex IV activity increased 74% in the PLT of 
TNFα+ compared to CON (P<0.05).  No evidence of altered reactive oxygen species was found.  
These data suggest that chronic systemic elevation of TNFα can alter TSP-2 which could  
contribute to losses in skeletal muscle capillary.  Reducing systemic TNFα+ may serve as a 
therapeutic target to reduce skeletal muscle dysfunction associated with capillary rarefaction.  
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Introduction 
Tumor necrosis factor alpha (TNFα) is an important inflammatory cytokine that is 
implicated in the co-morbidities, such as skeletal muscle dysfunction, of many chronic diseases 
[1-6].  For example, associations between elevated systemic TNFα and muscle dysfunction are 
often found with chronic obstructive pulmonary disease (COPD), chronic heart failure, and 
diabetes [2, 4, 6-10]   Interestingly, in a mouse model of TNFα overexpression (TNFα+), Zuo et 
al. have shown increased soleus (SOL) muscle fatigue and disrupted contractile kinetics in the 
extensor digitorum longus (EDL) of TNFα+ mice [11].  Tang et al. [12] also showed that in situ 
muscle endurance was decreased in this same mouse model.  In humans, COPD is also well 
known to decrease skeletal muscle exercise capacity, which is also associated with an increased 
circulating level of TNFα.  It has been proposed that skeletal muscle capillary loss in chronic 
disease could be a significant contributor to overall skeletal muscle dysfunction and comorbidity 
[2, 13-18].  The mechanism(s) by which increased circulating TNFα may disrupt skeletal muscle 
function and/or capillarity are undetermined. 
Angiogenesis is controlled by both positive and negative angiogenic proteins [19-21]. 
There is growing evidence that negative angiogenic regulators, such as the thrombospondins [21-
26] and endostatin [21, 27, 28], are critical microvessel regulators in both pathological and 
physiological skeletal muscle angiogenesis.  Thrombospondin (TSP)-1 and TSP-2 are large 
extracellular matrix multi-domain proteins that inhibit angiogenesis in vitro and in vivo [29-33].  
They share multiple binding receptors, such as CD36, CD47 and LRP-1, which inhibit 
endothelial cell proliferation, migration, tube formation, and induce apoptosis [29, 30, 32, 34].  
TSP-1 appears to play an important role in skeletal muscle capillary rarefaction occurring with 
hindlimb unloading [25] and has been implicated as an important regulator of whole body 
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exercise capacity through its powerful anti-angiogenic actions [24].  The role of TSP-2 in 
regulating skeletal muscle capillarity and its effects on exercise capacity are less well studied.   
Evidence from cell culture experiments have shown that TNFα can act to increase TSP-1 
in a myoblast specific manner [35], and increased systemic TNFα has been shown to increase 
circulating TSP-1 protein levels in humans [36].   Interestingly, TNFα knockout mice also 
display increased running capacity compared to controls [37].  It is tempting to speculate that the 
absence of TNFα might lower basal expression of TSP-1 and/or TSP-2 and thereby increase 
skeletal muscle capillarity that could explain the greater capacity for exercise.  Collectively these 
data hint to a potential mechanism that may link TNFα mediated chronic systemic inflammation 
to muscle expression of TSP-1/TSP-2, which could be responsible for skeletal muscle capillary 
rarefaction and muscle dysfunction [38]. 
In this study we examined the effects chronic systemic elevation of TNFa has on skeletal 
muscle structure and function. We used a lung specific TNFα overexpressing transgenic mouse 
model known to exhibit increased systemic TNFa.  We hypothesized that chronic systemic 
elevation of circulating TNFα would increase expression of TSP-1 and/or TSP-2 in skeletal 
muscle, and therefore decrease skeletal muscle capillarity. We also hypothesized that elevated 
thrombospondin levels would lead to decreased in vivo muscle function, as well as impaired 
skeletal muscle mitochondrial function. 
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Methods 
Animals:  Lung specific TNFα overexpressing mice were obtained as a gift from Dr. Peter 
Wagner (University of California, San Diego).  All procedures that involved animals were 
approved by the West Virginia University Institutional Animal Care and Use Committee.  These 
mice use a surfactant protein-C promoter to overexpress TNFα in the lung [39]. Transgenic 
TNFα overexpressing (TNF++, n=30) and littermate control (CON, n=25) mice were studied at 
5-6 months of age. 
 
Whole body and in vivo skeletal muscle exercise testing   
Whole body exercise capacity was assessed on a sub-set of animals (TNFα+ N=9, CON 
N=7).  The exercise endurance test was performed at least 48 hours before any tissues were taken 
for morphometric or molecular analysis.  This time frame was selected to ensure that the exercise 
bout did not influence basal protein levels in muscles harvested on the final study day [40].  
Exercise capacity was measured using a commercially available treadmill (Columbus 
Instruments, Columbus, OH).  The mice were allowed to warm-up at 4 meters/minute (m/min) 
for 5 minutes, at a 10 degree incline.  Thereafter, the treadmill speed was gradually increased to 
20 m/min over 10min.  The animals then ran as long as possible at 20m/min until they were 
exhausted or refused to run.  Exhaustion was defined as the inability of the animal to maintains 
its normal running position on the moving belt of the treadmill, and/or more than 5 seconds spent 
on the shock grid (at the rear of the treadmill).  Animals were continually encouraged to keep 
running by using noise from forced air jets and the electrical deterrence (<0.2 mA) via a shock 
grid at the rear of the treadmill.  Total run time was recorded and used as an assessment of whole 
body exercise capacity.     
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In vivo muscle fatigue in the hindlimb muscle of anesthetized mice was measured by 
stimulating the tibial nerve (TNFα+ N=15, CON N=7).  In vivo analysis was performed in an 
effort to keep the endogenous blood supply intact and most accurately reflect what is occurring 
in the conscious exercising animal. Briefly, mice were anesthetized with isoflourane (2%) and 
the left knee was secured in flexion by placing a metal rod on the lateral side of the knee. The 
left foot was then secured to a footplate connected to a servomotor (Cambridge Technology Inc. 
Model 6350*350, Cambridge, MA).  The ankle joint was then aligned with the axis of rotation of 
the servomotor and electrically evoked via the tibial nerve by insertion of platinum electrodes 
through the skin (Grass Medical Instruments).  The electrodes were placed through the skin so 
that they were flanking either side of the nerve. The left plantar flexor muscle group from each 
animal was subjected to standardized pulses to determine correct electrode placement (10v, 100 
Hz, 200 μs pulses).  Once completed, the animals were subjected to stimulation protocol (12v, 
40hz, 333ms, every second for 180 seconds) designed to mimic the modified Bruce protocol 
used in humans [41].  Fatigue was defined by a reduction to 60% of peak force during the 
protocol. 
 
Muslce Morphometry   
Hindlimb skeletal muscle was surgically excised and frozen in isopentane cooled by liquid 
nitrogen.  Frozen tissue was cut using a -20°C cyromicrotome (Jung-Reichert Cryocut 1800: 
Cambridge Instruments, Germany) to yield 10µm transverse sections.  Great care was taken to 
ensure the cryosectioned muscles were cut along the transverse plane.  Sections were stained for 
dipeptidly-peptidase IV (DPP IV) and alkaline phosphatase (AP) following the method of Lojda 
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[42, 43].  A light microscope (Zeiss primo star, Zeiss, Oberkochen, Germany) was used to 
digitally acquire (Axiocam IC c3, Axiovision 4.8.2.0, Zeiss, Oberkochen, Germany) 20X images 
of the gastrocnemius, plantaris, and soleus.  Capillary and myofiber counting was performed by a 
single individual blinded to group identification.  For the gastrocnemius muscle, we obtained 
images in a checkerboard fashion across the entire muscle, thus both superficial and deep regions 
within the gastrocnemius could be included in the analysis.  For the plantaris and soleus muscles, 
respectively, the entire muscle was imaged and analyzed.  Counting was performed by 
visualization from acquired images using a custom program in MATLAB (version 7.0.0.27, The 
Mathworks, MA, USA) allowing the operator to visually mark and count the capillaries and 
fibers on each image.  Capillary-to-fiber ratio (C:F, number of capillaries/number muscle fibers), 
capillary density (CD, number of capillaries/mm
2
 muscle fiber area), and fiber cross sectional 
area (FCSA) were separately calculated for the gastrocnemius (GA), soleus (SOL), and plantaris 
(PLT) (N=19-30 images/muscle/group), (TNFα+ N=15; CON N=7 per muscle).  
 
Protein Preparation   
GA, SOL, and PLT muscles from each group were excised and flash frozen in liquid nitrogen.  
For molecular analysis, muscle were then separately homogenized in a lysis buffer containing 50 
mM Tris/HCl (pH 7.4), 150mM NaCl, 0.5% Triton X-100, and protease inhibitors (Complete 
Tablet, Roche Applied Science, Indianapolis, IN).  Homogenates were centrifuged at 4°C, at 
10,000g for 10 minutes, and supernatants removed and placed in new tubes.  For citrate synthase 
(CS) activity, 10-50mg of muscle, depending on size of muscle, was separately homogenized in 
a simple homogenization buffer (175mM KCl, 2mM EDTA in DDH2O) as described previously 
[12, 44].  This was then spun for 1 minute at 8000 g.  These samples were then freeze-thawed 
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several times to stabilize protein content. Blood samples were obtained from the heart and 
allowed to coagulate on ice.  They were then centrifuged at 3000 g for 10 minutes and flash 
frozen in liquid nitrogen.  Total protein was measured from all samples by Bradford assay 
(#23236 Pierce Coomassie Plus Protein Assay Kit, Thermo Scientific, Rockford, IL) [45].  
 
Protein Analysis  
An Angiogenic Protein Array was performed on 100ug of SOL muscle using a protein 
array kit per manufacturer’s instructions (#ARY015, R&D Systems, Minneapolis, MN, USA). 
(TNFα+ N=2; CON N=2 per muscle)  
Quantification of VEGF was made from a total of 100μg of protein using a commercially 
available ELISA kit according to the manufactures instructions (# MMV00, R&D Systems, 
Minneapolis, MN, USA).  All samples were run in duplicate. (TNFα+ N= 22; CON N=13 per 
muscle) 
Quantification of TNFα was made from a total of either 50µL of serum or 100µg of 
muscle homogenate using a commercially available ELISA kit according to the manufactures 
instructions.  All samples were run in duplicate.  (TNFα+ N=6, CON N=6 per muscle) 
TSP-1 was analyzed via western blot.  In brief, samples were separated on a 3-8% SDS-
PAGE (NuPAGE Novex 3-8% Tris-Acetate Midi Gel, Invitrogen, Burlington, ON, Canada) and 
blotted onto a 0.45μm nitrocellulose membrane (Pierce nitrocellulose membrane, Thermo 
Scientific, Rockford, IL).  After blocking with 5% fat-free milk, membranes were probed using 
antibodies against TSP-1 (1:500 #59887, Santa Cruz, Dallas, TX, USA), β-tubulin (1:1000, 
#2148, Cell Signaling), secondary HRP-conjugated anti-mouse (1:1000,  #p0260, Dako, GE 
Healthcare, Piscataway, NJ) and secondary HRP-conjugated anti-rabbit (1:1000,  #P0217, 
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Dako).  Proteins were visualized using chemiluminescence detection (Pierce ECL, Thermo 
Scientific, Rockford, IL) and digitally imaged (G:BOX Gel imager, Syngene, Cambridge, UK) 
using Genesnap software (Ver. 7.01, Syngene, Cambridge, UK). Equal protein loading was 
verified by immunodetection of β-tubulin as our loading control.  Quantification of protein 
expression levels were carried out using NIH Image J Software (v1.62) and expressed as 
densitometric arbitrary units (AU).  All blots were run in duplicate to confirm results. (TNFα+ 
N= 8, CON N=8 per muscle) 
 
Reactive Oxygen Species 
DCF Assay: Total reactive oxygen species was measure in fresh tissue homogenates by 
dichlorofluoroscein (DCF) as described previously, with some modification [46].  In brief, the 
dichlorofluoroscin acetate (DCFH-DA) stock solution was made fresh by dissolving 1.25mM of 
DCF in 100% ethanol and storing it in the dark at -20°C.  DCFH-DA was dissolved in ethanol to 
aid in the transport across membranes.  2.5µL of PLT and 5µL of SOL homogenate were added 
to each well of a 96-well black walled plate containing 50µL of freshly made 0.1 M phosphate 
buffer (pH 7.2), and 40 μl of 1.25 mM DCFH-DA (total volume 92.5 or 95µL, SOL, PLT 
respectively).  Samples were run in duplicate, and each plate contained 2 blanks containing the 
phosphate buffer and DCFH-DA but no protein to serve as background controls. The assay 
mixture was incubated for 20 min at 37°C to allow the DCFH-DA to cross any membranes. DCF 
formation was determined fluorometrically (FlexStation 3 plate reader, Molecular Devices, 
California, United States) at excitation wavelength of 488 nm and emission wavelength of 525 
nm at 37°C.  Measurements were made every 10 min for 60 min, and the linear DCF production 
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rate was determined relative to the amount of protein added to each well. (TNFα+ N=6; CON 
N=6 per muscle) 
Lipid peroxidation: 
Lipid Peroxidation Assay Kit from Oxford biosciences was used per manufacturer's instructions. 
Total lipid quantification was adapted from Cheng et al. 2010 [47]. (TNFα+ N=6; CON N=6 per 
muscle) 
 
Mitochondrial Assessments 
Electron transport chain (ETC) complex activities: 
ETC activities of complexes I, III, and IV were measured spectrophotometrically from whole 
muscle homogenate as previously described [48-50]. Briefly, complex I activity was determined 
by measuring the oxidation of NADH at 340 nm as previously described [49]. The assay mixture 
for complex I contained 25 mM potassium phosphate buffer (pH 7.2), 5 mM MgCl2, 2 mM 
KCN, 2.5 mg/ml BSA, 50 µM NADH, 10 µM decylubiquinone, and 2 µg/ml antimycin A. The 
reaction was initiated by the addition of muscle homogenate, and enzyme activity was measured 
for 3 min, with values recorded every 10 s after the initiation of the reaction. Complex I-specific 
activity was inhibited by 2 µg/ml rotenone.  Complex III activity was determined as previously 
described [48, 49] by following the reduction of cytochrome c at 550 nm in the presence of 
reduced decylubiquinone (50 µM). Briefly, the assay buffer for complex III consisted of 500 mM 
sucrose, 2 mM EDTA, 100 mM Tris ·HCl, (pH 7.4), 1 mM cytochrome c, 200 mM KCN, 
1mg/ml antimycin A, and educed decylubiquinone.  Finally, complex IV activity was determined 
by measuring the oxidation of cytochrome c at 550 nm. Briefly, the assay mixture for complex 
IV consisted of 10 mM phosphate buffer (pH 7.4) and 20 µM reduced cytochrome c. Protein 
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content was determined as described previously via the bradford assay [45], and values are 
expressed as activities in nmol substrate consumed per min 
-1
 per mg protein
-1. (TNFα+ N=6; 
CON N=6 per muscle) 
Statistics 
All data are presented as means ± SEM. To examine body mass, organ masses, muscle capillarity 
ex vivo muscle stimulation, and mETC activity we used a student’s T-test. An alpha level at 
P<0.05 was selected for statistical significance. 
 
Results 
Body and Muscle Mass 
 Shown in Table 1, TNFα+ animals were 19% smaller than CON animals (P<0.001).  
There was a significant decrease in muscle mass of the GA and SOL muscle of the TNFα+ when 
compared to the CON.  The GA was decreased by 13% (P<0.01) and the SOL was decreased by 
15% (P= 0.01) in TNFα+ compared to CON.  Lung mass was also increased 180% (P<0.001).  
There was no difference in the PLT or heart (HRT) mass between TNFα+ and CON (Table 1). 
 When muscle masses were normalized to body mass, to account for the size of the 
animal, none of the skeletal muscle/body masses were different between the TNFα+ and CON.  
However, HRT mass/body mass was significantly increased by 10% (P<0.01).  Lung mass/body 
mass was increased by over 200% (P<0.001) (Table 1). 
Exercise capacity and muscle function. 
 The TNFα+ animals had a 120% decrease in endurance running capacity (P=0.02) 
(Figure 1), but there was no difference in in vivo muscle fatigue between the TNFα+ and CON 
animals (Figure 2). 
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TNFα serum and muscle levels 
TNFα serum levels were increased by 299% in the TNFα+ animals (P<0.001) (Figure 3).  
There was no difference in TNFα levels of the SOL, PLT, or GA muscles between the TNFα+ 
and the CON (Table 2). 
Skeletal muscle capillarity 
 There was a 16% decrease in capillary-to-fiber ratio (C:F) in the SOL muscle of the 
TNFα+ animals when compared to the CON (P<0.02) (Figure 3).  There was no change in the 
PLT capillarity (Figure 4).  There was also no difference in either of the muscles in capillary 
density (CD) or fiber cross sectional area (FCSA) (Figures 3 & 4) 
Angiogenic protein content 
 There was no difference in TSP-1 in either of the muscles tested (SOL, PLT) (Figures 3 
and 4).  There was also no difference in VEGF levels in either of the muscles tested (Figures 3 
and 4). 
An angiogenic protein array was used to screen a wide set of angiogenic regulators that 
could be altered in the TNFα+.  These data revealed that only TSP-2 was significantly increased 
(by 87%, p<0.05) (Figure 5).  Despite a similar trend seen in other factors, such as keratinocyte 
growth factor (+158%, P=0.06), matrix metalloproteinase 9 (+182%, P=0.07), and coagulation 
factor III (+88%, P=0.06), only TSP-2 resulted in a statistically significant outcome (Figures 5).  
Mitochondrial ETC Activity 
 There was a significant 170% increase in complex III activity in the SOL of the TNFα+ 
mice when compared to the CON (P<0.01) (Table 3).  There was no difference in the complex 
activities of either complex I or IV in the SOL. 
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 In the PLT, there was also a significant 74% increase in complex IV activity (P<0.05) 
(Table 3).  However there was no difference in any of the activities of the other complexes. 
Reactive oxygen species (ROS) assessment 
 DCF analysis revealed that there was no significant difference in gastrocnemius (GA) 
ROS production between the TNFα+ and CON animal (Figure 6).  The lipid peroxidation assay 
revealed that there was also no increase or decrease in lipid oxidation in the SOL or PLT of the 
TNFα+ compared to the CON.  This remained true when corrected for both total lipid and total 
protein content (Figure 7). 
 
Discussion 
 The main finding of this study was that there was a significant decrease in soleus muscle 
capillarity of mice with increased levels of systemic circulating TNFα that is associated with an 
elevated expression of TSP-2, but not TSP-1. This suggests that TNFα could play a role in 
skeletal muscle dysfunction that may be mediated by TSP-2.  
 
Increased systemic TNFα decreases capillarity 
 Angiogenesis, the process of vessel growth from the existing vascular network, plays an 
essential role in meeting the metabolic demands of skeletal muscle.  It is not surprising that 
capillary regression is associated with decreased exercise tolerance in several pathological 
conditions [2, 13, 14, 16, 18, 51-54], but the molecular mediators responsible for capillary 
regression in many of these conditions are still unknown.  In this study, we showed that a TNFα 
overexpressing mouse model resulted in a ~300% increase in circulating TNFα compared control 
mice.  A finding similar to that previously reported in this TNFα+ mouse model [12, 55]. Despite 
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a significant decrease in SOL capillarity in TNFα+ mice, we found no change in capillarity of the 
PLT muscle. While a full explanation for this difference is not immediately evident, it has been 
shown previously in this same model of TNFα overexpression that the SOL muscle function is 
more greatly affected by TNFα when compared to less oxidative muscles [12].  Those data, and 
that of our manuscript, may seem to suggest that there is a fiber-type specific response to chronic 
systemic inflammation, as the SOL is composed of primary slow MHC fibers, while the PLT is 
primarily fast MHC fibers.  The reasons for this fiber type specific response also remain 
unknown.  However, in human diseases such as COPD, there is decreased overall aerobic 
capacity, which coincides with similar fiber type specific changes.  Indeed, a reduction in the 
number of type I fibers in human quadriceps muscle is correlated with a decrease in overall 
exercise capacity more strongly in those with COPD than healthy controls [15].  Also, in 
previous work with this mouse model, it was shown that there was a shift in muscle fiber type 
composition in the SOL towards a faster fiber phenotype [12].  Further work will be needed to 
tease out this fiber specific response. 
 
Increased systemic inflammation leads to an increase in TSP-2  
Our protein analysis revealed a trend for an overall greater increases in angiogenic 
regulatory proteins in TNFa+ compared to controls, however of the over 50 proteins examined 
only TSP-2 was significantly altered in the TNFα+.  TSP-2 was found to be increased by over 
80% compared to CON. Surprisingly, we saw no change in TSP-1.  While the function and 
expression of TSP-1 has been examined in skeletal muscle [23, 25, 52], the role of TSP-2 in 
skeletal muscle is relatively unknown. Our finding suggests that TSP-2 could be playing a role in 
skeletal muscle capillary regression that has not been previously recognized.   Indeed, TSP-2 is 
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closely related to TSP-1 in both structure and function, and has been shown to decrease 
capillarity in tumor models [56, 57].  TSP-2 is found to be important in development [29, 33, 58] 
and in connective tissue structure and cardiac tissue healing [58-61].  TSP-2 also shares many of 
the common motifs of TSP-1 and has been shown to function through many of the same 
receptors as TSP-1 [29, 32, 33, 57, 60].  Collectively, we believe these data suggest that TSP-2 
may play a role in inflammatory induced skeletal muscle capillary regression. 
 
In vivo muscle stimulation, exercise capacity, and mitochondrial function 
Unlike previous studies which have used invasive stimulation models [11, 12], we chose 
in vivo muscle stimulation because it is minimally invasive and allows us to keep all of the 
vasculature and connective tissue intact, and therefore more closely reflects muscle activity in a 
conscious exercising animal.  Using this paradigm we did not find greater muscle fatigue in the 
TNFα+ mice. It should be noted, this in vivo stimulation paradigm reflects the fatigue of the 
whole hindlimb tricep complex and therefore can not differentiate between different muscle 
types (e.g. oxidative vs. glycolytic).  Given that we only found capillarity to be altered in the 
SOL, it is perhaps not surprising that there is no change in in vivo muscle function, as the SOL 
makes up the smallest contribution to overall force production in the hindlimb. 
Despite no evidence of muscle contractile dysfunction, TNFα+ mice exhibited a 
significant decrease in whole body exercise capacity (i.e. running endurance). This is most likely 
a consequence of the central lung pathology found in this model, which is similar to that 
observed in COPD [39]. Our data support the recent finding of decreased maximal running 
capacity observed in male TNFα+ mice [12]. Surprisingly, however, the previous study found no 
effect on exercise capacity in female mice [12]. Our study included both males and females, but 
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we did not find significant difference between the sexes. At present, the reason for this 
discrepancy between these studies is unknown, but will required further investigation. 
It has been shown recently that PGC-1α expression and citrate synthase activity is 
decreased in the SOL of TNFα+ mice [12]. Based on this observation, we expected that 
mitochondrial electron transport chain enzyme activity might be reduced. To the contrary, we 
found a 170% increase in complex III activity in the SOL and a 74% increase in complex IV 
activity in the PLT of the TNFα+, with a similar trend (albeit not statistically significant) for 
increased mitochondrial ETC activity across almost all of the complexes for both the SOL and 
PLT muscles.  This may be a mechanism by which skeletal muscle mitochondria are 
compensating for fewer mitochondria (i.e. decrease in CS activity).  Further work with electron 
microscopy will need to be conducted to elucidate what is happening with mitochondrial density.   
To further evaluate mitochondria function in the skeletal muscle of TNFα+ mice, we also 
measured total ROS content and lipid oxidation (LPO). We saw no change in LPO and/or any 
alterations in ROS production in the skeletal muscle. Both measures are non-specific 
measurements of overall ROS activity and suggest that the degree of muscle capillarity loss seen 
in the SOL muscle is not likely linked to a ROS mediated event. Given the prior evidence of 
reduced PGC1-α and citrate synthase activity in this mouse model [12], and our measurements 
showing no changes in ROS, it seems likely that TNFα+ mice simply have less mitochondria, 
rather than dysfunctional mitochondria per se.  This is also supported by the finding that 
mitochondrial ETC data were not decreased in TNFα+ mice, but rather, in some cases actually 
increased.  
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Summary 
In summary, we show that increased systemic TNFα decreases skeletal muscle 
capillarity. This rarefaction appears to be specific to oxidative skeletal muscle, and may be 
linked to TSP-2 expression.  While endurance exercise capacity was reduced, muscle 
mitochondrial electron transport chain activity was increased and muscle contractile function 
was not changed, suggesting the exercise intolerance is not at the mitochondrial or muscle 
contractile level. While the mechanisms that connects capillary rarefaction and systemic 
inflammation still remain obfuscated, our data suggest that chronic elevation of TNFα may act 
by stimulating TSP-2 expression and that this TNFα/TSP-2 axis may provide a fruitful 
therapeutic target aimed at combating skeletal muscle co-morbidities. 
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Figure Legends 
 
Figure 1: Endurance running capacity is significantly decreased in TNFα+ mice.  There was a 
120% decrease in running capacity in the TNFα+ group compared to WT.  Mice ran at 20m/min 
at a 10° angle for as long as possible.  Values ± SE. 
 
 Figure 2: In vivo muscle fatigue is unchanged in TNFα+ mice.  The whole triceps surae complex 
was subjected to a fatigue protocol (12v, 40hz, 333ms, every second for 180 seconds ) via 
stimulation of the tibial nerve. A) Absolute values.  B) % Change from first time point  Values ± 
SE. 
 
Figure 3: Soleus capillarity is decreased in TNFα+ animals, while TSP-1 and VEGF remain 
unchanged.  A) There was a 16% reduction in capillary-to-fiber ratio (C:F) in the SOL.  B) & C) 
Despite a trend (P=0.01) there was no change in capillary density (CD), or fiber cross sectional 
area (FCSA).  D) & E) There was no change in VEGF measured via ELISA or TSP-1 levels 
measured via western blot.  F) Representative TSP-1 blot.  Values ± SE. 
 
Figure 4: Plantaris capillarity, TSP-1, and VEGF remain unchanged in TNFα+ mice.  A-C) There 
was no change in capillary-to-fiber ratio (C:F), capillary density (CD) or fiber cross sectional 
area (FCSA)  in the PLT.  D) & E) There was no change in VEGF measured via ELISA or TSP-
1 levels measured via western blot.  F) Representative TSP-1 blot.  Values ± SE. 
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Figure 5: Angiogenic array reveals of 53 proteins measured, only TSP-2 is changed in TNFα+ 
mice.  100ug of total protein was analyzed for 53 different angiogenic proteins.  The only protein 
that was statistically changed  in the TNFα+ was TSP-2 (82% increased, P=0.02) . Values ± SE. 
 
Figure 6: No change in overall ROS content in TNFα+ mice.  The DCF assay revealed no change 
in overall ROS content in the SOL or PLT of TNFα+ animals. A) SOL, B) PLT.  Values ± SE. 
 
Figure 7: No change in lipid oxidation in TNFα+ mice.  There was no change in lipid oxidation 
as measured by the LPO assay in the GA of TNFα+ mice. A) Absorbance/total lipid content B) 
Absorbance/total protein content.  Values ± SE. 
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Chapter 6: General Discussion  
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Thrombospondin-1 is critical in physiological angiogenesis, but it does not play a role in 
inflammatory induced capillary regression 
While TSP-1 was discovered almost half a century ago, it wasn’t until 1990 that it was 
shown in vivo to be a potent anti-angiogenic protein [1], and it wasn’t until some years later that 
it was suggested to be important in skeletal muscle [2, 3].  Since then, the body of work 
supporting the role of TSP-1 in skeletal muscle has grown, but a void continues to exist and 
critical questions remain unanswered.  While TSP-1 has been shown to be important in cancer, 
only a limited amount of work has been performed on its role in physiological skeletal muscle 
angiogenesis [2-5], and an even smaller body of work has been published on its potential role in 
pathological skeletal muscle angiogenesis [5-7]. 
In chapter 3, we showed that TSP-1 is critical in controlling physiological skeletal muscle 
angiogenesis.  Through the chronic administration of a TSP-1 mimetic, we showed that the 
actions of TSP-1 result in a decrease of skeletal muscle capillarity across three distinct muscle 
types (oxidative, glycolytic, and mixed muscles).  Further, because the mimetic used in this study 
is a CD36 agonist, this provides evidence that TSP-1’s anti-angiogenic properties in skeletal 
muscle involve a CD36 mediated mechanism.  Indeed, this is consistent with previous work 
showing the binding of TSP-1 to CD36 is anti-proliferative, anti-angiogenic, and pro-apoptotic 
[8-12].  Because we showed this same response in skeletal muscle under physiological 
conditions, there appears to be a putative role for TSP-1/CD36 in decreasing vascularity across 
multiple tissues.  In combination with the findings that TSP-1 KO’s having increased 
capillarity[3], these data provide clear evidence thatTSP-1 is a physiological regulator of skeletal 
muscle vascularity.  Indeed, further work from our lab supports the importance of TSP-1 by 
showing there is a reduction in TSP-1 protein in response to training during the time that 
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capillary adaptation is occurring (figure 1 of the appendix). This supports previous work with 
mRNA [2], and suggests that TSP-1 may serve in the course of training as a vascular regulatory 
protein, furthering TSP-1’s role beyond the basal control of capillarity seen in chapter 3.  These 
data then sets the ground work to study aberrant skeletal muscle angiogenesis and /or capillary 
rarefaction in chronic disease conditions. 
In chapter 5, we pursued one of the mechanisms that is potentially important in skeletal 
muscle co-morbidities of chronic disease.   Chronic systemic inflammation has been suggested to 
play a crucial role in skeletal muscle capillary rarefaction associated with chronic conditions.   
Chronic sytemic inflammation has been shown to be important in a host of syndromes and 
diseases [13-16], where it has been suggested to be linked to both co-morbidities and overall 
health outcomes [17].  The chronic-inflammatory model we chose for chapter 5 is a lung specific 
overexpressor of TNFα.  TNFα is an important inflammatory cytokine that is linked to many of 
the secondary effects of chronic disease [13-16, 18, 19].  The lung specific overexpression in this 
model results in a spill over systemically, resulting in higher circulating TNFα.  This mouse line 
has been suggested to be representative of chronic lung disease in humans, such as chronic 
obstructive pulmonary disease (COPD) [20-22].  COPD is also associated (by an unknown 
mechanism) with skeletal muscle dysfunction [5, 23-29], and it has been suggested this could be 
due in part to alterations in skeletal muscle capillarity [5, 24, 30]. 
The main finding of our studies in chapter 5 was that there was a reduction in skeletal 
muscle capillarity in association with increased systemic TNFα.  The reduction in capillarity was 
only found in the soleus, and not the plantaris.  Although we cannot establish a direct cause-and-
effect relationship between TNFα and muscle capillarity based solely on these data, there are 
numerous studies that find elevated circulating TNFα in concert with reduced skeletal muscle 
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capillarity [14, 21, 23-25, 28, 31-33].  This work, in combination with our data, points to a 
causative role of TNFα in the reduction of skeletal muscle capillarity, and establishes the 
importance of TNFα in chronic inflammation induced muscle dysfunction.  
We hypothesized a TNFα-TSP-1 axis mediated mechanism for capillary rarefaction 
based on in vitro work pointing to a skeletal muscle specific TNFα-TSP-1 connection  [34].  
Surprisingly, we found that skeletal muscle TSP-1 protein levels were unchanged in vivo with 
elevated systemic TNFα.  This was true for both muscles where capillarity was changed (soleus) 
and those that remained unchanged (plantaris).  This led us to conclude that, at least in the 
context of TNFα systemic overexpression, TSP-1 is not the key player linking chronic systemic 
inflammation to a loss in capillarity.   
However, given the apparent importance of TPS-1 in physiological angiogenesis, as 
shown in chapter 3, we also examined TSP-1’s expression in three other rodent models of 
systemic inflammation- two obesity models and a cigarette smoke exposure model.  Previously, 
it has been shown that all of these have increased general levels of systemic inflammation, and 
increased levels of TNFα specifically [35, 36].  Supporting the work in chapter 5, none of these 
models showed any change in skeletal muscle TPS-1, despite clear previous evidence of 
decreased capillarity [33, 37]. 
Given the lack of change in skeletal muscle TSP-1 in all of these models, we can only 
conclude that TSP-1 does not play an important role in TNFα driven, systemic inflammation 
induced, pathological capillary regression.  This is despite its apparent critical role in 
physiological angiogenesis (as seen in Chapter 3).  Supporting this notion, in a recent publication 
looking at what controls skeletal muscle angiogenesis in human COPD patients, basal levels of 
TSP-1 are unchanged between COPD patients and sedentary controls, yet the COPD individuals 
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have decreased capillarity [5].  However, with six weeks of exercise training TSP-1 levels drop 
significantly, which was not shown in the control group.  This lack of a baseline difference, but a 
retained response to an exercise stimulus, further suggests that TSP-1 is not important in the 
pathological loss of capillaries, but is important in the physiological response to an angiogenic 
stimulus.  
 
The Thrombospondins play an important role in the angiogenic balance 
An altered TSP-1 to VEGF ratio is thought to be important in the control of skeletal 
muscle capillarity [6, 38].  In chapter 3 we found a decrease in VEGF with chronically elevated 
levels of TSP-1, supporting these previous findings.  These data also support previous in vitro 
studies suggesting that TSP-1 may be binding and sequestering VEGF – resulting eventually in 
internalization and biological inactivation [39-43].  Explanations for the reduction in VEGF in 
chapter 3 may also involve suppression of VEGF production and/or VEGF signaling.  For 
example, there is a growing body of evidence showing that internalization of the VEGF/VEGFR-
2 complex by endocytosis results in downstream activation of several different signaling 
pathways [44].  There is also evidence that both CD36 and CD47 can associate with VEGFR-2, 
and when TSP-1 is present this association can prevent the VEGF ligand binding to its receptor, 
as well as inducing receptor dephosphorylation and preventing dimerization [45-48].  In this 
way, TSP-1 could prevent activation and/or endocytosis of the VEGF receptor, blocking yet 
another biologically active arm of VEGF/VEGF-R complex.  Co-precipitation pull down assays 
could be used to deteremine what TSP-1 is interacting with directly.  These studies could also 
yield important answers to when specific interactions are occurring in the angiogenic process, as 
the timeline of binding is unknown.  Regardless of the mechanism, our data supports the notion 
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that TSP-1 likely plays a regulatory role that also involves VEGF, thereby enhancing its already 
potent inherent anti-angiogenic capacity under physiological situations. 
Unlike chapter 3, the data in chapter 5 does not directly support the theory of a TSP-
1/VEGF balance, however it is not inconsistent.  While it trended downward, we did not see any 
change in VEGF in either of the muscles tested in chapter 5, as well as no change in TSP-1 as 
discussed previously.  While not what we anticipated, this null change in VEGF and TSP-1 still 
fits within the context of the balance theory.  That is, no change in the negative protein TSP-1 
would therefore spur no change in the positive angiogenic protein VEGF, with the converse also 
being true.  The lack of change in VEGF also suggests, as we argue for TSP-1, that there may be 
divergent pathways that regulate physiological vs. pathological angiogenesis, despite previous 
data to suggest VEGFs role in pathological skeletal muscle dysfunction [49].  Still, since there 
was a significant decrease in skeletal muscle capillarity in chapter 5 (yet no change in TSP-1 or 
VEGF) our data suggests that some other mediator(s), potentially specific to chronic systemic 
inflammation induced capillary loss, may be at play with chronic systemic inflammation that 
may or may not be common to physiologically induced angiogenesis.  Little information exists 
as to which negative angiogenic proteins are most important in skeletal muscle angiogenesis 
[50], so more work will need to be done to identity which proteins are important in TNFα driven 
chronic systemic inflammation.  
To try and answer what proteins could be responsible for this pathological/inflammation 
induce capillary regression, we conducted a proteomic angiogenic array in chapter 5.  
Interestingly, we found that TSP-2 was the only protein of the 53 tested that was significantly 
changed (up by over 80% in the TNFα+ animals).  As discussed in chapter 1 (literature review) 
TSP-1 belongs to a family of six different proteins that all share some homology and functional 
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overlap [51-53].  Of those, TSP-1 and TSP-2 are the most closely related in terms of both form 
and function, with TSP-2 only lacking a limited number of the distinct regions of TSP-1, such as 
the TGF-β activating region [8].  TSP-2 has been shown to be anti-angiogenic in skeletal muscle 
[54], however its role in skeletal muscle is poorly studied.  Further work will be needed to clarify 
if TSP-2 is a central player in inflammatory induced capillary regression.  Still, we suggest here 
for the first time that TSP-2 could be the link between chronic systemic inflammation and 
skeletal muscle capillary rarefaction, thereby serving as a therapeutic target for the treatment of 
this important comorbidity in chronic disease. 
Given that TSP-2 is up-regulated in chapter 5, and VEGF is trending downwards or 
unchanged, this still agrees with the hypothesis that an altered angiogenic balance controls 
vascular growth, as seen in skeletal muscle under physiological settings (as in chapter 3 and 
other studies [6, 38]).  It is important to point out that while there is one publication showing 
increased skeletal muscle capillarity with the knock-out of TSP-2 [55] no further work has been 
done to build upon this.  Therefore, it has yet to be answered if TSP-2 has a controlling role in 
physiological or exercise induced capillary growth/regression (vs. pathological angiogenesis).  It 
would be interesting to see if TSP-2 has a decreased role in physiological angiogenesis, given 
TSP-1’s apparent dominant role.  Studies using the dual TSP-1/TSP-2 knockout suggests that 
wound healing is dictated by TSP-1 and not TSP-2 [56], which might suggest further that under 
normal (physiological) conditions TSP-1 is more important compared to TSP-2.  However, 
interestingly TSP-2 seems to be acting through the same CD36 receptor as TSP-1 in cancer, so 
the differences may be subtle [57].  If TSP-2 is indeed less important in physiological 
angiogenesis, but more important in pathological angiogenesis, it could suggest distinct and 
pivotal roles for the two closely related TSP family members. 
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We also observed that in the angiogenic array all of the 53 proteins tested, both positive 
and negative, are trending upwards in the TNFα+ animal.  Indeed, this includes 13 proteins with 
P values of less than 0.10.  This may suggest that under a chronic systemic inflammatory 
challenge with TNFα, as seen in our model, skeletal muscle could be in a constant state of 
angiogenic stimulus.  The increase in TNFα could be driving an increase in TSP-2 expression, 
and that of other potentially yet-unknown negative angiogenic markers (like IL-10, IP-10, or 
MMP-9 as suggested by the angiogenic array), resulting in a decrease in capillarity, and a 
rebound response in positive angiogenic proteins.  We hypothesize that constant elevated TNFα 
is increasing negative angiogenic factors causing a feed-forward loop. As the muscle reacts to 
the drop in capillarity caused by this increase in negative angiogenic proteins, it could spur a 
high expression of positive angiogenic factors as a compensatory mechanism.  This could then 
further stimulate an increase in negative proteins, causing a feed-forward consequence.  This 
could explain the general trend for increases in all angiogenic proteins.  In this way, the balance 
is constantly trying to be reestablished, potentially resulting in a state of high-angiogenic protein 
production.  Supporting this theory, preliminary work from our lab shows that both TSP-1 and 
VEGF are increased with physical detraining, even after capillarity is returned to baseline (figure 
3 of appendix).  It could be that an increase in TSP-1 drives the decrease in capillarity seen in 
that study, and VEGF is responding (increasing) to prevent too much capillary rarefaction, or 
slow the rarefaction, from occurring.  In this way, VEGF would be serving as a feedback 
mechanism.  Without a constant input, like that from TNFα as in chapter 5, this allows the 
system to be tightly regulated.  It is only when you have this constant TNFα mediated chronic 
systemic inflammatory insult that you push the system into a feed-forward response.  This is an 
intriguing hypothesis that will need further evidence for support.   
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Connecting this notion to those findings in chapter 3, endogenous TSP-1 and its CD36 
receptor are trending downward in response to exogenous chronic stimulation of a negative 
angiogenic pathway (TSP-1).  As discussed previously, VEGF is also decreased in these studies 
of chapter 3.  This suggests that skeletal muscle is reacting to an increase in the stimulation of 
the TSP-1 anti-angiogenic pathway, and the decreased expression of VEGF, by altering 
expression of endogenous TSP-1 and its receptors, likely in an effort to maintain homeostasis.  
This would be a similar feedback system as argued previously. While we admit in chapter 3 it 
could simply be that exogenous TSP-1 is directly binding and resulting in the endocytosis of 
VEGF (as argued previously in this discussion), these data is not inconsistent with this theory of 
a tightly controlled balance. 
Regardless, chapters 3 and 5, in combination with the available literature, not only point 
to TSP-1 and TSP-2 as important components in controlling skeletal muscle angiogenesis, but 
also build upon and add significantly to the hypothesis that skeletal muscle capillarity is 
regulated by a balance between negative and positive angiogenic proteins. 
 
TSP-1 appears to affect oxidative muscles preferentially   
It is interesting to point out that in chapter 3 soleus capillarity is affected to a greater 
degree than that of the plantaris or gastrocnemius.  While it is true that capillarity of the 
gastrocnemius and plantaris are both decreased in chapter 3, the soleus has the largest reduction 
in capillary-to-fiber ratio (35% reduction in the soleus vs. 20% in the gastrocnemius and 15% in 
the plantaris).  Interestingly, the gastrocnemius has the second greatest decrease, and it is the 
second most oxidative of the three muscles, with the plantaris being the least.  This may suggest 
that TSP-1 affects slow-fiber type muscles (i.e. oxidative) to a larger extent than the fast-fiber 
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muscles (i.e. glycolytic), as the soleus is comprised of a significantly greater proportion of slow 
muscle fibers when compared to either of the other muscles tested (i.e. type I and type IIa).  
Indeed, supporting this theory, in previous studies soleus capillarity in hind-limb unloading 
seems to be affected to a greater extent when compared to the plantaris [6], and only the soleus 
shows an increase in TSP-1 in this same model (again compared to the plantaris). 
Paralleling the findings in chapter 3, chapter 5 provides further proof that the soleus is the 
muscle preferentially affected.  In chapter 5 the soleus is the only muscle with capillary 
reduction.  However, potentially contrary to our hypothesis that TSP-1 may be driving this 
muscle-specific response, we only found a change in TSP-2, and not TSP-1, of the soleus in 
chapter 5.  This may suggest the preferential loss of capillaries is purely based on the fact that 
this muscle (soleus) generally has more capillaries, so may have a greater capacity to lose 
vasculature without affecting function.  That is, the soleus may be capable of absorbing some of 
the vascular loss because of its already high inherent capillarity.  However, this seems unlikely 
based on previous findings showing that there is decreased muscle function in the soleus [21, 
22]. 
It is more likely that there is a greater sensitivity in the soleus to the various forms of 
angiogenic stimuli (e.g. hypoxia, sheer stress, pH, etc.).  This could be related to the soleus 
having higher endothelial cell content, as endothelial cells are known to be angiogenic sensors, 
and significant contributors of angiogenic proteins [58-60].  Interestingly, when compared 
between the different muscles under untreated conditions in chapter 3, VEGF is significantly 
higher in the soleus when compared to the plantaris (P<0.01), and trends higher in the 
gastrocnemius (P=0.17).  This is also true of TSP-1 in chapter 5, which trends to be higher under 
basal conditions in the soleus when compared to the plantaris (P=0.2).  This may mean the soleus 
 150 
 
has the greatest capacity for changes in angiogenic protein expression, which could explain its 
relative sensitivity to capillary growth/loss, as suggested previously [6]. 
These differential effects on the soleus may explain why we do not see 
exercise/functional differences in chapters 3 and 5 as well.  In chapter 3 we do not see a change 
in maximal running speed.  While this has been shown to be an appropriate exercise model in 
other studies previously [3, 61, 62], it is limited in two important ways.  First, it is a 
measurement of the whole-body exercise capacity of the animal, and secondly it can be 
potentially limited by the biomechanics of the animal.  If it is true that oxidative muscles are 
more affected than glycolytic then it may also be true that the aerobic/endurance systems are also 
more affected, and hence these systems should be identified and tested.  It may be that in our 
studies it is more appropriate to use endurance testing, where the animals are put on a treadmill 
and allowed to run for as long as possible at a set speed.  Indeed, we decided to use endurance 
testing in chapter 5, based on this theory and the findings in chapter 3, and found a significant 
decrease in endurance time of TNFα+ mice, despite previous evidence suggesting no change in 
maximal running speed [22].  Supporting these findings further, in vivo muscle stimulation 
which tests the whole tricep surea yielded no significant difference in muscle fatigue between the 
TNFα+ and control mice.  Since the plantaris was shown to have no change in capillarity, and 
preliminary evidence suggests the gastrocnemius is also unchanged (not shown), and the soleus 
makes up the smallest contribution to the hindlimb muscle triad, it may not be surprising we saw 
no difference in function.  This would then agree with previous findings, where Tang et al. 
showed in TNFα+ mice soleus fatigue was increased, while the EDL remained unchanged in situ 
[22], again suggesting an oxidative specific response. 
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In summary, it appears that there is a capillary-specific loss in the soleus.  This could be 
significant in terms of overall function, and muscle function, in humans.  We rely heavily upon 
our aerobic muscles for daily tasks such as climbing stairs and walking.  In concert with a 
reduced exercise capacity from central pathological contributors found in many chronic diseases 
(e.g. lung function, cardiac output) [25-27, 63-65], even a small additional loss in 
capillarity/oxidative capacity of skeletal muscle could translate into large functional deficits.  In 
COPD there is a documented reduction in muscle function, VO2max, capillarity, and the number 
of type I fibers in human quadriceps muscle [24, 27].  The loss of type I fibers is correlated with 
a decrease in overall exercise capacity more strongly in those with COPD than healthy controls 
[27], thus pointing towards an important role for this potential muscle specific reduction in 
capillarity.  Despite the work here, what role TSP-1 plays in this specific response remains 
unclear, however chapter 3 points towards a potential regulatory role. 
 
The role of TSP-1 in skeletal muscle endothelial cell apoptosis remains unclear 
TSP-1 has been shown to be promote apoptosis acting through multiple mechanisms, 
including the CD36 receptor [66-71].  Endothelial apoptosis is a naturally occurring mechanism 
by which capillary regression can take place [72-75], and myocyte apoptosis has been shown to 
be central in muscle atrophy under some pathological conditions as well as aging and disuse [76-
80].  However, the role of TSP-1 and CD36 in myocyte and endothelial cell apoptosis in vivo is 
not well characterized. 
In chapter 3 we performed TUNEL staining to look at end stage apoptosis (DNA 
fragmentation) in response to a chronic administration of the TSP-1/CD36 agonist ABT-510.  
Surprisingly, we found no evidence of apoptosis in any of the muscles, either in myocyte or 
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endothelial cells.  The reason for this remains unclear.  This is, however, the first in vivo report 
of ABT-510s affects on skeletal muscle and it could be that ABT-510 is not sufficient to induce 
myocyte apoptosis in skeletal muscle.  This is supported by a lack of change in muscle fiber 
cross-sectional area (FCSA) in both chapters 3 & 4, despite both long and short-term chronic 
doses of the TSP-1 mimetic in each study, respectively.  However, much of the work with TSP-1 
and apoptosis pertains to cancer models (e.g. tumorigenesis), endothelial cells, and is typically 
done in vitro [66, 67, 70, 81].  Despite circumstantial evidence suggesting that removal of TSP-
1/CD47 can protect skeletal muscle from radiation injury [82], it could be that a TSP-1/CD36 
mechanism does not play a role in skeletal muscle apoptosis. 
However, this does not explain why we saw no endothelial cell apoptosis in chapters 3 or 
4.  However, chapter 3 examined only one time point.  We hypothesized that apoptosis could 
have occurred at an earlier time point than our single assessment at 14 days.  Indeed, it has been 
shown previously that hindlimb unloading results in capillary loss in as little as 5 days [6].  For 
this reason in chapter 4 we hypothesized that evidence of endothelial cell death would be present 
in the muscles of ABT-510 treated mice at 3 and/or 7 days.  Surprisingly, we still found no 
evidence of apoptosis, or necrosis (cell death), with either of these shorter time points.  The data 
from chapter 3 and chapter 4 together imply that the reduction in muscle capillarity that occurs 
with chronic exposure to a TSP-1 mimetic is not mediated by a traditional cell death mechanism 
(e.g. apoptosis).  This is an intriguing and novel finding that could have impact on the direction 
of further research into this area.   
It could be that there are increased levels of autophagy in response to the TSP-1 mimetic, 
resulting ultimately in cell dysfunction and death.  Autophagy has been shown to be important in 
other systems, including skeletal muscle [83-85].  While not directly linked to CD36, recently 
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the TSP-1 receptor CD47 has been implicated in autophagy, where CD47 agonists increase 
autophagy in cancer cells, as well as decreasing the capillary supply of tumors, all without 
causing any apoptosis [86].   It has also been shown that other anti-angiogenic proteins, such as 
endostatin, can trigger autophagy which results in inhibition of angiogenesis [87].  Interestingly, 
endostatin has been shown to up-regulate TSP-1, but what role this connection has in autophagy 
remains to be seen [88, 89].   While only speculative at this point, autophagy could be a non-
apoptotic mechanism for the removal of endothelial cells in skeletal muscle, or reduction in their 
viability, and hence a resultant shrinking of the capillary network. 
It is also important to point out possible experimental limitations in our methods to 
measure apoptosis in chapters 3 & 4.  While TUNEL has been a time-tested quality measurement 
of end stage apoptosis in many models [90-93], it only captures those nuclei undergoing DNA 
fragmentation.  With the number of endothelial cell nuclei being relatively low in a 10µm serial 
muscle section, it could be that we are simply not capturing enough sample to see significant 
apoptosis occurring.  But it does seem unlikely that the number of apoptotic nuclei would be 
significantly lower between groups and yet undetectable, given previous findings using similar 
methods [94]. 
This is why we chose the cell death ELISA in chapter 4, as it does not rely on 1 single 
snap shot of a muscle section, but rather captures what is going on in the entirety of the muscle.  
We hypothesized then that it would identify all cells undergoing cell death (including all 
endothelial cells) found in the tissue (skeletal muscle).  However, the ELISA is limited in that it 
does not specifically measure apoptosis, but measures total cell death (apoptosis, necrosis).  Still, 
it has been used to quantify endothelial cell death previously [95].  Regardless of these 
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limitations, we argue that the combination of the TUNEL staining and the ELISA together 
establish the lack of apoptosis in skeletal muscle endothelial cells in chapters 3 and 4. 
 
TSP-1 influences mitochondrial enzyme activity 
It was shown previously that TSP-1 can control mitochondrial biogenesis in young 
animals [96] and that TSP-1 KO animals have more intact mitochondria after an 8 weeks of 
treatment with radiation compared with wild-type animals [82].  While this suggests a regulatory 
role for TSP-1 in mitochondrial biogenesis and integrity, both of these studies are missing any 
direct measurement of mitochondrial function.  In chapter 4 we showed that mitochondrial 
electron transport chain (mETC) enzyme activity is decreased in response to increased TSP-1, 
and increased in TSP-1 KO.  In combination with decreasing capillarity, TSP-1’s control of 
mitochondrial function could be an additive response in its control of total muscle function.  That 
is, mitochondria have been shown to be vital in total exercise capacity [65, 97-102], and 
regulation of their oxidative capacity would therefore have a significant role in overall muscle 
function.  While mitochondria have been shown to be regulated by many different proteins, TSP-
1 could be an important player in this process [96, 103-105].   
The mechanism by which TSP-1 decreases mETC activity in chapter 4 is unknown.  It 
has been suggested that it could be due to TSP-1’s control of nitric oxide (NO) [96, 106-109].  
NO is a stimulator of mitochondrial biogenesis [110-112].  However, TSP-1’s control of NO has 
been shown to occur through its CD47 receptor [107, 113, 114].  In our studies in chapter 3 and 
4, we did not investigate CD47, rather we targeted the TSP-1/CD36 axis to examine how it 
affected capillarity and mitochondria function.  The work shown here is the first evidence that 
TSP-1 may be influencing mitochondria function through TSP-1/CD36.  There is only one other 
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study looking at CD36s role in mitochondria oxidative function, and that study found no 
difference in mitochondrial fatty acid enzyme activity in a whole-body CD36 KO [115].  
Interestingly, CD36 has been found in the mitochondrial membrane, where it is thought to 
control fatty acid translocation [116].  Whether TSP-1 is binding cell surface receptors and 
triggering a protein cascade, or is being translocated and binding CD36 on the mitochondria 
directly, is yet unknown.  
It could be that the decrease in mETC activity is simply due to a decrease in mitochondria 
number (i.e. less mitochondria, less total enzyme), as shown previously [96].  Long term hypoxia 
has also been shown previously to decrease mitochondrial density [117, 118], and so the anti-
angiogenic actions of TSP-1 could also be indirectly influencing mitochondria density and 
function.  The lack of any difference in the CD36 KO mitochondrial function [115, 116], but a 
decrement in our TSP-1 exposure model in chapter 3, may suggest that this is truly a TSP-1 
mediated function, and not a CD36 function per se.  It also supports the previous notion that 
perhaps TSP-1’s regulation of mitochondria is controlled by CD47’s regulation of nitric oxide 
[96], and not by CD36.  Further studies directed at TSP-1, CD36, CD47, will provide answers to 
these questions. 
Given the change in mitochondrial enzyme activity, we hypothesized that muscle 
function and whole body exercise capacity would be decreased with changes in TSP-1.  
However, in chapters 3 we show no change in overall exercise capacity in terms of maximal 
running speed, and in chapter 4 we show no change in ex vivo muscle function.  It could be that 
the changes we see are not enough to result in isolated muscle/whole body functional 
differences; however this seems unlikely, because the changes in mitochondrial enzyme activity 
found here are larger than those shown previously to occur with six weeks of exercise training 
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[119].  Further, a decrease in soleus capillarity of the magnitude found in chapter 3 is at least 
equal in magnitude to the increase in capillarity that exercise training stimulates.  This magnitude 
of change has been shown previously by our lab and others to affect overall exercise function 
[120-122], and is greater in magnitude than that seen with 9 days of hindlimb unloading [6].  
Therefore we must conclude that this is a functionally relevant decrease.  It is much more likely 
that while maximal running speed has been shown to be a good surrogate for VO2max in mice, as 
discussed previously, it may not be the best test to have performed in the context of this study 
(i.e. an endurance run test could have been a more appropriate test).  
This same concept could also be applied to the ex vivo preparation.  The strength of ex 
vivo muscle stimulation is that it removes central factors from the regulation of skeletal muscle 
function (i.e. the heart and lungs), and focuses solely on the muscle.  However, it is not the best 
reflection of the aerobic/endurance systems of the muscle.  That is, because the endogenous 
vascular network is removed in the process of excising the muscle, ex vivo stimulation divorces 
blood flow from its influence on muscle function.   Still, it is surprising we saw no change in ex 
vivo function in the TSP-1 KOs, as they have been shown to have increased endurance capacity 
as well as increased maximal running speed [3].  Of course, the mETC activities that we tested 
only make up one part of the oxidative capacity of the mitochondria, and it could be that the 
change in these specific enzymes are not enough to cause an overall change, especially since we 
are removing the muscles from their endogenous system.  The changes in the mETC enzymes 
may only be functionally relevant with the corresponding changes in vascularity (i.e. increased 
C:F in the KO and decreased C:F in the mimetic treated animals) since the ex vivo preparation 
provides a super-physiologic amount of metabolic substrate, and divorces endogenous blood 
flow.  In situ or in vivo muscle stimulation could answer these questions, as they keep the 
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endogenous vascular and metabolic systems intact.  Indeed, the reason we chose to do in vivo 
muscle stimulation in chapter 6 is precisely because of the findings in chapter 5.  If we want to 
answer what is occurring with aerobic exercise and muscle function in the future, these 
limitations will need to be addressed. 
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Chapter 7: Future Directions 
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Given the findings in all chapters of this dissertation, there are significant new questions 
that now will require further investigation. 
One interesting future direction would be to analyze what role TSP-2 has in both 
pathological and physiological angiogenesis.  It appears TSP-2 may be playing a role in 
pathological capillary regression, but the work in this dissertation is the first and only data to 
suggest this (chapter 5, figure 5).  Indeed, there is almost no work on TSP-2 in skeletal muscle 
under any conditions, and the data that does exist does not directly analyze what role TSP-2 
plays in skeletal muscle angiogenesis.  The potential importance of TSP-2 becomes even more 
intriguing when taken in context with the finding that TSP-1 likely has little or no role in chronic 
systemic inflammatory induced capillary rarefaction, yet seems to play an important role in 
physiological angiogenesis (chapter 5).  It would be interesting to look at TSP-2 in normal 
healthy animals, as well and also to determine what effects exercise training has on TSP-2.  This 
could yield further information as to TSP-2s role in controlling physiological angiogenesis, as 
exercise is one of the strongest stimulus for angiogenesis.  Further work with the TSP-2 KOs to 
see how their exercise capacity and skeletal muscle capillarity compares to normal animals 
would also yield powerful information not only on the role of TSP-2, but how TSP-2 compares 
to TSP-1 in this context.  These potentially divergent roles for the closely related TSP-1 and 
TSP-2 proteins have not yet been characterized.  Further, since capillary loss and an altered 
angiogenic response are strongly correlated with the muscle dysfunction in chronic disease 
finding a major regulator that could serve as either a) a biomarker or b) a therapeutic target of 
this dysfunction is of high interest to both scientists and clinicians alike.  We suggest that TSP-2 
could be this protein. 
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We have eliminated TSP-1 and VEGF as potential markers/mediators of capillary 
regression in a TNFα induced chronic systemic inflammatory insult, despite their apparent 
critical roles in physiological angiogenesis.  To date, we have speculated that the pathways that 
control pathological and physiological angiogenesis are regulated by the same protein mediators 
based on the available literature, however little evidence exists to either support or refute our 
hypothesis in skeletal muscle.  Our data suggests that there may be differences in the regulatory 
pathways of skeletal muscle angiogenesis that relate to specific conditions.  That is, we suggest 
that there are divergent pathways that control physiological vs. pathological angiogenesis in 
skeletal muscle.  Identifying these different pathways and the molecular mediators important to 
each could be important in a variety of settings, from exercise training prescription to clinical 
treatment of disease.  This suggests future work with broad-scope proteomics may help to 
identify how divergent pathways and proteins regulate pathological vs. physiological 
angiogenesis. 
Based on the data from chapters 3 and 4, we suggest it is now important to determine if 
autophagy is the mechanism by which capillaries are lost in skeletal muscle regression.  This is a 
new and untested hypothesis.  Autophagy is a critical regulatory process in many tissues and 
proven to be important in skeletal muscle.  While autophagy is a known to be an apoptotic 
trigger, very recent evidence suggesting that TSP-1 mediated autophagy does not trigger 
apoptosis, yet can still decrease vascularity [1]. While this study was performed in cancer cells, it 
fits well with our findings.  That is, we show no apoptosis or necrosis in the presence of a TSP-1 
mimetic, yet a decrease in capillarity (chapters 3 and 4).  At present, we are unaware of any 
studies that examine what role autophagy plays in skeletal muscle angiogenesis.   Further still, no 
data exists on TSP-1’s role in autophagy in any tissue beyond that recently reported in the 
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context of cancer.   While only speculative at this point, autophagy could be a non-apoptotic 
mechanism for the removal of endothelial cells in skeletal muscle, or reduction in their viability, 
and hence a resultant shrinking of the capillary network.  This is a potentially exciting new role 
for TSP-1 in skeletal muscle. 
One important protein that was not examined in this dissertation is CD47.  CD47 is a 
TSP-1 receptor that has been shown to be a critical component of the TSP-1 anti-angiogenic 
pathway.  However, its role in skeletal muscle is poorly studied.  Since CD47 is speculated to be 
a powerful global regulator of nitric oxide, it certainly could be playing an important role in 
skeletal muscle, as nitric oxide has a variety of functions that are important to skeletal muscle.  
The current work established that CD36 is important in skeletal muscle capillary rarefaction 
(chapters 3 and 4), however it would also be interesting and important to see how manipulation 
of CD47 affects skeletal muscle structure and function.  Indeed, CD47 has been shown to have 
overlapping functions with CD36, and may work in concert with CD36 to decrease vascularity.  
If this is true, we may see greater deficits with the manipulation of both CD36 and CD47, versus 
just CD36 alone.  This may also be why we do not see functional differences in muscle shown in 
chapters 3 and 4. 
Finally, our the work showing that TSP-1 is influencing mitochondrial function suggests 
further work in isolated mitochondria could yield an intriguing role for TSP-1 in skeletal muscle.  
The role that TSP-1 plays in mitochondrial function remains almost entirely unexplored, with the 
only work done in mitochondria and TSP-1 relating to biogenesis, and not function.  Indeed, if 
TSP-1 decreases mitochondrial number and/or function, as suggested by our data in chapter 4, it 
only strengthens the role for TSP-1 in controlling overall muscle function.  Our data in chapter 4 
is also the first to suggest that this regulation of mitochondria may occur through CD36, and not 
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CD47 as previously suggested [2].  Parsing out the pathways that are important in this potential 
TSP-1 control of mitochondrial number/function will provide important mechanistic 
understanding on TSP-1 role in muscle function.  Also, it would be interesting to determine what 
differential affects, if any, TSP-1 has on mitochondrial subpopulations in skeletal muscle 
(subsarcolemmal vs. interfibrillar), as each has been suggested to have distinct and important 
roles.   
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Figure 1: Time course protein expression of TSP-1 following training. Control mice are 
untrained, all others voluntarily trained using a running wheel for 3, 5, 7, 14, or 28 days (n=12/group). Following 
training, half of the mice per group (n=6) were evaluated under basal conditions (black bars), and the other half 
(n=6) performed a single bout of acute exercise (1 hour, 20 m/min, 10° incline) with muscles harvested 4-hours post 
exercise (gray bars). A.U.= arbitary densitometry units (normalized to GAPDH).  Animals from this study showed 
significant capillary increase (as measured by capillary-to-fiber ratio) by 7 days, which continued to increase 
through 28 days. #: Significantly different compared to 14-day trained Basal levels, p<0.05; &: significantly 
different compared to 28-day trained Basal levels, p<0.05; $: signifies p ≤0.10 compared to Basal control.  Adapted 
from Data submitted to The Journal of Physiology (May2013, preliminary acceptance) “Temporal response of positive and negative regulators 
in response to acute and chronic exercise training in mice” Sara A. Olenich, Navarre Gutierrez-Reed, Gerald N. Audet, and I. Mark Olfert 
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Figure 2: Chronic systemic inflammation does not change skeletal muscle TSP-1 levels in 
several different rodent models.  Thrombospondin-1 remained unchanged in the A) obese 
db/db(N=4/group) and B) chronic cigarette smoke mouse models (N=8-10/group).  The db/db mice have a 
genetically induced leptin deficiency which results in obesity and increased systemic inflammation.  Mice in panel B 
were subjected to 6 months of direct cigarette smoke exposure.  Mice were subjected to 12 cigarettes over 60 
minutes, 5 days a week.  Cigarette smoke has been shown previously to induce systemic inflammation.   C) Obese 
Zucker rats (N=6/group) also have no increased TSP-1 in two distinct muscles (SOL and PLT).  Obese Zucker rats 
are similar to the db/db mice in that they have dysfunctional leptin signaling and grow extremely obese and have 
been shown to have increased systemic inflammation.  Unpublished data    
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Figure 3: Detraining results in a loss of capillaries, along with increased TSP-1 and VEGF. 
Animals underwent 21 days of training where they had free 24 hour access to running wheels.  Animals spent 
apporximately 300-360 minutes per day running (data not shown).  A) After 21 days the D1 group was sacrificed, 
while groups D7-D28 had wheels removed but were allowed free range of their cages for either 7 (D7), 14 (D14), or 
28 days (D28).  After 21 days of training there was a signfiicant increase in capillarity, as expected. After 7 days 
without the wheels (i.e. detraining), there was significant drop in capillarity that remained low through 28 days.  B) 
This reduction in capillarity at 7 days coincided with an increase in TSP-1 protein levels.  C) Surprisingly, VEGF 
levels were increased from D1-D14. * P<0.05 from control; † P<0.05 from D1.  Adapted from data to be submitted to The 
Journal of Physiology (August 2013) “Effects of Detraining on the Temporal Expression of Key Positive and Negative Angioregulatory Proteins 
in Skeletal Muscle” Sara A. Olenich, Gerald N. Audet, Kathleen A. Roberts, and I. Mark Olfert 
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Abstract
Angiogenesis is an essential process for normal skeletal muscle function. There is a growing body of evidence suggesting
that thrombospondin-1 (TSP-1), a potent antiangiogenic protein in tumorigenesis, is an important regulator of both
physiological and pathological skeletal muscle angiogenesis. We tested the hypothesis that chronic exposure to a TSP-1
mimetic (ABT-510), which targets the CD36 TSP-1 receptor, would decrease skeletal muscle capillarity as well as alter the
balance between positive and negative angiogenic proteins under basal conditions. Osmotic minipumps with either ABT-
510 or vehicle (5% dextrose) were implanted subcutaneously in the subscapular region of C57/BL6 mice for 14 days. When
compared to the vehicle treated mice, the ABT-510 group had a 20% decrease in capillarity in the superficial region of the
gastrocnemius (GA), 11% decrease in the plantaris (PLT), and a 35% decrease in the soleus (SOL). ABT-510 also decreased
muscle protein expression of vascular endothelial growth factor (VEGF) in both the GA (2140%) and SOL (262%); however
there was no change in VEGF in the PLT. Serum VEGF was not altered in ABT-510 treated animals. Endogenous TSP-1 protein
expression in all muscles remained unaltered. Tunnel staining revealed no difference in muscle apoptosis between ABT-510
and vehicle treated groups. These data provide evidence that the anti-angiogenic effects of TSP-1 are mediated, at least in
part, via the CD36 receptor. It also suggests that under physiologic conditions the TSP-1/CD36 axis plays a role in regulating
basal skeletal muscle microvessel density.
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Introduction
Physiologic angiogenesis and homeostasis of adult blood vessels
is a complex process that is highly regulated by a balance between
positive and negative angiogenic proteins. While there is a
substantial body of evidence on the role positive angiogenic
factors, such as vascular endothelial growth factor (VEGF) [1,2,3],
the role of negative angiogenic factors is incomplete and poorly
understood [4].
There are a number of known angiogenic inhibitors, of which
thrombospondin-1 (TSP-1) is thought to play a prominent role in
skeletal muscle angiogenesis [4]. TSP-1 is a large (450 kD)
extracellular protein that has a wide array of functions [5]. First
discovered for its role in wound healing and platelet activation, it
also has important roles in apoptosis, inflammation, nitric oxide
signaling, and inhibition of positive angiogenic proteins
[6,7,8,9,10]. Acting through CD36 (one of its receptors), TSP-1
has been shown to prevent endothelial cell adhesion, growth, and
migration, as well as increase apoptosis [11,12,13]. The anti-
angiogenic effects of TSP-1 in cancer pathology are well
established. For example, a reduction in TSP-1 has been shown
to increase tumor vessel growth, whereas pharmacological
administration of several different TSP-1 mimetics has helped
decrease tumor size and disease progression in animal models
[14,15,16,17].
Under physiologic conditions, TSP-1 expression has been
shown to be responsive to exercise [18,19], which suggests that
TSP-1 may play a role in regulating exercise-induced skeletal
muscle angiogenesis. TSP-1 KO mice have elevated skeletal
muscle capillarity compared to wild-type mice, suggesting a critical
role for TSP-1 in the physiological maintenance of capillaries [4].
Evidence in rats also shows that hindlimb unloading increases
TSP-1 in association with decreases in skeletal muscle capillarity
[3]. Recently, TSP-1 and it’s receptor CD47 have also been
suggested to play a pivotal role in skeletal muscle mitochondrial
biogenesis, and therefore it is likely to be important in overall
skeletal muscle function and adaptation to exercise stress [20].
Given the growing data implicating that importance of TSP-1
as a key angiogenic regulator in skeletal muscle, we sought to
determine the consequences of chronically stimulating the TSP-1
pathway using ABT-510. ABT-510 is a mimetic of the conserved
type I repeat region of TSP-1 which has been shown previously to
inhibit angiogenesis through the CD36 receptor [12,13,21]. ABT-
510 has been synthesized to have a longer half life in circulation
than the native type I repeats of TSP-1 which allows for increased
chronic stimulation of the TSP-1/CD36 pathway [22]. ABT-510
has been shown to be a potent inhibitor of vascular growth in
tumorigenesis both in vitro and in vivo [15,23,24,25,26,27,28],
which has been attributed to its binding to the CD36 receptor.
Using this peptide we aimed to examine whether increased
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stimulation of the CD36 arm of the TSP-1 pathway affected
skeletal muscle structure and function. Given that TSP-1 is a
negative angiogenic regulator, we hypothesized that mice subject-
ed to the ABT-510 would have lower skeletal muscle capillarity,
mirrored by an altered balance between positive and negative
angiogenic proteins.
Methods
Animals
This study used 10–12 week old male C57BL/6 mice purchased
from Jackson Laboratories (Strain no. 000664, C57BL/6J, Bar
Harbor, ME). Mice were randomly selected to be placed in two
groups (control, n = 8; experimental n = 8). All procedures that
involved animals were approved by the West Virginia University
Institutional Animal Care and Use Committee.
Exercise Testing Protocol
Whole body exercise capacity was assessed using a graded
maximal exercise test (max test) 48 hours before pump implan-
tation and then again 48 hours before muscle harvest (12 days
after implantation). This was done to ensure that the exercise bout
did not influence protein levels in muscles harvested on the final
study day (Day 14) [18]. Maximal run test procedure: mice were
given a 5 minute warm-up (speed ,4 m/min) at a 10 degree
incline on a commercially available rodent treadmill (Columbus
Instruments, Columbus, OH). After the warm-up period, the
treadmill was increased 2 m/min every 30 seconds until the
animals reached exhaustion. Exhaustion was defined by a single
observer as the inability of the animal to stay on the treadmill at a
given speed, and/or more than 3 seconds spent on the shock grid.
Animals were encouraged to run as fast and as long as possible by
using forced air and a weak electrical deterrence. Final run time
and velocity were recorded and compared between groups.
Osmotic Pump Drug Delivery
The TSP-1 mimetic ABT-510 was generously provided by
Abbott (Abbott, IL). This compound was chosen for use in this
study based on previous and preliminary work showing its
effectiveness in decreasing capillarity in tumors, both in vitro and
in vivo [15,22,23,24,25,29,30]. ABT-510 was dissolved in 5%
dextrose (vehicle) over a 48 hour period to ensure the compound
was fully dissolved, and then inserted into mini-osmotic pumps
(Model 1002, Alzet Osmotic Pumps, Cupertino, CA,). Pumps were
filled with either the drug or vehicle solution 24 hours in advance
of implantation as per manufacture instructions. We delivered the
maximum concentration of 30 mg/kg/day based on the maxi-
mum pump capacity (100 mL), the mass of the animals, and the
solubility of the drug (ABT-510 solubility curves [22]). Pumps were
surgically inserted (flow-moderator first) subcutaneously in the
scapular region while the mice were under anesthesia (2%
isoflurane). The surgical site was disinfected with iodine and
closed using sutures. Animals were then housed individually and
observed daily for the remainder of the study for pain or distress.
Pumps remained in the animals for 14 days, after which they were
sacrificed and tissue/organ samples were collected and stored at
280u for later analysis.
Morphometry
Hindlimb skeletal muscle was surgically excised and frozen in
isopentane cooled by liquid nitrogen. Frozen tissue was cut using a
220uC cyromicrotome (Jung-Reichert Cryocut 1800: Cambridge
Instruments, Germany) to yield 10 mm transverse sections. Great
care was taken to ensure the cryosectioned muscles were cut along
the transverse plane. Sections were stained for dipeptidly-peptidase
IV (DPP IV) and alkaline phosphatase (AP) following the method
of Lojda (1979), as applied to skeletal muscle tissue [31,32]. A light
microscope (Zeiss primo star, Zeiss, Oberkochen, Germany) was
used to digitally acquire (Axiocam IC c3, Axiovision 4.8.2.0, Zeiss,
Oberkochen, Germany) 206 images of the gastrocnemius,
plantaris, and soleus. Capillary and myofiber counting was
performed by a single individual blinded to group identification.
For the gastrocnemius muscle, we obtained images in a
checkerboard fashion across the entire muscle, thus both
superficial and deep regions within the gastrocnemius could be
included in the analysis. For the plantaris and soleus muscles,
respectively, the entire muscle was imaged and analyzed. Counting
was performed by visualization from acquired images using a
custom program in MATLAB (version 7.0.0.27, The Mathworks,
MA, USA) allowing the operator to visually mark and count the
capillaries and fibers on each image. Capillary-to-fiber ratio (C:F,
number of capillaries/number muscle fibers), capillary density
(CD, number of capillaries/mm2 muscle fiber area), and fiber
cross sectional area (FCSA) were separately calculated for the
gastrocnemius (GA), soleus (SOL), and plantaris (PLT) (n = 33–
101 images/muscle/group).
Protein Analysis
GA, SOL, and PLT muscles from each group were excised and
flash frozen in liquid nitrogen. They were then separately
homogenized in a lysis buffer containing 50 mM Tris/HCl
(pH 7.4), 150 mM NaCl, 0.5% Triton X-100, and protease
inhibitors (Complete Tablet, Roche Applied Science, Indianapolis,
IN). Homogenates were centrifuged at 4uC, at 8,000 g for
10 minutes, and supernatants removed and placed in new tubes.
Blood samples were obtained from the heart and allowed to
coagulate on ice. They were then centrifuged at 3000 g for
10 minutes and flash frozen in liquid nitrogen. Total protein was
measured by bradford assay (#23236 Pierce Coomassie Plus
Protein Assay Kit, Thermo Scientific, Rockford, IL).
Quantification of VEGF was made from a total of 100 mg of
protein using a commercially available ELISA kit according to the
manufactures instructions (# MMV00, R&D Systems, Minneap-
olis, MN, USA). Quantification of VEGFR-2 and P-VEGFR-2
were made from a total of 100 mg of protein using a commercially
available ELISA kit according to the manufactures instructions (#
7335S, #7340S, Cell Signaling, Danvers, MA, USA). TSP-1 and
CD36 were analyzed via western blot. In brief, samples were
separated on a 3–8% SDS-PAGE (NuPAGE Novex 3–8% Tris-
Acetate Midi Gel, Invitrogen, Burlington, ON, Canada) and
blotted onto a 0.45 mm nitrocellulose membrane (Pierce nitrocel-
lulose membrane, Thermo Scientific, Rockford, IL). After
blocking with 5% fat-free milk, membranes were probed using
antibodies against TSP-1 (1:1000, clone A6.1, #399300, Invitro-
gen, Burlington, ON, Canada), b-tubulin (1:1000, #2148, Cell
Signaling), CD36 (1:250 #552544, BD Pharmingen, Franklin
Lakes, NJ, USA), secondary HRP-conjugated anti-mouse (1:1000,
#p0260, Dako, GE Healthcare, Piscataway, NJ) and secondary
HRP-conjugated anti-rabbit (1:1000, #p0217, Dako). Proteins
were visualized using chemiluminescence detection (Pierce ECL,
Thermo Scientific, Rockford, IL) and digitally imaged (G:BOX
Gel imager, Syngene, Cambridge, UK) using Genesnap software
(Ver. 7.01, Syngene, Cambridge, UK). Equal protein loading was
verified by immunodetection of b-tubulin as our loading control.
Quantification of protein expression levels were carried out using
NIH Image J Software (v1.62) and expressed as densitometric
arbitrary units (AU).
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Apoptosis
Nuclei exhibiting apoptotic changes were identified by TdT-
mediated dUTP nick end labeling (TUNEL) according to the
manufacturer’s recommendations (Roche Molecular Biochemi-
cals, Pleasanton, CA). Briefly, muscle cross sections were cut on a
cryostat (10 mm) and fixed in 4% paraformaldehyde at room
temperature, blocked in 3% H2O2 in 100% methanol at room
temperature, and permeabilized in 0.1% Triton X and 0.1%
sodium citrate. TUNEL reaction mix was added in a 1:7.5
dilution, and the sections were incubated at 37uC for 1 h. Sections
were reacted with fluorescein antibody for 30 min at 37uC, and
substrate was added for color development. To control for false-
positives, samples were then counter stained by DAPI staining to
identify the nucleus. TUNEL staining was performed using a
fluorescein TUNEL kit at 1:7.5 dilution as recommended by the
manufacturer (Roche Molecular Biochemicals, Pleasanton, CA).
Positive nuclei were counted, and at high power (6400), it was
determined whether they were associated with the myofiber or
with the interstitial space. The number of positive nuclei is
expressed per whole muscle section. Positive controls were created
using a DNase treatment of 1 serial section (# AM1906, DNA-free,
Ambion, Austin, TX). Negative controls were created by staining 1
serial section only for DAPI without TUNEL staining. This
resulted in each sample containing 1 negative, 1 positive, and 2
experimental sections per slide.
Statistics
All data are presented as means+/2SEM. To examine body
mass, organ masses, muscle capillarity and molecular responses we
used a student’s T-test. A repeated measures ANOVA was used to
analyze the maximal running test. An alpha level at P,0.05 was
selected for statistical significance.
Results
Exercise Testing and Morphometry
Body and Muscle Mass. There was no significant difference
in the absolute body or individual hindlimb muscle masses
between ABT-510 (mimetic) and vehicle treated groups (Table 1).
Heart and skeletal muscle normalized to body mass were not
different between the groups (Table 1).
Maximal Running Test. There was no difference in
maximal running speed between vehicle and mimetic treated
animals pre- or post-treatment.
Morphometry. In the superficial region of the gastrocnemius
(GA) muscle there was a 20% decrease in C:F (P#0.05) and a
similar trend in CD (25% decrease, P = 0.055) in the mimetic
group compared to vehicle (Figure 1 & 2). There was no statistical
difference in C:F of the deep portion of the GA between groups,
however there was a significant 25% decrease in CD (P#0.05).
FCSA was not significantly different between groups in either
portions of the GA.
In the plantaris (PLT) muscle, there was a 11% decrease in the
C:F in the PLT in the mimetic group compared to vehicle
(P#0.05) (Figure 3). There was no difference in CD or FCSA in
the PLT.
In the soleus (SOL) muscle, there was a 35% decrease in the C:F
in the SOL in the mimetic group compared to vehicle (P#0.01)
(Figure 3). There was no difference in CD (P = 0.08) or FCSA
(P = 0.09).
Endogenous VEGF, VEGFR-2, p-VEGFR-2, TSP-1, and CD36
Levels
Skeletal muscle VEGF protein expression was decreased by
147% and 62% in the GA and SOL respectively (P#0.05,
Figure 4). In contrast, no significant change in VEGF protein
expression was seen in the in the PLT. Serum VEGF levels were
unchanged between ABT-510 and vehicle treated animals.
Total VEGFR-2 and phorphylated-VEGFR-2 (p-VEGFR-2)
levels were also assessed in the GA. There was no difference in
total VEGFR-2 levels, p-VEGFR-2 levels, or a ratio of VEGF-
R2/p-VEGF-R2 between ABT-510 and vehicle treated mice (data
not shown).
Endogenous TSP-1. protein expression of endogenous TSP-
1 was not significantly different in any of the muscles analyzed
(SOL, PLT, GA) between the treated groups (data not shown).
CD36 levels. There was no difference in the receptor levels of
CD36 in the GA as assessed by western blot (data not shown).
Table 1. Muscle and Body Masses.
Vehicle ABT-510
Body Mass (g) 27.561.23 27.160.87
GA (mg) 136.864.56 140.864.09
PLT (mg) 19.760.90 19.060.53
SOL (mg) 7.760.47 7.86.048
HRT (mg) 123.565.76 134.365.82
GA/BM (mg/g) 5.060.07 5.260.12
PLT/BM (mg/g) 0.7260.04 0.7060.02
SOL/BM (mg/g) 0.2960.01 0.2860.01
HRT/BM (mg/g) 4.460.26 5.060.17
Values: Mean 6 Standard Error.
*P = 0.05.
doi:10.1371/journal.pone.0055953.t001
Figure 1. Representative figures of the histology sections. A)
Superficial Gastrocnemius Muscle B) Deep Gastrocnemius Muscle C)
Plantaris Muscle, D) Soleus Muscle.
doi:10.1371/journal.pone.0055953.g001
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Apoptosis
Apoptosis was assessed using TUNEL staining for fragmented
DNA. There was no difference in the number of TUNEL positive
nuclei in any of the muscles between the two treated groups
(Figure 5).
Discussion
The main finding of this study is that chronic exposure to the
TSP-1 mimetic ABT-510 significantly decreases skeletal muscle
capillarity (Figure 1). To our knowledge, these are the first data to
show that chronic stimulation of the TSP-1/CD36 pathway in
healthy mammals results in decreased skeletal muscle capillarity.
These data are consistent with the anti-angiogenic function of
TSP-1 and, more importantly, support the notion that TSP-1
through its CD36 receptor is a critical regulator of skeletal muscle
capillarity under physiologic conditions. Indeed, when coupled
with the previous observation that loss of TSP-1 increases skeletal
muscle capillarity (25) these data provide evidence that the actions
of TSP-1 directly influence homeostatic maintenance and/or
development of skeletal muscle microvessels.
Skeletal muscle capillarity is decreased in mimetic treated
mice
TSP-1 has been shown previously to be important in
maintaining skeletal muscle capillarity, where TSP-1 KO mice
have approximately 2 fold the number of capillaries as WT
controls [33]. Further, TSP-1 has been shown to be important in
maintaining capillarity with hindlimb unloading [34]. In this
manuscript we build upon this small body of evidence for the
importance of TSP-1 in the context of the basal regulation of
angiogenesis.
The actions of TSP-1 are complex and multifunctional, due in
large part to the diversity of receptors it binds, such as lipoprotein
receptor-related protein 1 (LRP-1), CD47, and CD36 [11,35].
Our use of this the TSP-1 mimetic ABT-510, which is a potent
CD36 binding peptide, resulted in a decrease in capillarity across
three different distinct skeletal muscles. This suggests that TSP-1s
Figure 2. Superficial gastrocnemius capillarity, but not deep, is decreased in the ABT-510 group. Chronic administration of ABT-510
30 mg/kg/day decreased capillary to fiber ratio (C:F) and capillary density (CD) in the superficial gastrocnemius (GA). Despite a similar trend, no
significant changes in capillarity were seen in the deep GA. There was no change in fiber cross sectional area in either the deep or superficial portions
of the GA. * = P#0.05.
doi:10.1371/journal.pone.0055953.g002
ABT-510 Reduces Skeletal Muscle Capillarity
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e55953
anti-angiogenic properties in skeletal muscle involves a CD36
mediated mechanism. Indeed, this is consistent with the physio-
logical activity of CD36 where TSP-1 binding to CD36 has been
shown to be anti-proliferative, anti-angiogenic, and pro-apoptotic
[12]. The importance of the TSP1/CD36 pathway has been
proven in tumorigenesis, where down regulation of TSP-1 and its
binding to CD36 results in a pro-tumorigenesis environment and
increase in tumor size [14,36,37,38]. Here we show similar actions
in skeletal muscle under physiological conditions. This suggests a
putative role for TSP-1 in decreasing vascularity across multiple
tissues, and not just in tumors.
Given these findings, it is tempting to speculate that elevated
skeletal muscle TSP-1 may serve as a biomarker for skeletal muscle
dysfunction associated with several chronic conditions known to
result in muscle capillary rarefaction, such as that found in
diabetes [39,40], and chronic heart and lung disease [41]. It may
even be that therapeutic interventions to limit basal TSP-1
expression and/or reduce circulating levels of TSP-1 could be
clinically exploited to attenuate the decrements in skeletal muscle
function often accompanying these diseases.
Chronic stimulation of the TSP1/CD36 pathway
decreases VEGF
It has been shown previously that TSP-1 can counter the effects
of VEGF by multiple mechanisms; including interacting directly
with VEGF protein and disrupting its actions at the receptor level
[42,43,44,45,46]. For example, TSP-1 has been suggested to bind
VEGF via its type I repeat region (or 3TSR). Once bound the
protein heterodimer is internalized by the scavenger receptor low
density lipoprotein receptor-related protein 1 (LRP-1). Here, we
show that a chronic administration of ABT-510 (a TSP-1 type I
repeat mimetic), results in a decrease in total VEGF protein in
both the gastrocnemius muscle and the soleus muscle, along with
the decrease in capillarity. It is unclear why a similar decrease in
VEGF protein was not seen in the PLT which also showed
decreased capillarity, nevertheless these data support previous
Figure 3. Plantaris and soleus capillarity is decreased in the ABT-510 group. Chronic administration of ABT-510 30 mg/kg/day decreased
capillary to fiber ratio (C:F) in the plantaris muscle (PLT) but did not decrease capillary density (CD). ABT-510 decreased capillary to fiber ratio (C:F) and
capillary density (CD) in the soleus (SOL). There was no change in fiber cross sectional area in either the PLT or SOL muscle. * = P#0.05.
doi:10.1371/journal.pone.0055953.g003
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studies suggesting that TSP-1 may be binding and sequestering
VEGF – resulting eventually in internalization and biological
inactivation [42,43,44,45,46]. Explanations for the reduction in
VEGF may also involve suppression of VEGF production and/or
VEGF signaling. For example, there is a growing body of evidence
showing that the internalization of the VEGF/VEGFR-2 complex
by endocytosis results in downstream activation of several different
signaling pathways [47]. There is also evidence that both CD36
and CD47 can associate with VEGFR-2, and when TSP-1 is
present this association can prevent the VEGF ligand binding to its
receptor, as well as inducing receptor dephosphorylation and
preventing dimerization [13,21,48,49]. In this way, TSP-1 could
prevent activation and/or endocytosis of the VEGF receptor,
blocking yet another biologically active arm of VEGF/VEGF-R
complex. Regardless of the mechanism, our data supports the
notion that TSP-1 likely plays a regulatory role involving VEGF,
thereby enhancing its already potent inherent anti-angiogenic
capacity.
In endothelial cells, TSP-1 can also disrupt VEGF actions at the
receptor level by dephosphorylating the important receptor
VEGFR-2 (Flk-1) [50]. TSP-1 can disrupt VEGFR-2 activation
by binding the CLESH region of CD36, triggering a cascade of
events which results in direct binding of VEGFR-2, and a resultant
decrease in tyrosine phosphorylation of VEGFR-2 [12,13,21].
This includes dephosphorylating the important tyrosine 1175
region; which is critical to initiate downstream VEGF signaling.
While it has also been shown previously that ABT-510 significantly
decreases the amount and phosphorylation status of VEGFR-2 in
endothelial cells in vitro [24,51], in vivo we found no significant
change in the phosphorylation levels of tyrosine 1175 of VEGFR-
2. Given that the mimetic is a type I repeat, and that total VEGF
protein levels were decreased, we were surprised that VEGFR-2
phosphorylation was also not decreased. But, because we only
have one time point, it could be that levels of phosphorylation
were lower earlier in the chronic dosage but by the end of the
study returned to normal levels. While ABT-510 has been shown
to decrease VEGFR-2 phosphorylation in tumors [24], it may be
that this response is different in skeletal muscle under physiological
conditions. It could also be that phosphorylation status in vivo is not
lowered by endogenous TSP-1 (or the addition of a mimetic),
rather TSP-1 limits or prevents an increase in phosphorylation
levels with a VEGF stimulus. This is yet to be elucidated.
Administration of ABT-510 did not significantly alter endoge-
nous levels of TSP-1 in skeletal muscle, indicating that there was
no feedback response from the mimetic binding to CD36 to alter
endogenous TSP-1 levels in skeletal muscle. However, the
Figure 4. Skeletal muscle VEGF protein content is decreased in the ABT-510 group, but not serum levels. Chronic administration of the
mimetic (ABT-510 30 mg/kg/day) decreased VEGF protein in the GA, and SOL muscles of C57/BLK6 mice. There was no change in the PLT muscle or in
Serum levels. * = P#0.05.
doi:10.1371/journal.pone.0055953.g004
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reduction of skeletal muscle VEGF protein levels in association
with the mimetic adds support to the idea that physiologic
angiogenesis is controlled by a balance between both positive and
negative angiogenic factors, particularly VEGF and TSP-1. It
would have been interesting to deliver a higher dose of ABT-510
(.30 ug/kg/day) which may have resulted in greater reductions
in muscle VEGF and capillarity; however the dose used was the
maximum we could deliver using the small pumps suitable for
mice and the 2-week duration we sought. Although shorter
duration would allow greater concentrations of drug delivery, we
opted to deliver the drug for 14 days to ensure that vascular
remodeling would have sufficient time to occur. It could be
hypothesized that tipping the scale towards an anti-angiogenic
state (stimulated by the presence of ABT-510) would result in a
response of positive angiogenic factors to counter this challenge.
However, at least with respect to VEGF this was not the case. A
decrease in VEGF and no change in endogenous TSP-1 suggests
that the muscle has been pushed towards an anti-angiogenic
phenotype.
Regardless of mechanism, these data show that the altered
angiogenic state of the skeletal muscle can be driven by an increase
in a TSP-1 mimetic. The resulting decrease in capillarity
establishes the importance of TSP-1/CD36 pathway in maintain-
ing and regulating basal skeletal muscle microvessel density.
Skeletal muscle and endothelial apoptotic levels do not
differ between groups
In addition to its anti-angiogenic properties, TSP-1 is also been
known to promote apoptosis [6,52,53,54,55,56,57,58]. TSP-1 is
known to induce apoptosis through the CD36 pathway, as shown
in previous studies, including those using ABT-510 [5,24,59].
Endothelial apoptosis is a natural mechanism by which capillary
regression occurs [60,61,62,63], and has been shown to be central
in muscle atrophy during some pathologies, aging, and disuse
[64,65,66,67,68]. Knowing this, we performed TUNEL staining to
look at end stage apoptosis (DNA fragmentation) in all three of the
excised muscles. Surprisingly, we found no evidence of apoptosis
in any of the muscles, either myocyte or endothelial. The reason
for this remains unclear. This is, however, the first in vivo report of
ABT-510s affects on skeletal muscle and it could be that ABT-510
is not sufficient to induce myocyte apoptosis in skeletal muscle
under these conditions. Indeed, much of the work with TSP-1 and
apoptosis pertains to cancer models (e.g. tumorigenesis), endothe-
lial cells, and is typically done in vitro. It is possible that TSP-1 is
not as potent a pro-apoptotic protein in skeletal muscle as that seen
in endothelial cells or tumors. This is supported by the finding that
there was no change in muscle fiber cross-sectional area (Figures 2
and 3). Whether or not the ABT-510, or the TSP-1/CD36 axis,
alters in vivo skeletal muscle myocyte apoptosis will require further
study.
However, this does not explain why we saw no endothelial cell
apoptosis. As mentioned previously, our study only examines one
time point. It is possible that apoptosis occurred at an earlier time
point than our assessment at the 14 day time point. Indeed, it has
been shown previously that hindlimb unloading results in capillary
loss in as little as 5 days [34]. If changes in endothelial cell number,
and therefore total vasculature, are occurring by 5–7 days it may
not be surprising that evidence of apoptosis has been lost by the
end of the study (14 days). That is, perhaps apoptosis has already
occurred, the cells cleared from the tissue, and the architecture of
the vascular network at 14 days has already returned to a new
steady state condition absent of apoptotic nuclei. We have yet to
elucidate this and more experimentation is needed to determine
exactly when apoptosis and regression is occurring.
Summary
In conclusion, we provide evidence for the importance of TSP-
1/CD36 pathway in regulating basal skeletal muscle capillarity by
showing that a chronic dosage of a TSP-1 mimetic for the CD36
pathway decreases skeletal muscle capillarity and VEGF expres-
sion. We did not find any differences in the VEGFR-2 expression
or its phosphorylation status, nor was there greater skeletal muscle
apoptosis. These data show that, despite the multifunctional effects
of TSP-1 and its CD36 receptor, the primary consequence of
elevating circulating TSP-1 (i.e. using a TSP-1 mimetic targeted to
its CD36 receptor) relates to its anti-angiogenic function. These
data may be useful in exploring therapeutic interventions for
individuals with skeletal muscle dysfunction resulting from
capillary regression.
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Figure 5. There is no difference in skeletal muscle apoptosis
between the mimetic and control groups. TUNEL staining shows
that chronic administration of the mimetic (ABT-510 30 mg/kg/day) did
not increase or decrease skeletal muscle apoptosis in any of the muscles
tested. Representative GA samples, PLT and SOL data not shown. A)
Representative mimetic GA B) Representative positive control mimetic
GA C) Representative control GA D) Representative positive control
vehicle GA.
doi:10.1371/journal.pone.0055953.g005
ABT-510 Reduces Skeletal Muscle Capillarity
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e55953
References
1. Breen EC, Johnson EC, Wagner H, Tseng HM, Sung LA, et al. (1996)
Angiogenic growth factor mRNA responses in muscle to a single bout of
exercise. Journal of Applied Physiology 81: 355–361.
2. Olfert IM, Howlett RA, Tang K, Dalton ND, Gu Y, et al. (2009) Muscle-specific
VEGF deficiency greatly reduces exercise endurance in mice. The Journal of
Physiology 587: 1755.
3. Roudier E, Gineste C, Wazna A, Dehghan K, Desplanches D, et al. (2010)
Angio-adaptation in unloaded skeletal muscle: new insights into an early and
muscle type-specific dynamic process. The Journal of Physiology 588: 4579–
4591.
4. Olfert IM, Birot O (2011) Importance of Anti-angiogenic Factors in the
Regulation of Skeletal Muscle Angiogenesis. Microcirculation 18: 316–330.
5. Jack L (2000) The functions of thrombospondin-1 and-2. Current Opinion in
Cell Biology 12: 634–640.
6. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, et al. (2000)
Signals leading to apoptosis-dependent inhibition of neovascularization by
thrombospondin-1. Nature medicine 6: 41–48.
7. Lange-Asschenfeldt B, Weninger W, Velasco P, Kyriakides TR, von Andrian
UH, et al. (2002) Increased and prolonged inflammation and angiogenesis in
delayed-type hypersensitivity reactions elicited in the skin of thrombospondin-2–
deficient mice. Blood 99: 538–545.
8. Varma V, Yao-Borengasser A, Bodles AM, Rasouli N, Phanavanh B, et al.
(2008) Thrombospondin-1 Is an Adipokine Associated With Obesity, Adipose
Inflammation, and Insulin Resistance. Diabetes 57: 432–439.
9. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, et al. (2005)
Nitric oxide regulates angiogenesis through a functional switch involving
thrombospondin-1. Proceedings of the National Academy of Sciences of the
United States of America 102: 13147–13152.
10. Kvansakul M, Adams JC, Hohenester E (2004) Structure of a thrombospondin
C-terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J
23: 1223–1233.
11. Chen H, Herndon ME, Lawler J (2000) The cell biology of thrombospondin-1.
Matrix Biology 19: 597–614.
12. Febbraio M, Hajjar DP, Silverstein RL (2001) CD36: a class B scavenger
receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid
metabolism. Journal of Clinical Investigation 108: 785–792.
13. Primo L, Ferrandi C, Roca C, Marchio` S, di Blasio L, et al. (2005) Identification
of CD36 molecular features required for its in vitro angiostatic activity. The
FASEB journal 19: 1713–1715.
14. Ren B, Yee KO, Lawler J, Khosravi-Far R (2006) Regulation of tumor
angiogenesis by thrombospondin-1. Biochimica et Biophysica Acta (BBA) -
Reviews on Cancer 1765: 178–188.
15. Hoekstra R, de Vos FYFL, Eskens FALM, Gietema JA, van der Gaast A, et al.
(2005) Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the
Thrombospondin-1–Mimetic Angiogenesis Inhibitor ABT-510 in Patients With
Advanced Cancer. Journal of Clinical Oncology 23: 5188–5197.
16. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, et al. (2002)
Inhibition of tumor growth by systemic treatment with thrombospondin-1
peptide mimetics. International Journal of Cancer 98: 682–689.
17. Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, et al. (2006) Preclinical
Evaluation of Antiangiogenic Thrombospondin-1 Peptide Mimetics, ABT-526
and ABT-510, in Companion Dogs with Naturally Occurring Cancers. Clinical
Cancer Research 12: 7444–7455.
18. Olfert IM, Breen EC, Gavin TP, Wagner PD (2006) Temporal thrombospon-
din-1 mRNA response in skeletal muscle exposed to acute and chronic exercise.
Growth Factors 24: 253–259.
19. Olfert IM (2012) Unpublished Data.
20. Frazier EP, Isenberg JS, Shiva S, Zhao L, Schlesinger P, et al. (2011) Age-
dependent regulation of skeletal muscle mitochondria by the thrombospondin-1
receptor CD47. Matrix Biology.
21. Dawson DW, Pearce SFA, Zhong R, Silverstein RL, Frazier WA, et al. (1997)
CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on
endothelial cells. The Journal of cell biology 138: 707.
22. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, et al. (2005)
Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor
growth: design, synthesis, and optimization of pharmacokinetics and biological
activities. Journal of medicinal chemistry 48: 2838–2846.
23. Anderson JC, Grammer JR, Wang W, Nabors LB, Henkin J, et al. (2007) ABT-
510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant
glioma growth in vivo by inhibiting angiogenesis. Cancer biology & therapy 6:
454.
24. Greenaway J, Henkin J, Lawler J, Moorehead R, Petrik J (2009) ABT-510
induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic,
syngeneic model of epithelial ovarian cancer. Molecular cancer therapeutics 8:
64.
25. Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, et al. (2006) Preclinical
evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and
ABT-510, in companion dogs with naturally occurring cancers. Clinical cancer
research 12: 7444.
26. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, et al. (2005)
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic
effect of the thrombospondin peptide ABT-510: a complementation antiangio-
genic strategy. Clinical cancer research 11: 6678.
27. Campbell NE, Greenaway J, Henkin J, Moorehead RA, Petrik J The
Thrombospondin-1 Mimetic ABT-510 Increases the Uptake and Effectiveness
of Cisplatin and Paclitaxel in a Mouse Model of Epithelial Ovarian Cancer.
Neoplasia Press Inc.
28. Isenberg JS, Yu C, Roberts DD (2008) Differential effects of ABT-510 and a
CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on
fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells.
Biochemical Pharmacology 75: 875–882.
29. Hasina R, Martin LE, Kasza K, Jones CL, Jalil A, et al. (2009) ABT-510 is an
effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of
oral carcinogenesis. Cancer Prevention Research 2: 385.
30. Joyce D, Mulji G, Gutierrez L, Castellino F (2006) Evaluation of the
Thrombospondin-1 analogue ABT-510 in the APCMin/+ mouse intestinal
adenoma model. Journal of Clinical Oncology 24: 13545.
31. Mra´zkova´ O, Grim M, Carlson BM (1986) Enzymatic heterogeneity of the
capillary bed of rat skeletal muscles. American Journal of Anatomy 177: 141–
148.
32. Lojda Z (1979) Studies on dipeptidyl(amino)peptidase IV (glycyl-proline
naphthylamidase). Histochemistry 59: 153–166.
33. Malek MH, Olfert IM (2009) Global deletion of thrombospondin 1 increases
cardiac and skeletal muscle capillarity and exercise capacity in mice.
Experimental physiology 94: 749–760.
34. Roudier E, Gineste C, Wazna A, Dehghan K, Desplanches D, et al. (2010)
Angio-adaptation in unloaded skeletal muscle: new insights into an early and
muscle type-specific dynamic process. The Journal of Physiology 588: 4579.
35. Bornstein P (2009) Thrombospondins function as regulators of angiogenesis.
Journal of Cell Communication and Signaling 3: 189–200.
36. Lawler J (2000) The functions of thrombospondin-1 and-2. Current opinion in
cell biology 12: 634–640.
37. Zhang X, Lawler J (2007) Thrombospondin-based antiangiogenic therapy.
Microvascular research 74: 90–99.
38. Lawler J, Detmar M (2004) Tumor progression: the effects of thrombospondin-1
and -2. The International Journal of Biochemistry & Cell Biology 36: 1038–
1045.
39. Kivela R, Silvennoinen M, Lehti M, Jalava S, Vihko V, et al. (2008) Exercise-
induced expression of angiogenic growth factors in skeletal muscle and in
capillaries of healthy and diabetic mice. Cardiovascular Diabetology 7: 13.
40. Kivela¨ R, Silvennoinen M, Touvra A-M, Lehti TM, Kainulainen H, et al. (2006)
Effects of experimental type 1 diabetes and exercise training on angiogenic gene
expression and capillarization in skeletal muscle. The FASEB journal 20: 1570–
1572.
41. Duscha BD, Kraus WE, Keteyian SJ, Sullivan MJ, Green HJ, et al. (1999)
Capillary density of skeletal muscle: A contributing mechanism for exercise
intolerance in class II–III chronic heart failure independent of other peripheral
alterations. Journal of the American College of Cardiology 33: 1956–1963.
42. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, et al. (2007)
Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and
internalization via the low density lipoprotein receptor-related protein-1 (LRP-
1). Journal of cellular physiology 210: 807–818.
43. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel R (1999) Binding and
displacement of vascular endothelial growth factor (VEGF) by thrombospondin:
Effect on human microvascular endothelial cell proliferation and angiogenesis.
Angiogenesis 3: 147–158.
44. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD (1999)
Inhibition of Angiogenesis by Thrombospondin-1 Is Mediated by 2 Independent
Regions Within the Type 1 Repeats. Circulation 100: 1423–1431.
45. Rodrı´guez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, et al.
(2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits
activation of matrix metalloproteinase-9 and mobilization of vascular endothelial
growth factor. Proceedings of the National Academy of Sciences of the United
States of America 98: 12485.
46. Sun J, Hopkins BD, Tsujikawa K, Perruzzi C, Adini I, et al. (2009)
Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary
survival in the developing retina. American Journal of Physiology-Heart and
Circulatory Physiology 296: H1344.
47. Simons M (2012) An Inside View: VEGF Receptor Trafficking and Signaling.
Physiology 27: 213–222.
48. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, et al. (2010)
Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its
Association with CD47. Journal of Biological Chemistry 285: 38923–38932.
49. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, et al. (2009)
Thrombospondin-1 modulates vascular endothelial growth factor activity at the
receptor level. The FASEB journal 23: 3368–3376.
50. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, et al. (2009)
Thrombospondin-1 modulates vascular endothelial growth factor activity at the
receptor level. The FASEB journal 23: 3368.
51. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, et al. (2002)
Inhibition of tumor growth by systemic treatment with thrombospondin 1
peptide mimetics. International journal of cancer 98: 682–689.
ABT-510 Reduces Skeletal Muscle Capillarity
PLOS ONE | www.plosone.org 8 February 2013 | Volume 8 | Issue 2 | e55953
52. Friedl P, Vischer P, Freyberg M (2002) The role of thrombospondin-1 in
apoptosis. Cellular and molecular life sciences 59: 1347–1357.
53. Guo N, Krutzsch HC, Inman JK, Roberts DD (1997) Thrombospondin 1 and
type I repeat peptides of thrombospondin 1 specifically induce apoptosis of
endothelial cells. Cancer research 57: 1735.
54. Miao W-M, Lin Seng W, Duquette M, Lawler P, Laus C, et al. (2001)
Thrombospondin-1 Type 1 Repeat Recombinant Proteins Inhibit Tumor
Growth through Transforming Growth Factor-b-dependent and -independent
Mechanisms. Cancer research 61: 7830–7839.
55. No¨r J, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, et al. (2000)
Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis
by activating the caspase death pathway. Journal of vascular research 37: 209–
218.
56. Isenberg J, Frazier W, Roberts D (2008) Thrombospondins: from structure to
therapeutics: Thrombospondin-1: a physiological regulator of nitric oxide
signaling. Cellular and Molecular Life Sciences CMLS 65: 728–742.
57. Isenberg JS, Hyodo F, Matsumoto KI, Romeo MJ, Abu-Asab M, et al. (2007)
Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-
mediated vascular smooth muscle relaxation. Blood 109: 1945.
58. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, et al. (2005)
Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-
dependent manner. Proceedings of the National Academy of Sciences of the
United States of America 102: 13141.
59. Wintergerst ES, Jelk J, Rahner C, Asmis R (2000) Apoptosis induced by oxidized
low density lipoprotein in human monocyte-derived macrophages involves
CD36 and activation of caspase-3. European Journal of Biochemistry 267:
6050–6059.
60. Meeson AP, Argilla M, Ko K, Witte L, Lang RA (1999) VEGF deprivation-
induced apoptosis is a component of programmed capillary regression.
Development 126: 1407–1415.
61. Tang K, Breen EC, Gerber H-P, Ferrara NMA, Wagner PD (2004) Capillary
regression in vascular endothelial growth factor-deficient skeletal muscle.
Physiological Genomics 18: 63–69.
62. Meeson A, Palmer M, Calfon M, Lang R (1996) A relationship between
apoptosis and flow during programmed capillary regression is revealed by vital
analysis. Development 122: 3929–3938.
63. Dimmeler S, Zeiher AM (2000) Endothelial Cell Apoptosis in Angiogenesis and
Vessel Regression. Circulation research 87: 434–439.
64. Degens H, Alway SE (2006) Control of muscle size during disuse, disease, and
aging. International journal of sports medicine 27: 94–99.
65. Siu PM, Pistilli EE, Butler DC, Alway SE (2005) Aging influences cellular and
molecular responses of apoptosis to skeletal muscle unloading. American Journal
of Physiology - Cell Physiology 288: C338–C349.
66. dalla Libera L, Zennaro R, Sandri M, Ambrosio GB, Vescovo G (1999)
Apoptosis and atrophy in rat slow skeletal muscles in chronic heart failure.
American Journal of Physiology - Cell Physiology 277: C982–C986.
67. Dupont-Versteegden EE (2005) Apoptosis in muscle atrophy: Relevance to
sarcopenia. Experimental Gerontology 40: 473–481.
68. Allen DL, Linderman JK, Roy RR, Bigbee AJ, Grindeland RE, et al. (1997)
Apoptosis: a mechanism contributing to remodeling of skeletal muscle in
response to hindlimb unweighting. American Journal of Physiology - Cell
Physiology 273: C579–C587.
ABT-510 Reduces Skeletal Muscle Capillarity
PLOS ONE | www.plosone.org 9 February 2013 | Volume 8 | Issue 2 | e55953
E
xp
er
im
en
ta
lP
hy
si
ol
og
y
1138 Exp Physiol 96.11 pp 1138–1150
Research Paper
Expression of angiogenic regulators and skeletal muscle
capillarity in selectively bred high aerobic capacity mice
Gerald N. Audet1, Thomas H. Meek2, Theodore Garland Jr2 and I. Mark Olfert1
1West Virginia University School of Medicine, Center for Cardiovascular and Respiratory Sciences, Division of Exercise Physiology,
Morgantown, WV 26508, USA
2University of California-Riverside, Department of Biology, Riverside, CA 92521, USA
Selective breeding for high voluntary wheel running in untrained mice has resulted in a
‘mini muscle’ (MM) phenotype, which has increased skeletal muscle capillarity compared
with muscles from non-selected control lines. Vascular endothelial growth factor (VEGF) and
thrombospondin-1 (TSP-1) are essential mediators of skeletal muscle angiogenesis; thus, we
hypothesized that untrained MM mice with elevated muscle capillarity would have higher
basal VEGF expression and lower basal TSP-1 expression, and potentially an exaggerated VEGF
response to acute exercise.We examined skeletalmusclemorphology and skeletalmuscle protein
expression of VEGF and TSP-1 in male mice from two (untrained) mouse lines selectively bred
for high exercise capacity (MM and Non-MM), as well as one non-selected control mouse
line (normal aerobic capacity). In the MM mice, gastrocnemius (GA) and plantaris (PLT)
muscle capillarity (i.e. capillary-to-fibre ratio and capillary density) were greater compared with
control mice (P< 0.05). In Non-MM mice, only muscle capillarity in PLT was greater than in
controlmice (P < 0.001). The soleus (SOL) showedno statistical differences inmuscle capillarity
among groups. In the GA, MMmice had 58% greater basal VEGF (P < 0.05), with no statistical
difference in basal TSP-1 when compared with control mice. In the PLT, MM mice had a 79%
increase in basal VEGF (P < 0.05) and a 39% lower basal TSP-1 (P < 0.05) compared with the
control animals. Non-MMmice showed no difference in basal VEGF in either the GA or the PLT
compared with control mice. In contrast, basal TSP-1 was elevated in the PLT, but not in the
GA, of Non-MM mice compared with control mice. Neither VEGF nor TSP-1 was significantly
different in SOL muscle among the three mouse lines. In response to acute exercise, MM mice
displayed a 41 and 28% increase (P < 0.05) in VEGF in the GA and PLT, respectively, whereas
neither control nor Non-MM mice showed a significant VEGF response to acute exercise. In
contrast, TSP-1 levels were decreased by 90% in GA (P < 0.05) but increased by 50% in PLT
(P < 0.05) in response to acute exercise inMMmice. The SOL showedno response to exercise for
either VEGF or TSP-1 for any of themouse lines. These data, with the exception of the Non-MM
plantaris muscle, suggest that elevated capillarity is associated with altered balance between
positive and negative angiogenic regulators (i.e. VEGF versus TSP-1, respectively). Based on the
greater capillarity and significant VEGF response to exercise in MM mice, these data suggest
that VEGF expression may, at least in part, be genetically determined.
(Received 11 February 2011; accepted after revision 25 July 2011; first published online 31 July 2011)
Corresponding author I. M. Olfert: West Virginia University School of Medicine, Center for Cardiovascular and
Respiratory Sciences, Division of Exercise Physiology, PO Box 9105, Morgantown, WV 26508, USA.
Email: molfert@hsc.wvu.edu
DOI: 10.1113/expphysiol.2011.057711 C© 2011 The Authors. Journal compilation C© 2011 The Physiological Society
) at West Virginia University on December 16, 2011ep.physoc.orgDownloaded from Exp Physiol (
Exp Physiol 96.11 pp 1138–1150 Muscle vascular endothelial growth factor response in mini mice 1139
The importance of genetic influences in determining
aerobic exercise capacity has been highlighted by selective
breeding approaches used to developed high aerobic
capacity lines of rodents (Swallow et al. 2009; Feder
et al. 2010). For example, Koch & Britton (2001) have
developed separate high (HCR) and low aerobic capacity
rat (LCR) lines via respective breeding of rats for either
high or low endurance capacity on a motorized treadmill.
This has resulted in a diverging phenotype, where HCRs
have a higher cardiovascular (Koch et al. 1999; Howlett
et al. 2009) and respiratory capacity (Henderson et al.
2002) and increased skeletal muscle metabolism (Howlett
et al. 2003), underpinning their greater innate aerobic
endurance capacity compared with LCRs. Data obtained
from this artificial selection experiment also highlights the
importance of reduced/impaired physical activity for the
pathogenesis of chronic disease, as the incidence of some
cardiovascular risk factors is significantly greater in LCRs
compared with HCRs (Wisloff et al. 2005).
Continuous selective breeding for high voluntary wheel
running in laboratory house mice has also resulted in
the development of four replicate lines of mice with a
significantly increased aerobic exercise capacity (Swallow
et al. 1998a,b; Garland et al. 2011). The ‘gene pool’ of
the original outbred population of mice from which this
experiment originated included a Mendelian recessive
allele whose most notable feature is to cause a 50%
reduction in hindlimb muscle mass when present in the
homozygous condition (Garland et al. 2002; Houle-Leroy
et al. 2003). This ‘mini-muscle’ phenotypewas favouredby
the selective breeding regimen and increased in frequency
in two of the four replicate selected lines (Garland
et al. 2002). Further study of the mini-muscle mice
(MM mice) has indicated several distinct physiological
characteristics that may be advantageous with respect to
wheel running. The most distinct feature is a significant
reduction in the mass of most hindlimb muscles, but also
includes fibre-type alterations favouring more oxidative
fibres, increased tibia length (Syme et al. 2005; Guderley
et al. 2008; McGillivray et al. 2009; Wong et al. 2009),
increased mitochondrial enzymatic activity (Guderley
et al. 2006), a smaller overall body mass (Swallow et al.
1999) and an increased maximal oxygen uptake (V˙O2 max)
when tested in hypoxia (Rezende et al. 2006a,b). More
recently, it has also been shown that MM mice exhibit
greater capillarity in the gastrocnemius compared with
mice that have normal-sized muscles, especially around
the medium and large fibres (>2000μm2; Wong et al.
2009).
Given that oxygen delivery to skeletal muscle is
dependent on gas exchange across the microvascular
capillary bed, one important mechanism to increase
oxygen delivery to working muscle is to increase the
number and density of capillaries surrounding the fibres
(Andersen & Henriksson, 1977; Wagner, 2003). Two
potentially important mediators in the angiogenic process
are vascular endothelial growth factor (VEGF; a positive
angiogenic factor) and thrombospondin-1 (TSP-1; a
negative angiogenic factor). In normal skeletal muscle,
it has been shown that acute aerobic exercise increases
VEGF (Breen et al. 1996; Gavin & Wagner, 2001; Olfert
et al. 2001; Gustafsson et al. 2002; Lloyd et al. 2003)
and TSP-1 gene expression (Olfert et al. 2006), and that
chronic or repeated exercise bouts ultimately decrease
TSP-1 mRNA while VEGF mRNA remains elevated
(Gavin & Wagner, 2001; Olfert et al. 2001; Waters et al.
2004). Indeed, the importance of VEGF in regulating
skeletalmuscle capillarity is emphasizedby recent evidence
demonstrating that significant losses in VEGF result in
reduced skeletal muscle capillarity (Tang et al. 2004; Olfert
et al. 2009) and altered vascular function (Lee et al. 2007).
Moreover, training-induced skeletal muscle angiogenesis
is absent in VEGF-deficient mice (Olfert et al. 2010).
By the same token, the importance of TSP-1 expression
in preventing hypercapillarization of the skeletal muscle
vascular bed has been shown using TSP-1 knockout mice
(Malek & Olfert, 2009).
Given the importance of VEGF and TSP-1 to skeletal
muscle structure and function, we sought to examine
VEGF and TSP-1 expression from two of the four selected
mouse lines with inherited high aerobic capacity [one
with the MM phenotype and another without the MM
phenotype (i.e. Non-MM)] comparedwith a non-selected
control line. We chose to examine two high capacity
lines in our study, MM (Garland designated line 3) and
Non-MM (Garland designated line 8), in order to more
generally evaluate the high aerobic capacity phenotype,
and not only the MM phenotype, compared with a
non-selected control line (Garland designated line 2). In
essence, the Non-MM mouse serves as an additional
high capacity experimental group compared with the
control line, but also as an additional high capacity group
compared with MM mice (which have a very distinctive
mini-muscle phenotype). For each of the three mouse
lines, we examined basal expression and the response to
acute exercise of VEGF and TSP-1 protein in the triceps
surae hindlimb muscle. As both the MM and the Non-
MM mice have increased maximal oxygen consumption
and treadmill endurance capacity during forced exercise
compared withmice from control lines (Meek et al. 2009),
and it has been shown that MM mice display elevated
gastrocnemius muscle capillarity (Wong et al. 2009), it
was first hypothesized that Non-MM mice would also
have elevated skeletal muscle capillarity compared with
control mice and second, that basal levels of VEGF would
be higher in bothMMandNon-MMhigh aerobic capacity
mice compared with control mice. Moreover, given that
all three mouse lines were untrained, we reasoned that
we might see an exaggerated gene response to acute
exercise in the high aerobic capacity lines compared with
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control animals due to the selection of genetic influences
(resulting from the selected breeding strategy) that would
favour greater skeletal muscle capillarity and high aerobic
capacity mice, in the absence of training. On the other
hand, as the high aerobic capacity lines are expected to
have elevated muscle capillarity (and in normal mice
elevated skeletal muscle capillarity has been associated
with reduced VEGF responsiveness to exercise, at least in
the context of training), it could also be hypothesized that
simply having elevated capillarity (even in the absence of
training) might diminish or attenuate the VEGF response
to exercise in the high capacity selected lines compared
with control mice.
In this study, we report data from the triceps surae
muscles (which are known to have varying oxidative
and glycolytic capacity) in order to identify potential
differences in the skeletal muscle angiogenic response
between muscles; but more specifically, we sought to
exploit the innate difference between the respectivemouse
lines as an approach that might be a useful in unravelling
the environmental versus genetic influences on skeletal
muscle vascularization.
Methods
Animals
Male MM mice (laboratory designation selected line 3,
n= 12), Non-MM mice (selected line 8, n = 12) and
control mice (line 2, n = 12) were bred and raised at the
University of California, Riverside. For a comprehensive
review on the breeding and selection process, please see
Swallow et al. (1998a). Briefly, eight independent lines
of mice were created in the early 1990s from a common
population of outbred Hsd:ICR laboratory mice. All lines
were provided with running wheels for 6 days when the
mice were ∼6–8 weeks of age. In the four selected lines,
the top-runningmale and female fromwithin each of∼10
families, each generation, were used for breeding and the
continuation of the line. The breeders were selected for the
greatest distance run on the fifth and sixth day of wheel
exposure. The other four lines were bred at random with
respect to the amount of running, and served as control
lines. After ∼16 generations, the four ‘high runner’ lines
ran approximately 2.7 times as far as the control lines, and
had begun to display a number of characteristics unique
to these lines (Swallow et al. 1998b, 2001, 2009; Koteja
et al. 1999). In the present study, the mouse lines we
examined came from the 54th generation, at which time
the four selected lines were runningmore than three times
further than control lines on a daily basis (T. Garland,
unpublished observations). All procedures that involved
animals were approved by the University of California,
Riverside, Institutional Animal Care andUse Committee.
Acute exercise protocol
A subgroup of mice (n = 6) in each line were randomly
assigned to perform a single bout of acute exercise in order
to access growth factor response to an angiogenic stimulus.
These mice ran in a custom-built treadmill (Meek et al.
2009). The clear Plexiglass lane in which the mouse ran
haddimensions 6.5 cmwide, 12.5 cmhigh and44 cm long.
All animals were familiarized with the treadmill for 5 min
prior to the acute exercise bouts. After this initial period,
mice ran for 1 h at 20mmin−1 with 10 deg incline. A run
time of 1 h was selected because it has been shown to
elicit a robust exercise-induced angiogenic gene response
in rodents (Breen et al. 1996; Olfert et al. 2001). Animals
were killed 4 h after the acute exercise at a time point
known to correspond to peak VEGF protein expression
(I. M. Olfert, unpublished data).
Tissue preparations
Each animal was killed by CO2 inhalation, and the triceps
surae [gastrocnemius (GA), soleus (SOL) and plantaris
(PLT)] muscles from each leg were immediately excised.
Muscles from the right leg were weighed and immediately
flash frozen in liquid N2, then later processed for VEGF
protein expression.Muscles fromthe left legweremounted
on cork disks and quickly frozen in isopentane cooled
in liquid N2, then processed later for morphometrical
analysis. All samples were then stored at –80◦C until
processed for molecular or morphological analyses.
Morphometry
Frozen tissue was cut using a –20◦C cyromicrotome
(Jung-Reichert Cryocut 1800; Cambridge Instruments,
Nussloch, Germany) to yield 10-μm-thick transverse
sections. Great care was taken to ensure that the
cryosectioned muscles were cut along the transverse
plane. All tissues were stained for capillarity using the
lead nitrate-ATPase method described by Rosenblatt
et al. (1987). A light microscope (Nikon Eclipse 80i;
Nikon Instruments Inc.) was used to digitally acquire
(Photometrics CoolSnap ES; Photometrics, Tucson, AZ,
USA) ×20 images of sectioned muscles in a checkerboard
fashion across the entire muscle. Capillary and myofibre
counting was performed by a single individual, who
was blinded to the identity of each of the samples.
For the gastrocnemius muscle, we obtained images in a
checkerboard fashion across the entire muscle, thus both
superficial and deep regions within the gastrocnemius
were included in the analysis. For the plantaris and
soleus muscles, the entire muscle was imaged and
analysed. Counting was performed by visualization from
acquired images using a custom program in MATLAB
C© 2011 The Authors. Journal compilation C© 2011 The Physiological Society
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Table 1. Body, heart and hindlimb muscle mass (means ± SEM)
P value for
Control MM Non-MM three-group comparison
Body mass (g) 32.8 ± 0.56 29.9 ± 0.83∗† 32.5 ± 0.55 0.01
Heart mass (mg) 152.4 ± 3.18 161.2 ± 4.81 154.5 ± 3.04 0.24
Heart mass/body mass (mg g−1) 4.65 ± 0.11 5.39 ± 0.08∗† 4.76 ± 0.12 < 0.01
Gastrocnemius mass (mg) 123.9 ± 4.23 59.2 ± 2.08∗† 134.3 ± 3.22 < 0.01
Gastrocnemius mass/body mass (mg g−1) 3.78 ± 0.08 1.98 ± 0.05∗† 4.13 ± 0.08∗ < 0.01
Plantaris mass (mg) 14.2 ± 0.53 9.8 ± 0.62∗† 12.9 ± 0.35 0.01
Plantaris mass/body mass (mg g−1) 0.43 ± 0.03 0.33 ± 0.03∗ 0.40 ± 0.03 0.049
Soleus mass (mg) 7.6 ± 0.93 9.8 ± 0.93∗† 6.4 ± 1.04 < 0.01
Soleus mass/body mass (mg g−1) 0.23 ± 0.02 0.51 ± 0.02∗† 0.20 ± 0.01 < 0.01
Student’s unpaired t tests indicate ∗P < 0.05 compared with control line; and †P < 0.05 compared with Non-MM line.
(version 7.0.0.27; The Mathworks, Natick, MA, USA),
allowing the operator to visually mark and count the
capillaries and fibres on each image. Capillary-to-fibre
ratio (C:F; number of capillaries/number muscle fibres),
capillary density (CD; number of capillaries/muscle fibre
area) andfibre cross-sectional area (FCSA)were separately
calculated for the gastrocnemius, soleus andplantaris from
a minimum of 175 images per mouse line.
Protein analysis
The GA, SOL and PLT muscles from each group were
separately homogenized in a lysis buffer containing 50mM
Tris–HCl (pH 7.4), 150mM NaCl, 0.5% Triton X-100 and
protease inhibitors (CompleteTM Tablet; Roche Applied
Science, Indianapolis, IN, USA). Homogenates were
centrifuged at 4◦C, 8000g for 10min, and supernatants
removed and placed in new tubes. Total protein was
measured by the bicinchoninic acidmethod (BCA protein
assay kit; Bio-Rad laboratories, Hercules, CA, USA).
Quantification of VEGF was made from a total of
100μg of protein using a commercially available ELISA
kit according to the manufacturer’s instructions (Model
MMV00; R&D Systems, Minneapolis, MN, USA).
Denatured samples (20μg) from GA and PLT muscles
were separated on a 3–8% SDS-PAGE and blotted onto a
0.45μm nitrocellulose membrane (Pierce nitrocellulose
membrane; Thermo Scientific, Rockford, IL, USA).
After blocking with 5% fat-free milk, membranes were
probed using antibodies against TSP-1 (1:250 dilution;
clone A6.1, no. 399300; Invitrogen, Burlington, ON,
Canada), β-tubulin (1:1000 dilution; no. 2148; Cell
Signaling, Danvers, MA, USA), horseradish peroxidase-
conjugated anti-mouse (1:1000 dilution; no. p0260;
Dako, GE Healthcare, Piscataway, NJ, USA) and
horseradish peroxidase-conjugated anti-rabbit (1:1000
dilution; no. p0217; Dako). Proteins were visualized
using chemiluminescence detection (Pierce ECL; Thermo
Scientific) and digitally imaged (G:BOX Gel imager;
Syngene, Cambridge, UK). Images were captured using
Genesnap software (version 7.01; Syngene). Equal protein
loading was verified by immunodetection of β-tubulin as
our loading control. Quantification of protein expression
levels were carried out using NIH ImageJ Software
(version 1.62) and expressed as densitometric arbitrary
units (a.u.). The TSP-1 expression was normalized to
β-tubulin expression level. Owing to insufficient sample
volume, we were not able to runWestern analysis of TSP-1
on the SOL muscle.
Statistics
All data are presented as means± SEM. To examine body
mass, organ masses and muscle capillarity (measured
only in basal conditions), we used a one-way ANOVA
comparing the three lines of mice. To examine protein
expression, we used a two-way ANOVA comparing the
three lines of mice in basal conditions and in response
to acute exercise, while also testing for an interaction
between line and exercise condition. Separate analyses
were performed for each of the three muscles studied
(StatView, 5.0.1). When a main effect was observed,
post hoc testing was performed using Student’s unpaired
t test. An α level of P< 0.05 was selected for statistical
significance.
Results
Body and muscle masses
Body mass differed significantly among lines (P = 0.006).
As seen inTable 1,MMmice had 9% lower bodymass than
Non-MM mice (P = 0.008) and 10% lower than control
mice (P = 0.003). The MM mice also had a 16% larger
heart mass (per gram body mass) compared with control
line mice (P < 0.001) and a 13% increase over the Non-
MM line (P < 0.001). There was no statistical difference in
relative heart mass between the Non-MM and the control
animals.
All three muscles of the triceps surae differed
significantly in mass among all lines (GA, P < 0.001; SOL,
P < 0.01; and PLT,P < 0.05), evenwhen expressed relative
to body mass (GA, P < 0.001; SOL, P < 0.001; and PLT,
P < 0.05; Table 1). The MM mice had a 56% decrease in
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GAmass compared with Non-MM line (P < 0.001) and a
52% reduction compared with control mice (P < 0.001).
The Non-MM line also had 8% greater GA mass than
control mice (P = 0.036). On a mass-specific basis, the
MMmice had a 48% reduction comparedwith the control
mice (P < 0.001) and a 52% reduction compared with the
Non-MM line (P < 0.001). The Non-MM line also had
an 8% increase when corrected for body mass compared
with the control mice (P < 0.001). As expected (Guderley
et al. 2008; Wong et al. 2009), superficial portions of the
GA muscle in MM mice showed the distinct appearance
of many small fibres not present in either of the other lines
(Fig. 1).
The PLT of the MM mouse was also 32% smaller than
in the Non-MM line (P = 0.039) and 45% smaller than in
controlmice (P = 0.004). Therewas nodifference between
the Non-MM line and control mice. On a mass-specific
basis, only the MM mice and control mice showed any
statistical difference, with a 30% reduction in the MM
PLTmass (P = 0.015) compared with the control animals.
The SOL of MMmice was 53% larger than in the Non-
MM mice (P < 0.001) and 29% larger than in the control
mice (P = 0.005). There was no statistical difference
between the Non-MM line and the control mice. On a
mass-specific basis, the MM line had 155% greater SOL
mass than the Non-MM line (P < 0.001) and a 122%
greater mass than the control line (P < 0.001). There was
no difference between the Non-MM line and the control
animals after correcting for body mass.
Morphometry
There was a significant main effect for C:F, CD and FCSA
among all groups for the GA (all P < 0.001) and PLT (all
P < 0.05), but not for the SOL muscle. In the GA, MM
mice had a 25% greater C:F and 43% greater CD than the
Non-MM line (P < 0.001) and 38% greater C:F and 46%
greaterCD than the controlmice (P < 0.001; Fig. 2). There
was no difference in C:F or CD between the Non-MM and
control mice for the GA. The GA FCSA was decreased by
39 and 36% in the MM mice compared to Non-MM and
control mice, respectively (P < 0.001; Fig. 2).
In the PLT, there was no difference in C:F, CD and
FCSA between MM mice and the Non-MM line (Fig. 2);
however, the MM mice and Non-MM mice had a 35
(P = 0.002) and 27% (P = 0.005) greater C:F, and a 24
(P < 0.034) and 31% (P < 0.003) greater CD in the PLT
compared with control mice (Fig. 2).
Figure 1. Representative images of triceps surea muscles
A, superficial gastrocnemius. B, soleus. C, plantaris. Capillaries were stained using lead-ATPase appear as black
dots outside the muscle. The presence of very small muscle fibres in the gastrocnemius muscle (A) is evident in MM
mice compared with control and Non-MM mice. Capillary-to-fibre ratio is significantly elevated in gastrocnemius
muscle of MMmice (A) compared with control and Non-MMmice (P < 0.001), and significantly greater in plantaris
muscle of MM mice (B) compared with control mice (P < 0.001), but not Non-MM mice. No difference in soleus
muscle capillarity was observed between the groups (C).
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Table 2. Muscle fibre-type composition
Type I (%) Type II (%)
Control MM Non-MM P value Control MM Non-MM P value
Gastrocnemius (deep) 20 ± 4 30 ± 4† 24 ± 3 0.18 79 ± 4 70 ± 4† 75 ± 3 0.15
Gastrocnemius (superficial) 2 ± 1 12 ± 3∗ 7 ± 3 0.04 98 ± 1 89 ± 3∗ 95 ± 2 0.02
Plantaris 38 ± 6 38 ± 1 39 ± 2 0.96 62 ± 6 62 ± 2 61 ± 2 0.91
Soleus 40 ± 2 32 ± 5 39 ± 4 0.32 61 ± 3 68 ± 5 61 ± 3 0.29
P value represents ANOVA comparison among three groups; ∗P < 0.05 compared with control line; and †P = 0.07
compared with control line.
There was not a significant main effect for C:F, CD or
FCSA in the SOL (data not shown).
There was a significant main effect for fibre type for the
superficial GA between the mouse lines (P < 0.05). Post
hoc analysis revealed that MM mice had 86% more type I
fibres (P = 0.014) and 10% fewer type II fibres (P = 0.007)
than control mice (Table 2). In the deep GA, a significant
main effect forfibre typewasnot foundbetween themouse
lines (type I, P = 0.179; and type II, P = 0.154); however,
this region of the GA exhibited a similar trend towards
having an increase in the proportion of type I and decrease
in proportion of type II myofibres in MM compared with
control mice. There was no significant difference between
MMmice and Non-MMmice in either portion of the GA.
No significant differences in fibre type between the mouse
lines in either the PLT or SOL were observed.
Protein expression of VEGF
Basal levels. There was a main effect among mouse lines
for basal VEGF expression in the GA (P = 0.017) and the
PLTmuscles (P = 0.031). In the GA, MMmice had a 58%
higher basal expression of VEGF compared with control
mice (P = 0.006; Fig. 3). Although basal VEGF expression
was also 33% greater in Non-MM compared with control
mice, this difference did not reach statistical significance
(P = 0.055). There was no significant difference in basal
VEGF expression between MM and Non-MM mice.
In the PLT muscle, we observed 79% greater VEGF
expression in MM mice compared with control mice
(P = 0.010), but no significant difference between MM
and Non-MM mice (P = 0.081). There was also no
significant difference between Non-MMmice and control
mice, despite a similar tendency for 28% greater VEGF
levels in Non-MM mice (P = 0.251), like that seen in the
gastrocnemius.
No significant main effect for basal VEGF expression
was observed in the SOL muscle (data not shown).
Response to acute exercise. There was a main effect
for VEGF response among mouse lines (P = 0.0003)
and a significant exercise× line interaction in the GA
(P = 0.047; Fig. 3). Only the MM mice showed a
significant VEGF response to acute exercise, resulting in
Figure 2. Capillary-to-fibre ratio (C:F), capillary density (CD) and fibre cross-sectional area (FSCA) of the
triceps surae muscles
In the gastrocnemius, MM mice had an increase in C:F and CD and a decrease in FCSA compared with both
control and Non-MM mice. In plantaris, MM and Non-MM had an increased C:F and CD compared with control
mice. ∗P < 0.05 compared with control mice; and †P < 0.05 compared with Non-MM mice.
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a 41% increase in VEGF in the GA from basal levels
(P = 0.009). The control mice had a very similar 38%
increase in VEGF from baseline, but this did not reach
statistical significance (P = 0.081), which was probably
due to the greater variability observed in the VEGF
response to exercise in these mice. Surprisingly, there was
no VEGF response to exercise in the Non-MM line GA.
There was no statistically significant interaction
between the VEGF response to exercise and line in either
of the other muscles studied (i.e. PLT and SOL). However,
similar to the GA, VEGF in the PLT increased 28% in
response to exercise in MM mice (P = 0.038). Non-MM
mice showed a non-significant increase (21%;P = 0.158)
for VEGF in the plantaris, while control mice did not
respond to exercise.
No significant difference between groups for the VEGF
response to exercise was observed in the SOLmuscle (data
not shown).
Figure 3. Comparison of basal and postexercise levels of vascular endothelial growth factor (VEGF) and
thrombospondin-1 (TSP-1) in the triceps surae muscles
A, there was a statistically significant interaction between acute exercise and VEGF levels in the gastrocnemius
(GA) and plantaris (PLT). In both muscles, MM mice had increased basal levels of VEGF compared with control
animals, and a significant VEGF response to acute exercise. The VEGF levels did not differ between the Non-MM
and control mice in either muscle, although there was a trend for an increase in the GA (P = 0.055). B, there was
a statistically significant interaction between acute exercise and TSP-1 levels in the GA and PLT. In basal conditions
in the PLT, the MM mice had lower TSP-1 levels than either the control or Non-MM mice, and in the GA and PLT
the MM mice had a significant TSP-1 response to acute exercise. The Non-MM mice had significantly higher basal
levels of TSP-1 in the PLT than control mice. Also in the PLT, control animals had a significant TSP-1 response to
acute exercise. C, representative Western blots from TSP-1 analysis (B). ∗P < 0.05 compared with control mice,
same exercise state (basal or acute exercise); and #P < 0.05 compared with basal levels.
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Protein expression of TSP-1
Basal levels. Basal levels of TSP-1 in the GA muscle were
not different among mouse lines. However, a significant
main effect for basal TSP-1 expression in the PLT was
observed among mouse lines. In the PLT, MM mice
had 39% lower TSP-1 levels compared with control mice
(P < 0.01) and 58% lower compared with the Non-MM
mice (P < 0.01; Fig. 3). Non-MM mice exhibited a 46%
increase in basal TSP-1 compared with control mice
(P < 0.001; Fig. 3).
Response to acute exercise. There was a significant
exercise× line interaction in the GA (P = 0.014; Fig. 3).
In the GA, control mice and Non-MM mice showed
no statistical TSP-1 response to acute exercise, whereas
MMmice exhibited a 90% decrease in TSP-1 (P = 0.003).
In the PLT, there was also a significant effect for TSP-1
in response to acute exercise (P = 0.005), where TSP-1
expression increased by 47% (P < 0.01) in control mice
and by 55% (P < 0.05) in MM mice (Fig. 3). There was
no significant acute exercise response in Non-MM mice
(Fig. 3).
Discussion
The main finding of this study is that elevated skeletal
muscle capillarity in MM mice bred for high aerobic
capacity is associated with an altered balance between
VEGF and TSP-1 protein expression (Fig. 3). These data
are consistent with the observations that VEGF and
TSP-1 are essential regulators of the skeletal muscle
microvascular bed. Surprisingly, in Non-MM mice a
similar diverging correlation between VEGF and TSP-
1 in relation to changes in muscle capillarity was not
found in the PLT muscle. In general, however, these
data support the notion that VEGF and TSP-1 are key
physiological regulators of angiogenesis within skeletal
muscle. Moreover, when comparing the basal expression
of these factors inMMmice against controlmice, these are
among the first data to suggest that muscle capillarity and
the capacity for exercise-induced angio-adaptation may,
in part, be accounted for by inherited traits related to the
expression of VEGF, and possibly TSP-1, within skeletal
muscle.
Basal expression of VEGF and TSP-1 correlates with
elevated skeletal muscle capillarity in MM mice,
but not in Non-MM mice
In this study, we report that MM mice have increased
capillarity in the both the GA and the PLT (Fig. 2), which
is associated with elevated basal expression of VEGF in
each muscle (Fig. 3). At the same time, we observed no
difference in basal skeletal muscle TSP-1 expression in
the GA, but a significant decrease in the PLT (Fig. 3)
which, when combined with the elevated expression of
VEGF in both GA and PLT, is consistent with a pro-
angiogenic environment within the muscle. In contrast,
neither capillarity nor VEGF expression was different in
the SOL muscle of MM or Non-MMmice compared with
control mice.
In Non-MMmice, which are also high aerobic capacity
mice but without the unique ‘mini-muscle’ phenotype, we
found that only the PLT had elevated capillarity, whereas
neither GA nor SOL muscle capillarity was different
compared with control animals (Fig. 2). Although there
was a trend for elevated basal VEGF expression in
the PLT of Non-MM mice (P = 0.07), we also found
elevatedbasalTSP-1 expression (P < 0.01),which together
could be argued as an anti-angiogenic state rather than
pro-angiogenic. Nonetheless, an increase in PLT muscle
capillarity was observed in Non-MM mice (Fig. 2). In
contrast, no significant changes in basalVEGFwere seen in
either the GA or SOLmuscles of Non-MMmice. Likewise,
TSP-1 was not different in GA muscle, and no differences
in capillarity were seen in either the GA or the SOL of
Non-MM mice compared with control animals.
Taken together, the elevatedmuscle capillarity in theGA
of MM mice is most probably explained by elevated basal
VEGF. In the PLT, elevated muscle capillarity occurred
in the presence of decreased basal TSP-1 expression and
little or no increase in VEGF, suggesting that TSP-1 may
also be playing an important role, at least in the PLT
of MM mice. Despite the differences in these individual
muscles, there is growing evidence that physiological
regulation of angiogenesis is dependent on the balance
between positive and negative angiogenic proteins such
that the ratio of VEGF to TSP-1 expression may actually
be more important than their individual expression
levels per se (Olfert & Birot, 2011). The present results
support the notion of an altered balance leading to
capillary adaptation, with the notable exception of the
PLT muscle in Non-MM mice. One explanation for this
discrepancymay be that other angiogenic regulators (such
as endostatin, angiopoetins and their receptors, matrix
metalloproteinases) are also playing a role, but are not
accounted for in this study. Indeed, while we focused on
VEGF and TSP-1 because of their recognized prominence
in effecting changes in the skeletal muscle vascular bed, it
is entirely possible (and likely) that other regulators also
contribute to the basal angiogenic state (Olfert & Birot,
2011).
It is interesting to note that increased capillarity
occurred predominately in skeletal muscle composed of
glycolytic myofibres (i.e. GA and PLT) and not in muscle
composed of mostly oxidative myofibres (i.e. SOL). This
observation is consistent inbothhigh aerobic selected lines
(i.e. MM and Non-MM), and might suggest that muscles
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with greater glycolytic metabolic profiles experienced the
greatest amount of evolutionary change in these selectively
bred lines of mice. This idea is consistent with the
observation that glycolytic myofibres may be principally
responsible for driving the angiogenic response to acute
exercise (Birot et al. 2003; Waters et al. 2004). It may also
be that muscles having a predominant role in locomotor
activity (i.e. GA and PLT) would be the most evolved in
these mice, whereas postural skeletal muscles (such as the
SOL) are less likely to have been influenced.
Exercise capacity, angiogenesis and VEGF
It remains clear that muscles found to have elevated
basal VEGF expression are also the muscles with elevated
capillarity (Fig. 4). In TSP-1 knockout mice, increases
in skeletal muscle capillarity (achieved without exercise
training) are also associated with greater exercise capacity
(Malek&Olfert, 2009),whereas losses inmuscle capillarity
(due to deletion of VEGF in myocytes) are shown to
reduce exercise performance (Olfert et al. 2009). The
strong association between exercise capacity and muscle
capillarity is also supported in selectively bred rats with
high and low aerobic capacity (Howlett et al. 2003). Thus,
the present findings are consistent with the evidence that
skeletal muscle capillarity and muscle O2 conductance
are critical determinants of aerobic exercise performance
(Howlett et al. 2003). It is interesting to note, however,
that V˙O2 max is not statistically different between MMmice
and any of the other high aerobic capacity mouse lines,
except during exercise in hypoxia (Rezende et al. 2006a,b).
If O2 transport in the mouse is principally limited at the
muscle–capillary interface, as implied by these and the
other aforementioned data, then the greater capillarity in
GA muscle of MMmice could help explain the advantage
in V˙O2 max seen during hypoxic exercise over Non-MM
mice (Rezende et al. 2006a). Although these data do
not establish a cause-and-effect relationship, they are in
harmony with the view that VEGF-mediated increases in
skeletalmuscle capillarity contribute to the greater exercise
capabilities observed in mice with an innate high aerobic
capacity. Given the positive relationship noted for VEGF
and C:F (Fig. 4) and the notable absence of an inverse
relationship for TSP-1 and C:F (Fig. 4), it could be argued
thatVEGFmaybe themost critical determinant formuscle
capillarity.More importantly, the fact that VEGF andTSP-
1 had different responses within the triceps surae muscles
between these two high aerobic capacity lines (i.e. MM
Figure 4. Correlation of muscle VEGF and TSP-1 levels to capillary-to-fibre ratio (C:F)
Least-squares linear regression of C:F on basal VEGF and TSP-1 levels in the GA and PLT muscles of the three
mouse lines. Large symbols indicate mean values for each line and small symbols are values for individual animals.
Squares indicate control mice, triangles MM mice and circles Non-MM mice.
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versus Non-MM) suggests that basal angiogenic protein
expression may be, at least in part, an inherited trait that
may also account for some of the biological variability in
exercise capacity.
Genetic background may influence angiogenic
responses to acute exercise
In the context of exercise training, it has been shown
in standard laboratory mice and rats that the VEGF
response to acute exercise is attenuated in skeletal muscle
post-training (Olfert et al. 2001; Malek & Olfert, 2009).
It has been postulated that this is a direct response to
training-induced angio-adaptation (i.e. increased muscle
capillarity, improved blood flow distribution to working
muscle, and increased O2 conductance into the myocyte)
that functions to relieve metabolic stress on the myocyte
that is imposed by exercise. Given that local tissue hypoxia
is thought to be among the key stimuli for the VEGF
response to exercise (Levy et al. 1995; Breen et al. 1996;
Richardson et al. 1999; Olfert et al. 2001), we have
previously speculated that the attenuated VEGF response
to an acute bout of exercise post-training is the result of
increased muscle capillarity and greater O2 conductance
during exercise (Olfert et al. 2001; Malek & Olfert, 2009).
The present data could be interpreted to suggest that a
mechanism other than local hypoxia may be involved
in the modulation of VEGF during acute responses to
exercise. Indeed, if increased capillarity reduces local tissue
hypoxia, and this is responsible for modulating the VEGF
response, then it would be expected that an attenuated
VEGF response to exercise would be seen in MM mice
(which inherently displayed a greater number of capillaries
in their muscle compared with normal mice). However, as
it has also previously been shown that MM mice have
increased aerobicmetabolic enzyme activities in hindlimb
muscles (Guderley et al. 2008), it could also be that MM
mice simply have a much higher oxygen flux and thus
the level of O2 within the muscles is relatively unchanged
compared with Non-MM and control mice (despite the
greater number of muscle capillaries). We also cannot
exclude the possibility that other mechanisms, such as
shear stress, local drops inmuscle pH,modulation of other
matrix regulators and/or other angiogenic factors, may
have indirect influences on the VEGF response to exercise.
Some support for modulation of other angiogenic
factors comes from the TSP-1 data in the present study.
Thrombospondin-1 is a potent inhibitor of angiogenesis
and of VEGF directly (Gupta et al. 1999; Greenaway et al.
2007). In the MM mice, we found that TSP-1 levels were
lower in the PLT in basal conditions and in the GA in
the acute exercise conditions (Fig. 3). In both of these
circumstances, VEGF is also increased. This supports the
notion of an altered balance between positive (e.g. VEGF)
and negative (e.g. TSP-1) angiogenic factors (Hanahan &
Folkman, 1996; Olfert & Birot, 2011). This altered balance
would be another elegant way that the MM mice are
genetically more able to adapt to an exercise stimulus.
Another potential explanation for the greater VEGF
response to exercise in MM mice may be that the
VEGF response to exercise is also genetically influenced.
Although it is difficult to decipher the relative contribution
of genetic versus environmental influences in setting an
individual’s exercise capacity, evidence supporting the
genetic influences can be seen from a recent report
involving fine genotypemapping ofMMmice (Hartmann
et al. 2008). Hartmann et al. (2008) localized the gene
responsible for themini-muscle phenotype to a 2.6335Mb
of MMU11, a region that harbours ∼100 expressed
or predicted genes, many with known roles in muscle
development and/or function. Upon examination of
the genes within this region, we have identified two
genes, Tnfsf12/TWEAK and Ephrin ligands/receptors,
both of which have been shown to have some regulatory
role in angiogenesis and/or endothelial cell proliferation
(Helbling et al. 2000; Cheng et al. 2002; Donohue et al.
2003).What role, if any, these factors may exert on skeletal
muscle VEGF remains to be determined, but it is tempting
to speculate that these (orother) genesmay support and/or
enhance angiogenesis in MM mice.
It should be noted that our data are not the first
to suggest that the VEGF response to exercise may be
influenced by genetic background. Prior et al. (2006)
have shown that genetic variants in the promoter
region of the VEGF gene correlate with whole-body
V˙O2 max in humans. Similar results were also reported in
response to hypoxia-mediated increased in VEGF gene
expression in cultured myotubes (Prior et al. 2006).
Our data, combined with these previous studies, imply
that individual gene responses may influence exercise
performance, and suggest that the VEGF response to
exercise may, at least in part, be an inherited trait.
Comparison of muscle mass and fibre-type profile
among mouse lines
It has previously been shown that MM mice have a
significantly decreased triceps surae muscle mass (Syme
et al. 2005; Guderley et al. 2006, 2008; McGillivray et al.
2009). Likewise, the present study shows that GA and
PLT muscle mass was decreased in the MM mice when
compared with the control and Non-MM mice (Table 1).
Opposite to what is seen in the GA and PLT muscles, the
SOL of the MMmice was increased over 130% (on a body
mass-specific basis) when compared with both the control
mice and the Non-MM line (Table 1).
In mice, the GA has an aerobic profile that is mixed,
with superficial portions of the muscle containing mainly
type IIb/x fibres, whereas the deep portions containsmany
type IIa and type I fibres (Guderley et al. 2008; Wong
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et al. 2009). In contrast, the SOL is comprised primarily
of type I or IIa fibres. Assessment of fibre type in these
mice reveals that MM mice have a greater proportion of
type I than type II myofibres compared with control and
Non-MMmice (Table 2). These findings are supported by
earlier observations that MM mice have increased type I
and type IIa fibres along with decreased type IIb fibres
in the medial GA muscle (Guderley et al. 2008). This
myofibre composition is consistent with the elevated C:F
ratio found in the GA of the MM mice in the present
study, further supporting the notion of a greater oxidative
muscle metabolic profile capable of supporting greater
aerobic capacity.
This also raises the issue of the influence of muscle
mass and/or fibre type/size on skeletal muscle aerobic
performance. It could be argued that greater cardiac
output (as indicated by larger cardiac mass in both
absolute terms and relative to body size) could itself
contribute to improved exercise capacity in MM mice
(Table 1). Perhaps the strongest argument against this
hypothesis is provided by the Non-MM mice, which
exhibit an equally high aerobic endurance capacity to
the MM mice but do not have greater cardiac mass
(in absolute or relative terms) compared with control
animals (Garland et al. 2002; Table 1). Moreover, we
would also contend (irrespective of any improvements in
central cardiac function) that blood flow to the working
muscle is also controlled by local metabolic demand. In
combination with the greater muscle metabolic potential
of MM mice, such as increased mitochondrial enzymatic
activity (Guderley et al. 2006), it is perhaps debatable
whether greater cardiac function in these MMmice might
be considered as improved or simply an attempt to
keep up with metabolic demand of the working muscle.
Nonetheless, there are presently no data which document
cardiac output or function in these mice, thus we do not
know if cardiac function is altered.
In summary, these data generally support the
notion that skeletal muscle angiogenesis in physiological
conditions is likely to be controlled by a balance between
pro- and anti-angiogenic factors, and also suggest that
the expression of VEGF versus TSP-1 may differ among
muscles. Moreover, the observation that basal VEGF and
TSP-1 expression, and the VEGF and TSP-1 response
to exercise, were different between the two high aerobic
capacity mouse lines seems to suggest first, that a
mechanism other than local hypoxia might be regulating
the VEGF response to exercise and second, that the
VEGF response to exercise may, in part, be genetically
determined.
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